I4V-MC-JAIR Protocol (d) 
 
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the 
Efficacy and S afety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata  
 
[STUDY_ID_REMOVED]  Approval Date: 02- Nov-2020 
I4V-MC-JAIR( d) Clinical Protocol Page 1
LY3009104Protocol I4V-MC-JAIR(d)
A Multicenter, Randomized, Double -Blind, Placebo -
Controlled, Phase 3 Study  to Evaluate the Efficacy  and 
Safety  of Baricitinib in A dult Patients with Severe or Very  
Severe A lopecia A reata
BRA VE-AA2
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should n ot be copi[INVESTIGATOR_487017] (LY3009104), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries .  
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Baricitinib (LY3009104)
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] 26 October 2018 .
Amendm ent (a) Electronical ly Signed and Approved by [CONTACT_229490] 09 -Nov- 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_11007] 05-Oct-2019
Amendm ent (c) Electronically Signed and Approved by [CONTACT_11007] 0 1-Jun-2020
Amendm ent (d) Electronically Signed and Approved by [CONTACT_878676].
Approval Date: 02-Nov-2020 GMT
I4V-MC-JAIR( d) Clinical Protocol Page 2
LY3009104Table of Contents
Section Page
Protocol  I4V-MC-JAIR(d) A Mult icenter, Randomized, Double -Blind, 
Placebo -Controlled, Phase [ADDRESS_1227437] ivities....................................................................................................... 17
3. Introduction ...................................................................................................................... 24
3.1. Study  Rati onale ............................................................................................................ 24
3.2. Background .................................................................................................................. 25
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_1227438] ives and Endpo ints.................................................................................................. 29
5. Study  Design ..................................................................................................................... 32
5.1. Overall Design ............................................................................................................. 32
5.1.1. Period 1:  Screening ( -35 to -3 day s).................................................................... 35
5.1.2. Period 2:  Doubl e-Blind Treatm ent Peri od (Weeks 0 – 36) ................................... 35
5.1.3. Period 3:  Long- Term  Extensi on.......................................................................... 35
5.1.4. Period 4:  Bri dging Extensio n............................................................................... 37
5.1.5. Period 5:  Posttreatment Follow -Up...................................................................... [ADDRESS_1227439] ions.................................................................................................... 50
6.4. Screen Failures ............................................................................................................. 50
7. Treatments ........................................................................................................................ 51
7.1. Treatments Admi nistered ............................................................................................. 51
7.1.1. Packaging and Labeling ....................................................................................... 51
7.2. Method of Treatment Assignment ................................................................................ 51
7.2.1. Selection and Timing o f Doses ............................................................................. 52
I4V-MC-JAIR( d) Clinical Protocol Page 3
LY30091047.2.2. Dose Adjustment for Renal Impairment ............................................................... 52
7.3. Blinding ....................................................................................................................... 52
7.4. Dosage Modification .................................................................................................... 53
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_1227440] to Follow -Up........................................................................................................ 61
9. Study  Assessments and Procedures ................................................................................... 62
9.1. Efficacy Assessments ................................................................................................... 62
9.1.1. Primary Efficacy  Assessments ............................................................................. 62
[IP_ADDRESS]. Severit y of Alopecia Tool  (SALT) Score ........................................................ 62
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 62
[IP_ADDRESS]. Alopecia Areata Patient -Reported Outcomes .................................................. 62
[IP_ADDRESS].1. Scalp Hai r Assessment PRO ™.................................................................62
[IP_ADDRESS].2. Other Patient Reported Outcomes for Appearance of 
Eyebrows, Appearance of Ey elashes, Ey e Irri tation, 
and Nail Appearance ................................................................................. 62
[IP_ADDRESS]. Other Clinician -Reported Outcomes for Ey ebrow Hai r 
Loss, Ey elash Hai r Loss, and Nail Appearance ............................................... 63
9.1.3. Health Outcom es and Qualit y-of-Life Measures ................................................... 63
[IP_ADDRESS]. Skindex -16 Adapted for Alopecia Areata ........................................................ 63
[IP_ADDRESS]. Medical Outcomes Study  36-Item Short -Form  Heal th 
Survey  Versi on 2 Acute .................................................................................. 63
[IP_ADDRESS]. EQ-5D-5L ...................................................................................................... 63
[IP_ADDRESS]. Hospi[INVESTIGATOR_469487] y and Depressio n Scale .......................................................... [ADDRESS_1227441] igator Global Assessment ................................................. 64
9.1.5. Appropriateness of Assessments .......................................................................... 64
9.2. Adverse Events ............................................................................................................ 64
9.2.1. Serious Adverse Events ........................................................................................ 65
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227442] ing.................................................................68
9.4.8. Hepati tis B Vi rus DNA Moni toring ...................................................................... 68
9.4.9. Venous Thromboembo lism Assessment ............................................................... 69
9.4.10. Safety Moni toring ................................................................................................ 69
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. [ADDRESS_1227443] ical Considerat ions........................................................................ 74
[IP_ADDRESS]. Analysis Methods ........................................................................................... 75
10.3.1 .2. Missing Data Imputation ................................................................................ 76
[IP_ADDRESS]. Multiple Com parisons/Mult iplicit y................................................................
.77
10.3.2. Treatment Group Comparabilit y........................................................................... 80
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 80
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 80
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 80
[IP_ADDRESS]. Treatment Compliance .................................................................................... 80
10.3.3. Efficacy Analyses ................................................................................................ 81
[IP_ADDRESS]. Primary Analyses ........................................................................................... 81
10.3.3 .2. Secondary  Analyses ........................................................................................ 81
I4V-MC-JAIR( d) Clinical Protocol Page 5
LY300910410.3.3.3. Exploratory  Analyses ..................................................................................... 81
10.3.4. Safety Analyses .................................................................................................... 81
10.3.5. Other Analyses ..................................................................................................... 82
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 82
10.3.6. Interim Analyses .................................................................................................. 82
[IP_ADDRESS] .Data Monitoring Committee ........................................................................... 82
[IP_ADDRESS]. Adjudicat ion Co mmittee ................................................................................. 83
[IP_ADDRESS]. Week 36 Primary  Outcom es Analyses and Other Interim 
Analyses ......................................................................................................... 83
11. References ........................................................................................................................ 84
12. Appendices ....................................................................................................................... 87
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227444] ....................... 59
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227445] of Figures
Figure Page
Figure JAIR.1. Illustrati on of  study  design for Clinical Protocol I4V-MC-JAIR. .................... 34
Figure JAIR.2. Graphical testing procedure for Clinical Protocol I4V- MC-JAIR. .................. 78
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227446] During Except ional 
Circumstances ............................................................................................. 106
Appendix 9. Protocol  Amendment I4V -MC-JAIR(d) Summary A Mult icenter, 
Randomized, Double -Blind, Pl acebo -Controlled, Phase 3 Study  to 
Evaluate the Efficacy and Safet y of Barici tinib in Adult Patients with
Severe or Very  Severe Alopecia Areata (BRAVE -AA2) .............................. 110
I4V-MC-JAIR( d) Clinical Protocol Page 9
LY30091041.Synopsis
Title of Study:
A Mult icenter, Randomized, Double -Blind, Pl acebo -Controlled, Phase 3 Study to Evaluate the 
Efficacy and Safet y of Barici tinib in Adult Pati ents wi th Severe or Very  Severe Al opecia Areata
Rationale: 
Although, in the past, alopecia areata (AA) has been considered by  [CONTACT_637614] a benign 
condi tion, severe AA is now recognized as a sign ificant m edical condit ion with emotional and 
psychosocial distress, including high prevalence of depression and anxiet y (Colón et al . 1991; 
Hunt and McHale 2005; Villasante Fricke and Miteva 2015).  Addit ionally , reducti on in healt h-
related quali ty of lifeexperienced by [CONTACT_878677] (Jankovi ćet al. 
2016; Liu et al. 2016; Rencz et al. 2016).  Alopecia areata can be reversible –either 
spontaneously or after various ty pes of  treatm ents, but resul ts are inconsistent (Islam et al. 2015) 
and there is currently no Food and Drug Administration (FDA) -approved treatm ent for AA. 
Baricitinib is an orally available, select ive inhibitor of Janus kinases (JAKs).  Janus kinases are a 
family o f tyrosine kinases that mediate cy tokine receptor signaling through phosphorylat ion and 
activat ion of signal transducers and act ivators of transcri ption (STAT) proteins.  There are 
4known JAK family members:  JAK1, JAK2, JAK3, and t yrosine kinase 2 (TYK2) (Clark et al. 
2014).  The relat ive affinit y of JAK inhibitors for different members of the JAK family  allows 
for different iation of JAK inhibitors in relat ion to their enzymat ic inhibitory profile.  In vitro 
assays indicate that baricit inib is a select ive inhibit or of JAKs wit h potency  and selectivit y for 
JAK1 and JAK2 and less potency  for JAK3 or TYK2 (Fridman et al. 2010).  
Dual  inhibit ion of JAK1 and JAK2, which may int errupt interferon gamma (IFN signaling and 
other inflammatory  pathways that contribute to the immunopathogenesis of AA, and clinical
evidence with other JAK inhibitors support the investigation o f baricit inib in the treatment of AA 
(Xing et al. 2014; Mackay -Wiggan et al. 2016; Craiglow et al. 2017; Liu et al. 2017; Jabbari 
etal. 2018; Liu and King 2018).  Results from the interim anal ysis o f the Phase 2 portion of the 
ongoing IV4- MC-JAHO ( JAHO )showed that the 2 -mg and 4 -mg baricit inib doses demonstrated 
numerical superi orityover placebo and the 1- mg dose in hairregrowth after 12 and 16 weeks of 
treatm ent wi th no new safet y signal.  This Phase 3, placebo -controlled study  will evaluate the 
efficacy  and safety  of baricit inib 2 -mg QD and 4 -mg QD for the treatment of severe (Severit y of 
Alopecia Tool [SALT] score of 50% -94%) and very severe AA (SALT score of 95% -100%).  
Lilly has init iated a clinical program to evaluate the efficacy and safet y of baricitinib in adult 
patients wi th severe (SALT score of 50% to94%) and very severe AA ( SALT score of 95% -
100%) of the scal p.
This clinical program currently co mprises 2 trials:
Study  JAHO is a double -blind, placebo -controlled ,adaptive Phase 2b/3 trial. In 
thePhase 2 dose -ranging portion of the study , 3 dose regimens were tested: 1- mg 
once daily  (QD), 2 -mg QD, and 4 -mg QD .  The results of the interim analysis o f the 
Phase 2 porti onconfirm edthe potenti al of baricitinib to restore hair growth and 
I4V-MC-JAIR( d) Clinical Protocol Page 10
LY3009104supported further evaluation o f the 2-mg QD and 4 -mg QD regimen in the Phase 3 
porti on of  the study . See Section 5.5(Justificat ion for dose) for more informat ion.
Study  I4V-MC-JAIR (JAIR) ,described in this protocol, is also a double -blind, 
placebo -controlled Phase [ADDRESS_1227447] ives for the 36 -week ,double -blinded ,placebo -controlled 
Treatment Period (Period 2).
During the long term  extensio n (Period 3), eligible patients will be able to participate in a 
rando mized downtitration.  The object ive of the rando mized downt itration is to evaluate the 
possibilit y of maintaining efficacy wit h a lower dose of baricit inib in eligible responder pati ents 
(SALT ≤20) .
Objective(s)/Endpoints:
Objectives Endpoints
Primary Objective 
These are pre -specified objectives that will be adjusted for multiplicity.
To test the hypothesis that the 4-mgdose or 2-mg
dose of baricitinib is superior to placebo in the 
treatment of patients with severe or very severe AAProportio nof patients achieving SALT ≤20atWeek 36
Key Secondary Objectives (Double –Blind, Placebo - Controlled Treatment Period)
These are pre -specified objectives that will be adjusted for multiplicity.
To compare the efficacy of baricitinib 4-mgdose or 
2-mg dose to placebo in AA during the 
double -blind, placebo -controlled treatment period as 
measured by [CONTACT_5936] -
assessed signs and 
symptoms of AAProportio nof patients achieving SALT ≤20at 
Weeks 16 and 24
Percent change from Baseline in SALT score at 
Week 36
Proportion of patients achieving SAL T50Week 12
Proportion of patients achieving  SALT 90 at Week 36
Proportion of patients achieving an absolute SALT ≤10at 
Weeks 24 and 36
Proportio n of patients achieving ClinRO Measure for 
EB Hair Loss 0 or 1 with ≥2-point improvement from 
Baseline at Week 36(among patients with ClinRO 
Measure for EB Hair Loss ≥2 at Baseline)
Proportio n of patients achieving ClinRO Measure for 
EL Hair Loss 0 or 1 with ≥2-point improvement from 
Baseline at Week 36(among patients with ClinRO 
Measure for EL Hair Loss ≥2 at Baseline)
To compare the efficacy of baricitinib 4-mgdose or 
2-mg dose to placebo in AA during the 
double -blind, placebo -controlled tre atment period as 
assessed by a PRO measureProportio n of patients with PRO for Scalp Hair 
Assessment score of 0 or 1 with a ≥ 2-point 
improvement from Baseline at Week 36 among patients 
with a score of ≥3 at Baseline
I4V-MC-JAIR( d) Clinical Protocol Page 11
LY3009104Objectives Endpoints
Other Secondary Objectives (Double –Blind, Placebo-Controlled Treatment Period)
These are pre -specified objectives that will NOT be adjusted for multiplicity .
To compare the efficacy of baricitinib 4-mgdose or 
2-mg dose to placebo in AA during the 
double -blind, placebo -controlled t reatment period as 
measured by [CONTACT_5936] -
assessed signs and 
symptoms of AAProportio n of patients achieving SALT 50at Weeks 16, 
24,and36
Proportion of patients achieving SALT 75at Weeks 24and 
36
Proportion of patients achieving SALT 90 at Week 24
Change f rom Baseline in SALT score at Weeks 12, 16, 
24, and 36
Percent change from Baseline in SALT score at Weeks 
12, 16, and 24
Time to achieve SALT ≤20
Proportio n of patients achieving SALT 100at Weeks 24 
and 36
Proportio n of patients achieving ClinRO Me asure for 
EB Hair Loss 0 or 1 with ≥2-point improvement from 
baseline at Week s 16 and 24 (among patients with 
ClinRO Measure for EB Hair Loss ≥2 at Baseline)
Proportio n of patients achieving ClinRO Measure for 
EL Hair Loss 0 or 1 with ≥2-point improvement from 
baseline at Week s 16 and24 (among patients with 
ClinRO Measure for EL Hair Loss ≥2 at Baseline)
To compare the efficacy of baricitinib 4-mgdose or 
2-mg dose to placebo in AA during the double -
blind, placebo -
controlled treatment period as 
assessed by [CONTACT_878678]Proportio n of patients with PRO for Scalp Hair 
Assessment score of 0 or 1 with a ≥2-point 
improvement from Baseline at Week s12 and 24 among 
patients with a score of ≥3 at Baseline
Proportio n of patients achieving PRO Measure for EB 0 
or 1 with ≥2-point improvement from baseline at 
Weeks 16, 24,and36(among patients with PRO
Measure for EB ≥2 at Baseline)
Proportio n of patients achieving PRO Measure for EL 0 
or 1with ≥2-point improvement from baseline at 
Weeks 16, 24,and36(among patients with PRO
Measure for EL ≥2 at Ba seline)
Mean change from Baseline at Weeks 24 and36
inSkindex -16 AA domain scores ( Symptoms, 
Emotio ns, Functioning)
Mean change from Baseline in HADS -
A and HADS -D 
total scores at Weeks 24 and 36  
I4V-MC-JAIR( d) Clinical Protocol Page 12
LY3009104Objectives Endpoints
Other Secondary (Patients entering Randomized Downtitration )
These are pre -specified objectives that will NOT be adjusted for multiplicity .
To compare the maintenance of efficacy for patients 
randomized to remain on 4-mgof baricitinib, 
compared with patients randomized to 2-mgof 
baricitinib at Week 52of the long -
term extension 
period, as measured by [CONTACT_5936] -assessed signs 
ofAAProportio n of patients maintaining SALT ≤20 at Weeks 
64, 76, 88, 104, 120, 136, 152, 168 , 184, and200
Proportio n of patients experiencing a loss of treatment 
benefit (>20 -point absolute worsening in SALT score) 
at Weeks 64 , 76, 88, 104, 120, 136, 152, 16 8, 184, and 
200
Time to loss of treatment benefit (>20 -point absolute 
worsening in SALT score)
For patients experiencing loss of treatment benefit 
after randomization to 2-mg of baricitinib at Week 
52:
To evaluate the recapture of efficacy for 
patients wh
o were retreated after experiencing a 
loss of treatment benefit during the long -term 
maintenance period as measured by [CONTACT_5936] -
assessed signs of AAProportio n of patients that achieve a SALT ≤20at
12,16, 24,and 36 weeks of retreatment with baricitini b
4-mg
Percent change in SALT score at 12, 16, 24 ,and 
36weeks of retreatment with baricitinib 4-mg
To evaluate the recapture of efficacy for 
patients who were retreated after experiencing a 
loss of treatment benefit during the long -term 
maintenance period as assessed by [CONTACT_878679]Proportio n of patients with a PRO for Scalp Hair 
Assessment score of 0 or 1 at12, 16, 24,and 36 weeks 
of retreatment with baricitinib 4-mg
Abbreviations:  AA= alopecia areata; ClinRO =clinician -reported outcome; EB= eyebrow; EL= eyelash;
HADS =Hospi[INVESTIGATOR_5620]; PRO = patient -reported outcome; SALT =Severity of Alopecia 
Tool; SALT 50= at least 50% improvement from Baseline in SALT score; SALT 75= at least 75% i mprovement 
from Baseline in SALT score; SALT 90= at least 90% improvement from Baseline in SALT score; 
SALT 100=100% improvement from Baseline in SALT score ;Skindex -16 AA = Skindex -16 Adapted for 
Alopecia Areata .
Summary of Study Design:   
Study  I4V-MC-JAIR(JAIR) is a Phase 3, mult icenter, randomized, double -blind, 
placebo -controlled, parallel -group study .  Efficacy and safet y of baricitinib 2-mg QD and 4 -mg 
QD will be co mpared to placebo in adult patients with severe (SALT score of 50% -94%) or v ery 
severe (SALT score of 95% -100%) scalp AA.  
Patients must have a current AA epi[INVESTIGATOR_878642] 6 months’ duration prior to screening (Visit 1),withat least 50% scal p invo lvement at 
screening AND Baseline (Visits 1 and 2) with no spontaneous improvem ent(no more than a 1 0-
point reduction in SALT) over the past [ADDRESS_1227448] 8years.   
The study  design is divided into 5periods :  a 5-week 
screening period, a 36- week double -blind, placebo -controlled treatmen t peri od, a 68 -week long -
term extensio n peri odthat includes a rando mized downtitration of baricit inib, a 96-week 
bridging extensio n, and a posttreatment fo llow-up peri od.
I4V-MC-JAIR( d) Clinical Protocol Page 13
LY3009104Approximately 476adult patients will  berando mized in a 2:2:3 ratio to receive plac ebo once 
daily  (QD), barici tinib 2-mgdose QD, or baricit inib 4-mgdose QD.  Patients will be stratified at
rando mizat ion by [CONTACT_1617] (North America , Asia, and Rest of World) and duration of 
current epi[INVESTIGATOR_878643] (less than 4years versus at least 4 years ).
Treatment Arms and Duration:   
At 
Baseline, pat ients will be rando mized in a 2:2:3 ratio to receive placebo QD, baricit inib 2-mg
dose QD, or baricit inib 4-mgdose QD for up to 200weeks.
Number of Patients:
Approximately  476participants will be enrolled, and approximately 678 patients will  be 
screened to achieve this enrollment.
Study Design :
The study  design includes 5periods:  a 5
-week screening period; a 36 -week double -blind, 
placebo -controlled treatment period; a 68 -week long-term extensio n peri od; a 96-week bridging 
extensio n
;and a posttreatment follow -up peri od.  
Period 1:  Screening period (Visit 1) is between 3 and 35 days prior to Visit 2 (Week 0). 
Period 2:  36-week double -blind, pl acebo -controlled treatment per iod is from Week 0 
(Baseline; Visit 2) to Week 36 ( Visit 8).
Period 3:  68 -week, long -term extensio n peri od with randomized wit hdrawal (for 
responders) is fro m Week 36 (Visit 8) to Week 104 (Visit 18).
Period 4:   Bridging Extensio n: from Week 104 (Visit 18) and up to Week 200 (Visit 
24).  Subj ects who have com pleted Week [ADDRESS_1227449] the possibilit y to remain in the trial for up to 9 6addit ional 
weeks (up to Week 200).
Period 5:  Posttreatm ent follow-up peri od; the posttreatment fo llow-up visit should occur 
approximately  [ADDRESS_1227450] (IP) (ie, 4weeks 
after Week 200(Visit 24) or the Early Terminat ion Visit [ET]). 
Note:  Patients who have discont inued IP prod uct but remain in the study for more than 
28days without IP will have an ET visit if they  choose to di scont inue early; however, a 
separate fo llow up visit (Vi sit 801) i s not requi red.  
Patients who have completed Week [ADDRESS_1227451] bey ond Week 200 do not need to complete Period 5 
(Visit 801).
At Week 36
Patients in the pl acebo treatm ent arm  who have not achieved a SALT ≤20at Week 36 
will be rescued to baricit inib and rando mized in a 1:1 ratio to baricit inib 2-mgdose or 
baricit inib 4-mgdose.
Patients in the pl acebo arm  who have achieved a SALT ≤20at Week [ADDRESS_1227452] experienced spontaneous regrowth will remain on 
I4V-MC-JAIR( d) Clinical Protocol Page 14
LY3009104placebo until Week 52, even if a relapse is observed between Week 36 and Week 52 
(refer to Week 52 for rescue of placebo patients who experience a loss of treatment 
benefit ).
All patients in the baricit inib treatment arms will continue in their current treatment 
group regardless of their treatment response at Week 36 (refer to Week 52 and Week 76 
sections below for addit ional rescue informat ion and discont inuat ion criteria).
At Week 52
Responders (SALT ≤20)
Patients in the 4-mgdose baricit inib treatment arm who achieve a SALT ≤20at Week 52 
(responders) are e ligible for randomized downtitratio n, provided that th ey have stayed on 
the sam e dose of baricit inib fro m initial randomizati on(Visit 2).
Patients who were rescued to baricit inib at Week 36 and patients rando mized to 2-mg
dose bari citinib will not be eligible for randomized downtitration and will remain in their 
same treatment group.
Eligible pat ientswill be autom atically randomized in a blinded manner by  [CONTACT_878680]-response system (IWRS) in a 1:1 rati o to ei ther stay  on thei r current 4-mgdose of 
baricit inib or transit ion to 2
-mgdose of baricit inib(randomized downti tration).
Patients in the pl acebo treatm ent arm  at Week [ADDRESS_1227453] achieved a SALT ≤20will 
remain on placebo.
Responders who experience a l oss of treatm ent benefit after Week 52(defined as 
>20-point absolute worsening in total SALT score) , and who :
owere randomized to 2- mgdose of baricit inibat Week 52 (rando mized 
downti tration), will be automat ically retreated with the 4-mgdose of baricitinib,
as rando mized at Baseline (Visit 2).
oremained on 
4-mgdose of baricit inib at Week 52 (rando mized downtitration), will 
continue to receive the same dose of baricit inib.
owere randomized to 
2-mgdose at Baseline (Visit 2), will be rescued to 4-mgdose.
ohad remained on placebo since Baseline (Visi t 2), will be rescued to bari citinib 
2-mg.
Note :  An unscheduled visit may be used to assess the patient who reports a loss of treatment 
benefit (see SOA [Section 2] for detailed requirements) .
I4V-MC-JAIR( d) Clinical Protocol Page 15
LY3009104Nonresponders (SALT   >20)
Patients who have been in the baricit inib 4-mgdose treatment group from Baseline AND 
have never achieved a SALT ≤20by [CONTACT_10585] [ADDRESS_1227454] a ≥2-point improvement 
from Baseline in clinician -reported outcom e(ClinRO) measure for ey ebrow or eyelash 
hair l oss at Week 52will be autom atically transit ioned to pl acebo.
Patients who have been in the baricit inib 4-mgdose t reatment group and have achieved 
aSALT ≤20before Week [ADDRESS_1227455] response, will remain on baricit inib 4-mg
dose.
Those who have been in the baricit inib 2-mg dose treatm ent group from  Baseline will be 
rescued to baricit inib 4-mgdose.
Those who were rescued to baricit inib at Week 36, will cont inue in their current 
treatm ent arm  at Week 52.
Those who were randomized to placebo at Baseline and were not eligible for rescue to 
baricit inib at Week 36 (spontaneous remissio n) will be rescued to baricit inib 2-mg. 
Note: Invest igators should consider discont inuing patients who do not present any 
improvement of AA lesio ns by [CONTACT_10585] 64 (Visit 14 ).
At Week 76
Patients who are nonresponders (SALT >20 )at Weeks [ADDRESS_1227456] a ≥
2-point improvement fro m 
Baseline in ClinRO measure for ey ebrow or ey elash hai r loss.
Statistical Analysis:
Unless otherwise specified, the efficacy and h ealth outcom e analyses o f the study  will be 
conducted on the Full Analysis Set (FAS) or other popul ations described in the 
statistical 
analysis plan ( SAP).  Safet y analyses will be conducted on safet y popul ation. 
Treatment comparisons of discrete efficacy variables will be made using a logistic regressio n 
analysis as primary analysis wit h geographic regio n, durati on of  current epi[INVESTIGATOR_878643] 
(<4years vs ≥4years), baseline value, and treatment group in the model unless, otherwise, 
stated.  Inthe cas e when logistic regressio n model does not produce statist ical results due to 
sparse data, Fisher exact test will be used .  The proporti ons and 95% confidence intervals (CIs) 
will be reported.  Patients will be generally considered nonresponders for the non responder 
imputati on-(NRI -) based analysis if they do not meet clinical response criteria or if they 
discontinued study  or study treatm ent at any  time pri or to the time po int of interest for any  
reason.  Addit ional analyses may be performed and will be de scribed in detail in the SAP for 
patients who discont inued the study and for patients missing measurements prior to a fixed time 
point. 
Treatment comparisons of continuous efficacy and healt h outcome variables will be made using 
analysis of covariance (A NCOVA) wi th geographic regi on, durati on of  current epi [INVESTIGATOR_878644] (<4 y ears vs ≥4 years), treatm ent group, and baseline value in the model ,unless 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227457] error, p -value, and 95% CI may also be 
reported. Addit ional efficacy or safet y interim analyses may  be perform ed prior to final data base 
lock (F -DBL) to support regulatory  submissi on and will be described in detai l in the SAP.
Time -to-event analysis will be done and analyzed using log -rank test.  A Cox proportional 
hazards model may  be used wi th treatm ent and other stratificat ion vari ables in the m odel.  
Hazard rati o with CIs m ay be reported.  Kaplan -Meier curves will also be produced.  Diagnostic 
tests for checking the validit y of the proporti onal hazards assumpt ion may be perform ed and 
these would be described in detail in the SAP.  If the assumption o f proporti onal hazards is not 
justified, nonproportionalit y may be modeled by [CONTACT_513460].
Fisher exact test will be used for all adverse events, discontinuat ion, and other categorical safet y 
data.  Continuous vital signs and laboratory  values will be analyzed by [CONTACT_376901] 
(ANCOVA) wit h treatment and B aseline values in the model.  
I4V-MC-JAIR( d) Clinical Protocol Page 17
LY30091042.Schedule of A ctivities
The Schedule o f Activities described below should be fo llowed for all participants enrolled in
Study  I4V-MC-JAIR (JAIR) .  In the event participation in this study  is affected by  [CONTACT_878681] (such as pandemics or natural disasters), please refer to Appendix 8and consult 
with thesponsor’s representative for addit ional guidance.
I4V-MC-JAIR( d) Clinical Protocol Page 18
LY3009104Table JAIR.1. Schedule of A ctivities
Screeni
ngDouble -Blind Treatment Period Long -Term ExtensionBridging ExtensionPTFU
Period 
1Period 2 (36 weeks) Period 3 (68 weeks)Period 4 (96 weeks) Period 
5
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24/ET UVa801b
Weeks from 
Randomization0 4 8 12 16 24 36 40 44 52 56 60 64 68 76 8810
4120 136 152 168 184 200Period 
2 to 4
Visit tolerance 
interval (days)-3 to
-35±4 ±4 ±4 ±4 ±7 ±7 ±4 ±4 ±7 ±4 ±4 ±4 ±4 ±7 ±7 ±7 ±10 ±10 ±10 ±10 ±10 ±10 28 ±4
Inclusion and 
Exclusion 
Review X X
Informed consent X
Randomization X XcXc
Clinical 
Assessments
Demographics X
Preexisting 
Conditions/Medic
al HistoryX
MPHL/FPHL 
Historyd X
Substance Use 
(alcohol, tobacco)X
Previous and 
Current AA 
TreatmentsX
Chest x- ray
(posterior -
anterior view)eX
TB testfX
Read [COMPANY_003] if 
applicable 
(48-72 hours after 
V1)gX
Physical 
ExaminationX
12-lead ECG 
(single, local)X
I4V-MC-JAIR( d) Clinical Protocol Page 19
LY3009104Screeni
ngDouble -Blind Treatment Period Long -Term ExtensionBridging ExtensionPTFU
Period 
1Period 2 (36 weeks) Period 3 (68 weeks)Period 4 (96 weeks) Period 
5
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24/ET UVa801b
Weeks from 
Randomization0 4 8 12 16 24 36 40 44 52 56 60 64 68 76 8810
4120 136 152 168 184 200Period 
2 to 4
Visit tolerance 
interval (days)-3 to
-35±4 ±4 ±4 ±4 ±7 ±7 ±4 ±4 ±7 ±4 ±4 ±4 ±4 ±7 ±7 ±7 ±10 ±10 ±10 ±10 ±10 ±10 28 ±4
Height X
Weight X X X X X X X X X X X X X X X X X X X X X X X X X
BMI X X
Vital signs (BP 
and Pulse)X X X X X X X X X X X X X X X X X X X X X X X X X
Symptom -
directed Physical 
ExamhX X X X X X X X X X X X X X X X X X X X X X X X X
MPHL/FPHL 
assessmentd X X X X
Adverse Events X X X X X X X X X X X X X X X X X X X X X X X X X
Concomitant 
MedicationX X X X X X X X X X X X X X X X X X X X X X X X X X
IWRS X X X X X X X X X X X X X X X X X X X X X X X X X X
IP dispensed X X X X X X X X X X X X X X X X X X X X X X X
IP returned and 
compliance 
assessed X X X X X X X X X X X X X X X X X X X X X X X
Scales/Questionn
aires
SALT (AA -
IGA)™ i X X X X X X X X X X X X X X X X X X X X X X X X X X
Hamilton -
Norwood Scaled X X X X X
ClinRO Measure 
for Eyebrow Hair 
Loss™X X X X X X X X X X X X X X X X X X X X X X X X
ClinRO Measure 
for Eyelash Hair 
Loss™X X X X X X X X X X X X X X X X X X X X X X X X
I4V-MC-JAIR( d) Clinical Protocol Page 20
LY3009104Screeni
ngDouble -Blind Treatment Period Long -Term ExtensionBridging ExtensionPTFU
Period 
1Period 2 (36 weeks) Period 3 (68 weeks)Period 4 (96 weeks) Period 
5
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24/ET UVa801b
Weeks from 
Randomization0 4 8 12 16 24 36 40 44 52 56 60 64 68 76 8810
4120 136 152 168 184 200Period 
2 to 4
Visit tolerance 
interval (days)-3 to
-35±4 ±4 ±4 ±4 ±7 ±7 ±4 ±4 ±7 ±4 ±4 ±4 ±4 ±7 ±7 ±7 ±10 ±10 ±10 ±10 ±10 ±10 28 ±4
ClinRO Measure 
for Nail 
Appearance™X X X X X X X X X X X X X X X X X X X X X X X X
PRO for Scalp 
Hair 
Assessment™X X X X X X X X X X X X X X X X X X X X X X X X X
PRO Measure for 
Eyebrows™X X X X X X X X X X X X X X X X X X X X X X X X
PRO Measure for 
Eyelashes™X X X X X X X X X X X X X X X X X X X X X X X X
PRO Measure for 
Eye Irritation™ X X X X X X X X X X X X X X X X X X X X X X X X
PRO Measure for 
Nail 
Appearance™X X X X X X X X X X X X X X X X X X X X X X X X
EQ-5D-5L X X X X X X X X X X
SF-36 X X X X X X X X X X
Skindex -16 
Adapted for AAX X X X X X X X X X
HADS X X X X X X X X X X
C-SSRS and Self -
Harm 
SupplementjX X X X X X X X X X X X X X X X X X X X X X X X X
Self-Harm 
Follow -up Formk X X X X X X X X X X X X X X X X X X X X X X X X X
Laboratory 
Assessment
Lipi[INVESTIGATOR_805] (Fasting 
Visit)l X X X X X X X X X X X X X X X
Clinical 
Chemistrym X X X X X X X X X X X X X X X X X X X X X X X
Hematology X X X X X X X X X X X X X X X X X X X X X X X
I4V-MC-JAIR( d) Clinical Protocol Page 21
LY3009104Screeni
ngDouble -Blind Treatment Period Long -Term ExtensionBridging ExtensionPTFU
Period 
1Period 2 (36 weeks) Period 3 (68 weeks)Period 4 (96 weeks) Period 
5
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24/ET UVa801b
Weeks from 
Randomization0 4 8 12 16 24 36 40 44 52 56 60 64 68 76 8810
4120 136 152 168 184 200Period 
2 to 4
Visit tolerance 
interval (days)-3 to
-35±4 ±4 ±4 ±4 ±7 ±7 ±4 ±4 ±7 ±4 ±4 ±4 ±4 ±7 ±7 ±7 ±10 ±10 ±10 ±10 ±10 ±10 28 ±4
Serum Pregnancy 
Testn X
FSHoX
TSH X
HIV X
HCV antibody 
testingp X
HBV testingqX
HBV DNAqX X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X X X X
Urine Pregnancy 
Testn X X X X X X X X X X X X X X X X X X X X X X X X
Pharmacogenetics
:  bloodX
Serum 
immunoglobulin 
(IgE)X X X X
Exploratory 
storage samples 
(serum, plasma)X X X X X X X X X X
RNA and 
biomarkers:  
bloodX X X X X X X X X X
I4V-MC-JAIR( d) Clinical Protocol Page 22
LY3009104Abbreviations:  AA= alopecia areata; AA-IGA = Alopecia Areata Investigator Global Assessment; AGA = androgenetic alopecia ; BMI = body mass index; 
BP=blood pressure; CKD -EPI = Chronic Kidney Disease Epi[INVESTIGATOR_10444]; ClinRO = clinician -reported outcome; C-SSRS = Columbia Suicide 
Severity  Rating Scale; DNA = deoxyribonucleic acid; ECG = elec trocardiogram; eGFR = estimated glom erular filtration rate; ET= early termination; EQ-
5D-5L = European Quality of Life –5 Dimensions –5 Level ;FPHL =female pattern hair loss; FSH = follicle -stimulating hormone; HBcAb = hepatitis B 
core antibody; HBsAb = hepatitis B surface antibody; HADS = Hospi[INVESTIGATOR_122140]; HBV = hepatitis B virus; HCV = hepatitis C virus; 
HIV =human immunodeficiency virus; IgE=immunoglobulin E ;IP= investigational product; IWRS = interactive web-response syste m; MPHL = male 
pattern hair loss; [COMPANY_003] = purified protein derivative; PRO = patient -reported outcome; PTFU = posttreatment follow -up; RNA =ribonucleic acid; 
SALT =Severity of Alopecia Tool; SF-36 = Short Form -36 Health Survey acute version 2; TB= tubercu losis; TSH =thyroid-stimulating hormone ; 
UV=unscheduled visit; V = Visit .
aOnly applicable to patients who experience a loss of treatment benefit after Week 52 if no scheduled visit available (SALT assessment required to confirm
loss of treatment benefit) (see Section 5.1.3 ). Not applicable to unscheduled visits conducted for other reasons.
bVisit 801 (Posttreatment Follow -Up Period) occurs approximately [ADDRESS_1227458] beyond Week 200 do not need to complete Period 5.
cSee Section 5.1.3 for details on t he randomization of placebo non -responders at Week 36 and of eligible baricitinib 4-mg responders at Week 52.
dPresence of MPHL (AGA) will be assessed at screening ,using the Hamilton -
Norwood Scales for male patients, through examination, and via patient 
interview; these will be re -eval uated at Weeks 36, 52, 104, and 200/ET.  Presence of FPHL (AGA) will be assessed at Weeks 36, 52 ,104, and 200/ET for 
female patients whose history of AGA is “no history” or unknown at screening .  
eA posterior –anterior view chest x -ray will be obtained locally at Screening (Visit 1), unless one has been performed in the past 6 months and the x -ray and/o r 
the report is available.
fTB test(s) including [COMPANY_003], QuantiFERON® -
TB Gold, and T SPOT® .TB.  See Exclusion Criterion [ 27] for description of TB testing. In countries where the 
QuantiFERON -
TB Gold test or T -SPOT is available, either test may be used instead of the [COMPANY_003] TB test.  It is preferred that the QuantiFERON -TB Gold test 
be performed centrally; the T -SPOT must be performed locally.  Note :  Patients with a history of active or latent TB who have documented evidence of 
appropriate treatment, have no history of re -exposure since their treatment was completed, and have a screening chest x -ray with no evidence of active TB 
may be enrolled if other entry c riteria are met.  Such patients would not be required to undergo the protocol -specific TB testing ,but must have a chest x -ray at 
screening.
gIf [COMPANY_003] testing was chosen to test for TB, then the patient must return and have the [COMPANY_003] test read 48 to 72 hours after Visit 1 (post -[COMPANY_003]) .
hThe symptom -directed physical examination may be repeated at the investigator’s discretion any time a patient presents with physical comp laints.
iAA-IGA will be automatically derived from the SALT scores.
jA “Baseline/Screeni ng” form is used at Visit 1. A “Since Last Visit” form used for all remaining visits.  A suicidal ideation and behavior subscales excerpt is
adapted for the assessment of 11 preferred ideation and behavior categories.
kThe Self -Harm Follow -Up Form is o nly required if triggered by [CONTACT_47584] -Harm Supplement Form .
lFasting lipid profile:  patients should not eat or drink anything except water for [ADDRESS_1227459] fasting lipi[INVESTIGATOR_487019].
mClinical chemistry will include the following value calculated from serum creatinine: eGFR (
calculated using the CKD -EPI c reatinine 2009 equation).
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227460] (central laboratory) will be performed at Visit 1.  Urine pregnancy tests (local laboratory) will 
be performed at Visit 2 and a t all subsequent study visits.  If required per local regulations and/or institutional guidelines, pregnancy testing can occu r at other 
times during the study treatment period.
oFor female patients ≥40 and <[ADDRESS_1227461] will be performed to confirm 
nonchildbearing potential (FSH ≥40 mIU/mL).
pFor patients who are positive for HCV antibody, a follow -up test for HCV RNA will be performed automatically.  Patients who are positive for HCV antibody 
and negative for HCV RNA may be enrolled.
qPatients who are positive for HBcAb and negative for HBV DNA may be enrolled.  Any enrolled patient who is HBcAb positive, re gardless of HBsAb status 
or level, must undergo HBV DNA testing per the sc hedule.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227462] , alopecia areata ( AA) has been considered by [CONTACT_878682] a benign 
condi tion, severe AA is now recognized as a significant medical condi tion wi th emotional and 
psychosocial distr ess,including high prevalence of depression and anxiet y (Colon et al . 1991 ; 
Hunt and McHale 2005 ; Villasan te Fri cke and Miteva 2015 ).  Addit ionally , reduct ion inhealth-
related quali ty of life experienced by [CONTACT_878677] ( Jankovićet al. 
2016; Liu et al . 2016 ;Rencz et al. 2016). Alopecia areata can be reversible ,either spontaneously 
or after various types o ftreatm ents, but resul ts are inconsistent (Islam et al. 2015 )and there is 
currently no Food and Drug Administration ( FDA )-approved treatment for AA. 
Baricitinib is an orally available, select ive inhibitor of Janus kinases (JAKs).  Janus kinases are a 
family o f tyrosine kinases that mediate cy tokine receptor signaling through phosphorylat ion and 
activat ion of signal tran sducers and act ivators of transcript ion (STAT) proteins.  There are 
4known JAK family members :  JAK1, JAK2, JAK3, and t yrosine kinase 2 (TYK2 ) (Clark 
etal.2014).  The relat ive affinit y of JAK inhibitors for different members of the JAK family 
allows for different iation of JAK inhibitors in relatio n to thei r enzymat ic inhibitory  profile.  In 
vitro assays indicate that baricitinib is a select ive inhibitor of JAKs with potency and select ivity 
for JAK1 and JAK 2 and less potency  for JAK3 or TYK2 (Fridman et a l. 2010).   
Dual  inhibit ion of JAK1 and JAK2, which may int errupt interferon gamma (IFN signaling and 
other inflammatory  pathways that contribute to the immunopathogenesis of AA, and clinical 
evidence with other JAK inhibitors support the investigation o f baricit inib in the treatment of AA 
(Xing et al. 2014 ;Mackay -Wiggan et al. 2016 ; Craigl ow et al . 2017 ; Liu et al . 2017 ; Jabbari 
etal. 2018 ; Liu and King 2018) . Results from the interim analysis o f the Phase 2 portion of the 
ongoing IV4- MC-JAHO ( JAHO ) showed that the 2 -mg and 4 -mg baricit inib doses demonstrated 
numerical superi ority over placebo and the 1- mg dose , in hair regrowth, after 12 and 16 weeks of 
treatm ent wi th no new safet y signal.
Lilly has init iated a clinical program to evaluate the efficacy and safet y of baricitinib in adult 
patients wi th severe ( Severit y of Alopecia Tool [SALT] score of 50%- 94%) and very  severe AA 
(SALT score of 95% -100%) of the scalp.
This clinical program curr ently co mprises 2 trials:
Study  JAHO is a double -blind, placebo -controlled adaptive Phase 2b/3 trial . In the Phase 
2 dose -ranging portion of the study , 3dose regimens were tested: 1-mg once daily (QD), 
2-mg QD, and 4 -mg QD .  The results of the interim analysis o f the Phase 2 portion 
confirmedthe potential  of baricit inib to restore hair growth and supported further 
evaluat ion of the 2- mg QD and 4 -mg QD regimen in the Phase 3 portion of the study .
See Secti on 5.5(Justificat ion for Dose ) for more informat ion.
Study  I4V-MC-JAIR (JAIR) ,described in this protocol , is also a double -blind, 
placebo -controlled Phase 3 trial and will evaluate the same doses regimens .
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227463] ives for the 36 -week ,double -blinded ,placebo -controlled 
Treatment Period (Perio d 2).
During the l ong-term extensio n (Peri od3), eligible  patients will be able to participate in a 
rando mized downtitration.  The object ive of the rando mized downt itration is to evaluate the 
possibilit y of maintaining efficacy wit h a lower dose of baricit inib in eligible responder pati ents 
(SALT ≤20)
.
3.2. Backgroun d
Alopecia areata is an autoimmune disease usually  characterized by  [CONTACT_878683] , face,and body ,with a lifet ime prevalence of approximately 2 % 
(Wasserman et al. 2007; Islam  et al . 2015 ;Korta et al. 2018).  The extent of hair lossin this 
condi tion can vary, including total hair loss on the scalp and loss of facial and/or other body  hair 
(Islam et al . 2015).  Alopecia areata can affect children, a dolescents, and adults (Hordinsky  and 
Donati  2014).  
Alopecia areata is one of the more commo n autoimmune diseases, and its visible phenoty pic 
characterist ic hair l oss and l ack of  FDA -approved treatm ents provi de a unique opportuni ty for 
novel treatment ap proaches with a d rug wi th immune m odulatory  effects such as baricit inib.  
Clinical manifestations of AA (hair loss and nail effects )may be constant or sporadic and can 
affect different areas of the scalp , face, or body at different times during life ,or cause hair loss in 
the ent ire scalp or the ent ire body  at once (Ol sen 2011).  As an autoimmune disease in which the 
patient’s own T cells produce cy tokines that inhibit hair fo llicle growth, AA may present as 
patchy  AA, wi th parti al hai r loss in one or m ultiple well -circumscribed round patches in the 
scalp (or other hair -bearing site) , or it can progress to hair loss involving the ent ire scalp 
(alopeci a areata totalis [AT]), or extend to complete hair loss of head and body  (alopecia areata 
universalis [AU]) (Olsen et al. 1999, 2004).  Patchy alopecia, AT, and AU are considered part of 
the clinical spectrum o f the sam e disease (Hordinsky  and Junqueira 2015).  A lopecia areata can 
cause significant emotional and psychosocial distress (Hunt and McHale 2005).  A 66% to 74% 
lifetime prevalence o f psychiatric disorders has been reported in patients with AA, with a 38% to 
39% lifet ime prevalence of depressio n and a 39% to 62% preval ence of generalized anxiet y 
disorder (Col on et al . 1991 ; Villasante Fricke and Miteva 2015).  Qualit y of life is also 
consistent ly diminished in patients with AA (Janković et al. 2016 ; Liu et al. 2016; Rencz et al . 
2016).  The Global Burden of Disease Study (GBD) determin ed the burden of AA to be a m ean 
of 19.[ADDRESS_1227464] (Karimkhani et al. 2015).  However, th isGBD study  did not 
account for other potential harms ,such as emot ional distress and financial impact (Karimkhani 
etal. 2015).
Insights into the immunopathogenesis of AA began wi th the recogni tion of the hair follicle as being 
an immune -privileged si te like the eye and testes (Paus et al . 2005).  Next, disrupti on of  this immune 
privilege occurs upon follicular influx by [CONTACT_331437] -reactive CD8+ T cells, leading to increases in maj or 
histocompat ibility complex (MHC) class I and II antigens and inflammati on disrupt ing hair fo llicle 
I4V-MC-JAIR( d) Clinical Protocol Page 26
LY3009104biology (Islam etal. 2015; Strazzulla et al . 2018).  Activati on of  the pat hogenic T cells leads to IFN 
producti on,which contributes both to enhanced MHC class I and II antigens and interleukin (IL)-15 
(Islam  et al. 2015; Strazzul la et al . 2018) accom panied by [CONTACT_878684] -2, IL-13, 
IL-23, and thymic strom al lymphopoi etin(Suárez -Fariñas et al.2015).  All of these inflammatory -
related cy tokines are dependent on JAK/STAT signaling, and of particular note IFN utilizes 
JAK1 and JAK2.  Animal models support the theory  of AA in which autoreactive T cells 
(NKG2D+) drive the hair loss by  [CONTACT_30212] I FNand inflammatory  gene expressio n signatures 
as noted above, which could be reversed using JAK inhibit ion in mice (Xing et al. 2014).  
There are currently no FDA -approved treatm ents for AA.  While not all patients with AA are 
likely  to requi re treatm ent because AA is often mild and intermittent (Tan et al. 2002; 
Wasserman et al. 2007), for pati ents wi th severe and persistent disease, safe and efficacious 
treatm ents are l acking. Use of a JAK 1/JAK 2 inhibitor such as baricit inib may reinit iate
producti on of  mature terminally  differentiated follicl es at si tes of  prior inflammat ion.  
3.3. Benefit/Risk Assessment
Several retrospective case series, case reports, and open -label studi es have been published 
describing posit ive outcomes in patients with severe (SALT score of 50% -94%) or very  severe 
AA(SALT score of 95% -100%) treated with different JAK inhibitors for 4 to 18 months. In 
these reports , more than one -half o f patients experienced hair regrowth of 50% or more after 
beginning treatment with a JAK inhibitor (Xing et al. 2014; Mackay -Wiggan et al . 2016 ; 
Craiglow et al . 2017 ; Liu et al . 2017 ; Jabbari et al. 2018 ; Liu and King 2018), including 
baricit inib (Jabbari et al. 2015).  A 66- patient, open -label study  reported that approximately 
one
-third of  patients achieved hair regrowth of >50% after treatment with tofacit inib; however, 
these patients were treated with a JAK inhibitor for only 3 months ( Kennedy  Crispin et al . 2016 ).
Results fro m the interim analysis o f the Phase 2 porti on of  the ongoing JAHOstudy  showed that 
the 2-mg and 4 -mg baricit inib doses demo nstrated numerical superi ority over placebo and the 
1-mg dose in hair regrowth after 12 (SALT 30) and 16 (SALT 5 0) weeks of treatment with no new 
safet y signal.   These results have been confirmed at the [ADDRESS_1227465] ically significant ly superior to placebo forthe primary  endpoint (SALT score ≤20) after 
36weeks of treatment.
Serious infect ions, venous thromboembo lic events ( VTEs ), hepatotoxicit y, and f etal 
malform ations were i dentified as important potential risks with baricit inib in RA studies.  
Although infect ions were seen in approximately one -half o f the study  populati on exposed to 
baricit inib in the RA program ,
only 3.6% of patients reported a serious treatment- emergent 
infect ion, and rates were similar in both baricit inib-and placebo -treated patients.  In the Phase 2 
atopi c dermati tis (AD) study , approximately 25% of pa tientstreated wi th the 4 -mg dose 
experienced a treatment -emergent adverse event (TEAE ) of infect ion and infestation, compared 
to 20% of patients treated with placebo.  There were no serious infect ions, opportunist ic 
infect ions,or herpes zoster infect ionsreported during the treatment period in the ADPhase 2 
study .There was no serious event reported at the time of the second interim analysis o f the 
Phase 2 portion of Study JAHO after 36 weeks of treatment .The nonserious infections for 
I4V-MC-JAIR( d) Clinical Protocol Page 27
LY3009104baricit inib noted i n the RA program (upper respi[INVESTIGATOR_81628], herpes zoster, herpes 
simplex) are readily  diagnosed andmanageable ,and ty pi[INVESTIGATOR_878645] l ong-term 
sequelae.   
It is recommended that, where indicated, herpes zoster vaccinat ion be offer ed to 
patients before receiving baricit inib; herpes zoster infect ions, when they have occurred, have 
generally been mild -to-moderate, localized, and without long -term problems. Exclusion criteria 
have been added to th isprotocol  to limi t enrol lment of pat ients who are at increased risk for
infect ion.
Cases of hepatotoxicit y have not been ident ified wit h baricit inib use, but increases in alanine 
aminotransferase ( ALT ), aspartate aminotransferase ( AST ), and total bilirubin (TBL) have been 
seen in RA pat ients.  Most of these increases improved with continued use or temporary 
discontinuat ion of baricit inib wit h no l ong-term effects .  Excl usion criteria to not enrol lpatients 
with liver failure or increased liver analytes, appropriate monitoring o f hepat ic analy tes and 
discontinuat ion criteria have been included in the protocol .  
In toxi cology studi es, fetal  malformat ions were reported at doses higher than what is used in 
human pat ients.  Only  a small number of pati ents have beco me pregnant in baricit inib clinic al 
trials, and there have been no reports of fetal malfo rmations in these pregnancies.  In current 
study  protocol s, pregnant patients are excluded from entry , contraceptive use is defined in the 
inclusio n criteria, and pati ents who becom e pregnant are di scontinued fro m the trial.
Venous thromboembo lic events have been determined to be an important potential risk for 
baricit inib. There was a numerical imbalance in reports of VTEs in the 24-week, placebo -
control led period of the Phase 3 trials o f patients with RA .  Available evidence does not establish 
a causal associat ion.  
The exposure -adjusted incidence rate of VTE for bari citinib-treated RA 
patients over l ong-term exposures was similar to the background rates published in the literature 
for the target p opulation
(ie,RA).  There was no pattern of increased or decreased risk during
long-term exposures, and cases observed with baricit inib were confounded by 1 ormore 
recogni zedrisk factors for a VTE (eg,history  of VTE, increased body  mass index [ BMI ], older 
age). Venous thromboembo lic event risk can be managed through risk mit igation strategi es.  
Exclusio n and di scontinuati on criteria have been added to the protocol to limit participat ion of 
patients who are at increased risk forVTE . Patients will be excluded if they  have a previ ous 
history  of a VTE, or have a combinat ion of 2or more risk factors for a VTE (eg ,increased BMI, 
older age, combinat ion use of oral contraceptive wit h smoking ).  History  of a previ ous VTE is 
the strongest risk factor for deve lopment of  a second VTE, and the exist ing exclusio n criteria for 
patients wi th previ ous history  ofaVTE will also serve to exclude pat ients with other ri sk factors.
Presymptom atic screening for hypercoagulable condit ionsis not currently reco mmended, even in 
the prescribing informat ion for medicati ons wi th known increased risk for VTEs.   Although 
temporary  interrupti on of  invest igational product (IP) is not a requirement at times o f increased 
potenti al risk forVTE ( eg, surgery , significant ai r travel , or other si tuations invo lving prolonged 
immo bilization) ,we recommend fo llowing appropri ate VTE prophylaxis guidelines to hel p 
manage the VTE risk under these circumstances.
I4V-MC-JAIR( d) Clinical Protocol Page 28
LY3009104There was no VTE reported at the time of the secon d interim  analysis o f the Phase 2 portion of 
Study  JAHO after 36 weeks of treatment.
Therefore, in the context of the cumulat ive knowledge, the benefit/risk balance for baricit inib for 
the treatment of adult patients with severe and very severe AAis asses sed to be favorable.
More detailed informat ion about the known and expected benefits, risks, serious adverse events 
(SAEs), and reasonably ant icipated adverse events (AEs) of baricit inib are to be found in the 
Invest igator’s Brochure (IB).
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227466] the hypothesis that the 4-mgdose or 2-mg
dose of baricitinib is superior to placebo in the 
treatment of patients with severe or very severe 
AAProportio nof patients achieving SALT ≤20 at Week 36
Key Secondary Objectives (Double –Blind, Placebo - Controlled Treatment Period)
These are pre -specified objectives that will be adjusted for multiplicity.
To compare the efficacy of baricitinib 4-mgdose 
or 
2-mgdose to placebo in AA during the 
double -blind, pl acebo -controlled treatment period 
as measured by [CONTACT_5936] -assessed signs and 
symptoms of AAProportio nof patients achieving SALT ≤20at Weeks 16 
and 24
Percent change from Baseline in SALT score at Week 36
Proportion of patients achieving SAL T50 at Week 12
Proportion of patients achieving SALT 90at Week 36
Proportion of patients achieving an absolute SALT ≤10at 
Weeks 24 and 36
Proportio n of patients achieving ClinRO Measure for EB 
Hair Loss 0 or 1 with ≥2-point improvement from 
Baseline atWeek 36(among patients with ClinRO 
Measure f or EB Hair Loss ≥2 at Baseline)
Proportio n of patients achieving ClinRO Measure for EL 
Hair Loss 0 or 1 with ≥2-point improvement from 
Baseline at Week 36(among patients with ClinRO 
Measure for EL Hair Loss ≥2 at Base line)
To compare the efficacy of baricitinib 4-mgdose 
or 
2-mgdose to placebo in AA during the 
double -blind, placebo -controlled treatment period 
as assessed by a PRO measureProportio n of patients with PRO for Scalp Hair 
Assessment score of 0 or 1 with a ≥2 point improvement 
from Baseline at Week 36among patients with a score of 
≥3 at Baseline
I4V-MC-JAIR( d) Clinical Protocol Page 30
LY3009104Objectives Endpoints
Other Secondary Objectives (Double –Blind, Placebo-Controlled Treatment Period)
These are pre -specified objectives that will NOT be adjusted for multiplicity.
To compare the efficacy of baricitinib 4-mgdose 
or 
2-mgdose to placebo in AA during the 
double -blind, placebo -controlled treatment period 
as measured by [CONTACT_5936] -assessed signs and 
symptoms of AAProportio n of patients achieving SALT 50at Weeks 16, 
24,and 36
Proportion of patients achieving SALT 75at Weeks 24and 
36
Proportion of patients achieving a SALT 90 at Week 24
C
hange f rom Baseline in SALT score at Weeks 12, 16, 
24, and 36
Percent change from Baseline in SALT score at Weeks 
12, 16,and24
Time to achieve SALT ≤20
Proportio n of patients achieving SALT 100at Weeks 24 
and 36
Proportio n of patients achieving ClinRO Measure for EB 
Hair Loss 0 or 1 with ≥2-
point improvement from 
baseline at Week s 16 and 24 (among patients with 
ClinRO Measure f or EB Ha ir Loss ≥2 at Baseline)
Proportio n of patients achieving ClinRO Measure for EL 
Hair Loss 0 or 1 with ≥2-point improvement from 
baseline at Week 16 and 24,(among patients with 
ClinRO Measure f or EL Hair Loss ≥2 at Baseline)
To compare the efficacy of baricitinib 4-mgdose 
or 
2-mgdose to placebo in AA during the double -
blind, placebo -controlled treatment period as 
assessed by [CONTACT_878685]Proportio nof patients with PRO for Scalp Hair 
Assessment scor e of 0 or 1 with a ≥2-point improvement 
from Baseline at Week s 12 and 24 among patients with a 
score of ≥3 at Baseline
Proportio n of patients achieving PRO Measure for EB 0 
or 1 with ≥2-point improvement from baseline at Weeks 
16, 24, and 36(among patien ts with PRO Measure for 
EB ≥2 at Baseline)
Proportio n of patients achieving PRO Measure for EL 0 
or 1 with ≥2-point improvement from baseline at Weeks 
16, 24, and 36(among patients with PRO Measure for 
EL ≥2 at Baseline)
Mean change from Baseline at Weeks 24 and 36in 
Skindex -16 AA domain scores (Symptoms, Emotio ns, 
Functioning)
Mean change from Baseline in HADS -
A and HADS -D 
total scores at Weeks 24 and 36  
I4V-MC-JAIR( d) Clinical Protocol Page 31
LY3009104Objectives Endpoints
Other Secondary (Patients entering Randomized Downtitration)
These are pre -specified objectives that w ill NOT be adjusted for multiplicity.
To compare the maintenance of efficacy for 
patients randomized to remain on 4-mgof 
baricitinib, compared with patients randomized to 
2-mg of baricitinib at Week 52of the long -term 
extension period, as measured by [CONTACT_5936] -
assessed signs of AAProportio n of patients maintaining SALT ≤20at Weeks 
64, 76, 88, 104, 120, 136, 152, 168, 184, and200
Proportio n of patients experiencing a loss of treatment 
benefit (>20 - point absolut e worsening in SALT scor e) at 
Weeks 64, 76, 88, 104, 120, 136, 152, 168, 184, and 200
Time to loss of treatment benefit (>20 -point absolute 
worsening in SALT score)
For patients experiencing loss of treatment benefit 
after randomization to 2-mg of baricit inib at Week 
52:
To evaluate the recapture of efficacy for 
patients who were retreated after experiencing 
a loss of treatment benefit during the 
long-
term maintenance period as measured by 
[CONTACT_5936] -assessed signs of AAProportio n of patients that achieve a SALT ≤20 at 
12, 16, 24, and 36 weeks of retreatment with baricitinib
4-mg
Percent change in SALT score at 12, 16, 24 ,and 
36weeks of retreatment with baricitinib 4-mg
To evaluate the recapture of efficacy for 
patient s who were retreated after experiencing 
a loss of treatment benefit during the 
long-term maintenance period as assessed by 
[CONTACT_878686]Proportio n of patients with a PRO for Scalp Hair 
Assessment score of 0 or 1 at 12, 16, 24 ,and 36 weeks
of retreatment with baricitinib 4-mg
Exploratory Objectives may include evaluating the response to baricitinib treatment regimens on clinical measures 
and PROs .  These endpoints may include dichotomous endpoints or change from Baseline for the following 
measures:  SALT ;AA-IGA;SALT 30;ClinROs for Nail Appearance, Eyebrows, and/or Eyelash Hair Loss ;PROs for 
Scalp Hair Assessment, Eyebrows, Eyelashes, Nail Appea rance ,and Ey e Irritatio n;Skindex -16AA; SF-36;
EQ-5D-5L; HADS.   Assessments of efficacy may be performed beyond Week 104 up to Week 200 .  
Abbreviations:  AA= alopecia areata; AA-IGA = Alopecia Areata Investigator Global Assessment; ClinRO =clinician -
reported outcome; EB= eyebrow; EL= eyelash; EQ-5D-5L = European Quality of Life –5 Dimensions –
5Level ;HADS = Hospi[INVESTIGATOR_122140]; PRO = patient -reported outcome; SALT =Severity of 
Alopecia Tool; SALT 30= at least 30% improvement from Baseline in SALT score; SALT 50= at least 50% 
improvement from Baseline in SALT score; SALT 75= at least 75% improvement from Baseline in SALT score; 
SALT 90= at least 90% improvement from Baseline in SALT score; SALT 100= 100% improvem ent from 
Baseline in SALT score ;SF
-36= Short Form -36 Health Survey acute version 2 ; Skindex -16 AA = Skindex -16 
Adapted for Alopecia Areata .
I4V-MC-JAIR( d) Clinical Protocol Page 32
LY30091045.Study  Design
5.1. Overall Design
Study  I4V-MC-JAIR(JAIR) is a Phase 3, mult icenter, randomized, double -blind, 
placebo -controlled, parallel -group study evaluating the efficacy and safet y of baricit inib2-mg 
QD and 4 -mg QD in adult patients with severe (SALT score of 50% -94%) or very  severe (SALT 
score of 95% -100%) scalp AA.  
Patients m ust have a current AA epi[INVESTIGATOR_184026] 6 months’ 
durati on pri or to screening (Visit 1),with at l east 50% scal p invo lvement at screening AND 
Baseline (Visits 1 and 2) with no spontaneous improvement (no more than a 1 0-point reducti on 
in SALT) over the past [ADDRESS_1227467] 8years.   The study  design is divided into 5periods :  a 5-week screening period, a 36 -week 
doubl e-blind, placebo -controlled treatment period, a 68- week long -term extensi on periodthat 
includes a randomized downtitration of baricit inib, a 96-week bridging extensio n,and a 
posttreatm ent follow-up peri od.  
Approximately 476adult patients will  berando mized in a 2:2:3 ratio to receive placebo once 
daily  (QD), barici tinib 2-mgdose QD, or baricit inib 4-mgdose QD.  Patients will be stratified at
rando mizat ion by [CONTACT_1617] (North America , Asia, and Rest of World) and duration of 
current epi[INVESTIGATOR_878643] (less than 4years versus at least 4 years ).
All procedures to be conducted during the study , including timing of all procedures, are i ndicated 
in the Schedule of Act ivities (SOA) (Secti on2).  Secti on9.4.4 describes co llection of laboratory  
samples; Appendix [ADDRESS_1227468] the specific laboratory  tests that will be 
perform ed for this study .  
Study  governance considerations are described in detail in Appendix 3 .  
Secti on 10.3.6 outlines informat ion regarding the interim analysis .
Figure JAIR. 1illustrates the study  design.   The full visit schedule is outlined in the SOA 
(Secti on 2).
I4V-MC-JAIR( d) Clinical Protocol Page 33
LY3009104Abbreviations :  AA-IGA = Alopecia Areata Investigator Global Assessment; ClinRO = clinician reported outcome; EC= exclusion criterion; eGFR = estimated 
glomerular filtration rate; ET= early termination; IP= investigational product; PBO = placebo; PTFU =posttreatment follow -up; QD= once daily  
administration; SALT = Severity of Alopecia Tool; V= Visit.

I4V-MC-JAIR( d) Clinical Protocol Page 34
LY3009104aApplicable to all patients at time of screening . See EC [9] for treatments that will require washout .
bThe maximal baricitinib dose for patients with renal impairment (defined as eGFR <60 mL/min/1.73 m2) will be 2 -mg QD (see Section 5.5.1).
cAt Week [ADDRESS_1227469] notachieved SALT ≤20 will be rescued and re -randomized in a 1:[ADDRESS_1227470] achieved an IGA 0 or 1 will remain on placebo at Week 36.
dAt Week 52, responders (SALT ≤20) in the baricitinib 4-mgtreatment group who are eligible (ie, stayed on the same dose of baricitinib from initial 
randomization at Visit 2) will be randomized ina 1:1 ratio to either stay on baricitinib 4-mgor transition to baricitinib 2-mg(randomized downtitration ).  See 
Section 5.1.[ADDRESS_1227471] never achieved a SALT ≤[ADDRESS_1227472] 
a ≥2-point improvement in Cl inRO measure for eyebrow or eyelash hair loss (nonresponders) at Week 52 will be automatically transitioned to placebo .  
fPatients who are nonresponders (SALT >20) at Weeks [ADDRESS_1227473] a ≥2-point 
improvement from Baseline in ClinRO measure for eyebrow or eyelash hair loss.  See Section 5.1.3 for more details.
gResponders who experience a loss of treatment benefit after Week 52 (>20 -point absolute worsening in SALT score) who were randomized to baricitinib 
2-mg at Week 52 (randomized downtitration) will be retreated with baricitinib 4-mg, as randomized at Baseline (Visit 2).  Patients who were randomized to 
remain on baricitinib 4
-mg(randomized downtitration) will continue to receive the same dose of baricitini b.See Section 5.1.3 for more detail.
hET Visit is required for patients that terminate IP early .  Patients w ho re main in the study for more than 28 days after discontinuation of IP do not need a 
separate follow -up visit (V801) .
iV801 occurs approximately [ADDRESS_1227474] beyond Week 
200 do not need to complete Period 5.
jPatient swho were randomized to placebo at Baseline and were not eligible for rescue to baricitinib at Week 36 ( due to s pontaneous remission) will be 
rescued to baricitinib 2- mgif they are nonresponders at Week 52 (AA -IGA ≥2) or exper ience a loss of treatment benefit after Week 52 (>20 -point absolute 
worsening in SALT score) .
kWeek [ADDRESS_1227475] been in the baricitinib 2 -mg dose treatment group from Baseline who experience a loss of treatment benefit after Week 52 (>20 -point absolute 
worsening in SALT score) will be rescued to baricitinib 4 -mg.
Figure JAIR. 1. Illustration of study design for Clinical Protocol I4V -MC-JAIR.
I4V-MC-JAIR( d) Clinical Protocol Page 35
LY30091045.1.1. Period 1 :  Screening ( -35 to -3 days)
The durati on of  the Screening Period is between 3 and 35 days prior to Visit 2 (Week 0).  
Therapi[INVESTIGATOR_878646] e randomization (Visit 2) are listed in 
Exclusio n Criterion[9].  Patients who receive a purified protein derivat ive ([COMPANY_003]) skin test at 
Visit1 will  return [ADDRESS_1227476].  Patients who are eligible for herpes 
zoster vaccine (pe r local guidelines) and have not previously received the vaccine will be 
encouraged to do so prior to randomizat ion. Vaccinat ionwith the live herpes zoster vaccinat ion
(single injection) must occur at least 28 days (4 weeks) prior to rando mizat ion.  Vacc ination with 
the non -live herpes zoster vaccine requires [ADDRESS_1227477] 4 weeks prio r to randomizat ion. For both vaccines, 
completion of the vaccinat ion may require rescreen ingthe pati ents to com ply wit h the m aximum  
allowed duration of the screening period .  In addit ion, investigators should review the 
vaccination status of their patients and fo llow the local  guidelines for vaccinat ion of those 
≥18years o f age wi th nonlive vaccines intended to prevent infect ious disease prior to entering 
patients into the study .  Pati ents who m eet all  of the inclusio n criteria (Secti on 6.1)and none of 
the exclusio n criteria (Secti on 6.2) will cont inue to Visit 2.
5.1.2. Period 2 :  Double -Blind Treatment Period (Weeks 0 –36)
At Visit 2 (Week 0, Baseline), study  eligibilit y for each pati ent will be reviewed on the basis of 
all inclusio n (Section 6.1) and exclusio n (Section 6.2) criteria and laboratory  test resul ts.  
Patients who m eet all eligibilit y criteria will proceed to randomizat ion and begin the 36- week 
doubl e-blind, placebo -controlled treatment period (Study Period 2). 
At Visit 2, after laboratory  samples are collected and all assessments are completed, patients will 
take th e first dose of IP in the clinic. 
Patients will be randomized in a 2:2:3 ratio to receive placebo QD, baricit inib 2-mgdose QD, or 
baricit inib 4-mgdose QD. 
During Study  Period 2 (double -blind treatment), medicat ions listed in Section 7.7.2 will be 
prohibited.  
The primary  efficacy  endpoint will be at Week 36 (Vi sit 8).  If a patient discont inues IP prior to 
Week
36 (Visit 8), the patient is encouraged to remain in the study and fo llow the regul ar visi t 
schedule to provide the primary efficacy and safety data through Week 36 (Visit 8).
5.1.3. Period 3 :  Long -Term Extension
All patients who have co mpleted Study  Period 2 (Week 36) will enter the l ong-term extensio n 
period (up to 68 weeks of addit ional treatment [Study  Period 3]). Patients will continue on their 
current treatment assignment unless predefined criteria are met for rescue.
During Study  Period 3 (long-term extensio n),medications listed in Section 7.7.2 will be 
prohibited.  
I4V-MC-JAIR( d) Clinical Protocol Page 36
LY3009104At Week 36 
Patients in the placebo treatment arm who have not achieved SALT ≤20at Week 36 will 
be rescued to baricit inib and rando mized in a 1:1 ratio to baricit inib2-mgdose or 
baricit inib 4-mgdose.
Patients in the pl acebo arm  who have achieved a SALT ≤20at Week [ADDRESS_1227478] experienced spon taneous regrowth will remain on 
placebo until Week 52, even if a relapse 
is observed between Week 36 and Week 52. 
(Refer to Week 52 for rescue of placebo patients who experience a loss of treatment 
benefit ).
All patients in the baricit inib treatment arms will continue in their current treatment 
group , regardless of their treatment response at Week 36 (refer to Week 52 and Week 76 
sections below for addit ional rescue informat ion and discont inuat ion criteria).
At Week 52
Responders ( SALT ≤20)
Patients in the 4-mgdose baricit inib treatment arm who achieve a SALT ≤20at Week 52 
(responders) are eligible for randomized downtitratio n, provided that th ey have stayed on 
the sam e dose of baricit inib fro m initial randomizati on(Visit 2).  
Patients who were re scued to baricit inib at Week 36 and patients rando mized to 2-mg
dose bari citinib will not be eligible for randomized downtitration and will remain in their 
same treatment group.   
Eligible pat ientswill be autom atically randomized in a blinded manner by  [CONTACT_878680]-response system (IWRS) in a 1:1 rati o to ei ther stay  on thei r current 4-mgdose of 
baricit inib or transit ion to2
-mgdose of baricit inib(randomized downti tration).  
Patients in the pl acebo treatm ent arm  at Week [ADDRESS_1227479] achieved a SALT ≤20will 
remain on placebo.
Responders who experience a loss of treatment benefit after Week 52(defined as 
>20-point absolute worsening in total SALT score) , and who :
owere randomized to 2- mgdose of baricit inibat Week 52 (rando mized 
downti tration),will be automat ically retreated with the 4-mgdose of baricitinib,
as rando mized at Baseline (Visit 2).
oremained on 
4-mgdose of baricit inib at Week 52 (rando mized downtitration), will 
continue to receive the same dose of baricit inib.
owere randomized to
2-mgdose at Baseline (Visit 2) , will be rescued to 4- mgdose.
ohad remained on placebo since Baseline (Visi t 2), will be rescued to baricit inib 
2-mg.
I4V-MC-JAIR( d) Clinical Protocol Page 37
LY3009104Note :  An unscheduled visit may be used to assess the patient who reports a loss of treatment 
benefit (see SOA [Section 2] for detailed requirements) .
Nonresponders ( SALT >20 )
Patients who have been in the baricit inib 4-mgdose treatment group from Baseline AND 
have never achieved a SALT ≤20by [CONTACT_10585] [ADDRESS_1227480] a ≥2-point improvement 
from Baseline in clinician -reported outcom e(ClinRO) measure for ey ebrow or eyelash 
hair l oss at Week 52will be autom atically transit ioned to pl acebo.
Patients who have been in the baricit inib 4-mgdose treatment group and have achieved a 
SALT ≤[ADDRESS_1227481] response, will remain on baricit inib 4-mgdose.
Those who have been in the baricit inib2-mgdose treatm ent group from Baseline will be 
rescued to baricit inib 4-mgdose.
Those who were rescued to baricit inib at Week 36 will cont inue in their current treatment 
arm at Week 52.
Those who were randomized to placebo at Baseline and were not eligible for rescue to 
baricit inib at Week 36 (spontaneous remissio n) will be rescued to baricit inib 2 -mg.
Note: Invest igators should consider discont inuing patients who do not present any 
improvement of AA lesio ns by [CONTACT_10585] 64 (Visit 14 ).
Week 76
Patients who are nonresponders (SALT >20 ) at Weeks [ADDRESS_1227482] a ≥2-point improvement fro m 
Baseline in ClinRO measure for ey ebrow or ey elash hai r loss.
5.1.4. Period 4 :  Bridging Extension
Patients who have completed Week [ADDRESS_1227483] the possibilit y to rem ain in the tri al for up to 96 addi tional weeks (up to Week 200).
During Peri od 4, pati ents will  continue to receive the same treatment they  received during Per iod 
3.
Patients who were randomized to placebo at Baseline and were not eligible for rescue to 
baricit inib at Week 36 or during Period 3 (spontaneous remissio n) will continue to have the 
opportunit y to be rescued to bari citinib 2 -mgif they experience loss of treatment benefit .
Baricitinib 4mg r esponders who had been rando mized to baricitinib 2 -mgat Week 52 
(randomized downtitration) and have remained on baricit inib [ADDRESS_1227484] the possibilit y to 
be retreated with baricitinib 4-mg if they experience a loss of benefit (defined as >20 -point 
absolute worsening in total SALT score) during Period 4 .
5.1.5. Period 5:  Post treatment Follow -Up
Patients who com plete the study  through Vi sit 24(Week 200), will have a posttreatment 
follow
-up visit (Visit 801) approximately  [ADDRESS_1227485] 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227486] bey ond Week 200 do not need 
to com plete Peri od 5 (Visit 801).
Patients who have received at least [ADDRESS_1227487] 
an early  terminat ion (ET) visit, and return for the posttreatment safet y follow-up visit (Visit 801) 
approximately  28days after the last dose of IP.
Patients who have discont inued IPproduct but remain in the st udy for more than [ADDRESS_1227488] an ET visit if they choose to discont inue early; however, a separate fo llow-up visit 
(Visit 801) is not required.
5.2. Number of Participants
Approximately  [ADDRESS_1227489] scheduled procedure shown in the SOA
(Secti on2) for the last patient.
5.4. Scientific Rationale for Study Design
Available data strongly suggest that AA results from an immune -mediated perturbation of hair 
follicle bio logy due to pro -inflammatory mediator s
,such as IFNγ and other cy tokines utilizing 
JAK-STAT si gnaling.  Therefore, there is strong scient ific and immunological rat ionale for 
studying the abilit y of baricit inib to restore hai r follicle growth in AA pat ients. Because the 
IFNγ receptor engages both JAK1 and JAK2, the dual mechanism of act ion for bari citinib that 
inhibits both JAK1 and JAK2 is ideally  suited for drug sel ection for pati ents wi th AA. The 
resul ts of the interim analysis o f the Phase 2 portion of Study JAHO confirm the potenti al of 
baricit inib to restore hair growth in pat ients suffering f rom AA.
A washout of systemic and topi[INVESTIGATOR_878647].  Durati ons of required washouts take into 
consideration that several weeks may be necessary before observing regrowth of hair in treated 
AA pat ients.
This tri al will enroll pat ients with severe AA (defined as a SALT score of 50% -94%) and very 
severe AA (defined as a SALT score of 95% -
100%) , as patients with more limited, scattered 
patches are often treated with topi[INVESTIGATOR_878648] 
(eg,triamcino lone) and topi[INVESTIGATOR_878649].  There is no approved treatment for the management 
of AA; therefore, this trial will  evaluate the efficacy  and safet y of 
2doses of baricit inib ( 4-mg
dose and 2-mgdose) versus placebo.
Eligible pat ients have at least [ADDRESS_1227490] months after onset. 
Hence, minimal chances of spontaneous hair regrowth confounding the abilit y of baricitinib to 
facilitate hair fo llicle regrowth were designed into this study .
I4V-MC-JAIR( d) Clinical Protocol Page 39
LY3009104The primary  endpoint is the proportion of patients reaching a SALT ≤ 20 (ie,≤20% of scalp 
involvement )and will be evaluated after 36 weeks of treatment.  Experience wit h other drugs has 
shown that i t can take several mo nths for pati ents wi th AA under treatment to grow new hair.   It 
is expected th at several weeks o f treatm ent will be necessary  to all ow hai r follicles to cy cle back 
to anagen phase after control of the inflammatory  response leading to hair regrowth ,and that it 
could take up to 9 m onths to observe maximum efficacy.  
Alopecia areata is a chronic and relapsing condit ion,and so me pat ients may require continuous 
treatm ent.  Pati ents wi th SALT ≤[ADDRESS_1227491] received baricit inib 4- mgdose 
over 52 weeks , 
will be randomized to either stay  on baricitinib 4-mgor transit ionto baricitinib2-
mgdose (in a 1:1 rati o) to assess the possibilit y to maintain efficacy wit h a lower dose.  These 
patients will  be retreated wi th baricitinib 4-mgif they present with a loss o f treatm ent benefit 
(loss of >20 points in total SALT score).
Period [ADDRESS_1227492] not met criteria 
for perm anent discont inuat ion, the possibilit y to remain in the trial for up to 96 additional weeks 
(up to Week 200).  This will allow for addit ional long-term effica cy and safet y informat ion to be 
collected, and provide patients the opportunit y to continue study  treatm ent until the ant icipated 
approval  of baricitinib in this indicat ion.
5.5. Justification for Dose
In a Phase 2 study  conducted in pat ients with moderate -to-severe atopic dermat itis 
(Study I4V-MC-JAHG [JAHG] ), both the 2 -mg and 4 -mg doses showed benefit on the primary 
and major secondary  endpoints ,as com pared to placebo, and both doses had an acceptable safet y 
profile at Week 16.  However, the 4
-mg dose appea red to dem onstrate a m ore rapi d benefi t (at 
4weeks) on more stringent endpo ints,compared to the [ADDRESS_1227493] been
included in the Phase 2 part of Study I4V-MC-JAHO (JAHO) , including a 1-mg dose, to cover 
the range of exposures where clinical responses could be ant icipated .The results of the interim 
analysis of the Phase 2 part of Study  JAHO showed that for both SALT 30(at least 30% 
improvement from Baseline in SALT score) at Week 12 a nd SALT 50(at least 50% improvement 
from baseline in SALT score) at Week 16, t he 2-mg and [ADDRESS_1227494] acebo and the 1 -mg dose. ForSALT 50at Week 16, the difference 
between the 4- mg dose and placebo was statisticallysignificant (p=.036). In the patients with 
greater disease severit y (AA-IGA = 4), the 4-mg dose seemed to provide a more dist inct 
response when compared withthe 2-mg dose .
This observat ion will need to be confirmed on 
larger sample sizes. These results were confirmed at the 2 -mg dose and 4 -mg dose by [CONTACT_878687] o f Phase 2 porti on of  Study  JAHO conducted after 36 weeks of treatment.  
There were no SAE s during the period of treatment and no new safet y findings.
I4V-MC-JAIR( d) Clinical Protocol Page 40
LY3009104The pharmaco kinet ic (PK) data from  sparse sampling suggest thatthe systemic exposure in AA 
patients increases in a dose -dependent manner (approximately  dose proporti onal) across the 
range fro m 1-mg to [ADDRESS_1227495] ion (stratified as 
estimated glo merular filtrat ion rate ( eGFR) 60 to <90 mL/min/1.73 m2and eGFR 30 to 
<60mL/min/1.73 m2, respectively), dose adjustm ent is not requi red for pati ents wi th eGFR 
≥60mL/min/1.73 m2.  Pati ents w ith eGFR <60 mL/min/1.73 m2who are randomized to the 4 -mg 
dose will receive a dose of 2 -mg QD, which will ensure that exposures do not exceed those of 
the 4-mg QD dose in pat ients with eGFR ≥60 m L/min/1.[ADDRESS_1227496] ment for 
renal impairment will be managed by [CONTACT_878688].  This 
study  will not enroll pat ients with screening eGFR <40 mL/min/1.[ADDRESS_1227497] ion (eGFR) during the stud y is detailed in 
Secti on 7.2.2 .
I4V-MC-JAIR( d) Clinical Protocol Page 41
LY30091046.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted. 
Study  investigator(s) will review patient history  and screening test results at Visit [ADDRESS_1227498] be completed and reviewed before 
the pati ent is randomized.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet allof the fo llowing cri teria at 
screening:
Informed Consent
[1] Are at l east 18 years and ≤60 y ears f or males (≤70 years o f age for females )at 
the time o f informed consent .  
Note:  Use local requirements to provide consent if the age of adulthood is 
defined as >[ADDRESS_1227499] been included for male 
and female patients, based on difference in the prevalence of conco mitant 
androgenet ic alopecia .  
[2] Are able to read, understand, and give documented (electronic or paper 
signature) informed consent .
Type of Patient and Disease Characteristics
[3] Have severe or very  severe AA,as determined by [CONTACT_21129] o f the following:
a.Current AA epi[INVESTIGATOR_184026] 6 months’ durat ion and hair l oss 
enco mpassing ≥50% of the scalp
,as measured by  [CONTACT_773333] (AA -IGA of 3 or 
4) at Vi sit1 AND Visit 2.
b.Nospontaneous improvement (ie,no m ore than 10point spontaneous 
reducti on in SALT) over the past 6 months.
c.Current epi[INVESTIGATOR_878650] 8years. 
Note: patients who have severe or very  severe AA f or ≥8years m ay be 
enrolled if epi[INVESTIGATOR_878651], spontaneous or under treatment, have been 
observed on the affecte d areas of the scal p over the past 8 y ears.
[4] Agree not to use any AA treatm ents during the study , including, but not 
limited to the fo llowing:
a.Systemic therapi[INVESTIGATOR_014] (eg,methotrexate, cy closporine , corti costeroi ds, JAK 
inhibitors , apremilast, dimethyl f umarate derivat ives, hydroxychloroquine, 
mycopheno late-mofetil, IFNγ, azathioprine )and biologics (eg, m onocl onal 
antibodies) 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227500] ions
c.Topi[INVESTIGATOR_12491], including irritants and immunotherapi[INVESTIGATOR_014] (eg, 
diphenylcyclopropenone ) 
d.Phototherapy , including lasers
e.Platelet-rich plasma inject ion
f.HMG CoA reductase inhibitors or “Stati ns” (eg ,simvastatin, simvastatin + 
ezetimibe ) for treatm ent of AA
g.Cryotherapy
Note :  Treatment with bima toprost ophthalmic solution for eyelashes may be 
continued if the patient has been on a stable dose for 8 weeks prior to 
rando mizat ion.  Treatm ent wi th finasteride (or other 5 alpha reductase inhibitors ) or 
oral or topi[INVESTIGATOR_878652] a stable dose 
for 12mont
hsand are ant icipated to con tinue on a stable dose up until Week 36 . 
[5] Are male or nonpregnant, nonbreastfeeding female patients .
a.Male patients will either remain abstinent (if thi s is thei r pref erred and usual 
lifest yle) or agree to use 2 forms of birth control ( 1must be highly  effect ive, 
see below) while engaging in sexual intercourse with female partners of 
childbearing potential and agree to not father a child while enro lled in the 
study  and f or at l east [ADDRESS_1227501] dose of IP.  Men who are in 
exclusively  same sex rel ationships (when it is their preferred and usual 
lifest yle) are not required to use contraception.
b.Female pat ients of child -bearing potenti al who are abstinent (if this is 
complete abst inence, as their preferred and usual lifest yle) or in a same -sex 
relationship (as part of their preferred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same -sex rel ationship wit hout sexual 
relationships wit h males.  Peri odic abst inence (eg, calendar, ovulat ion, 
symptothermal, post -ovulation methods), decl aration of abst inence just for 
the duration of a trial, and vaginal withdrawal are not acceptable methods of 
contraception.
Otherwi se, female pa tients of childbearing potential must agree to use [ADDRESS_1227502] dose of IP. 
The fo llowing birth control methods are considered acceptable (the patient should 
choose [ADDRESS_1227503] ive):
Highly effect ive birth control methods:  oral, injectable, or implanted hormonal 
contraceptives (combined estrogen/progesterone or progesterone only, 
associ ated wi th inhibit ion of ovulat ion); intrauteri ne device or intrauterine 
system  (eg,progestin -releasing co il); or vasectomized male (with appropriate 
post-vasectomy documentation o f the absence of sperm in the ejaculate). 
I4V-MC-JAIR( d) Clinical Protocol Page 43
LY3009104Effect ive birth control  methods:  condom with a spermicidal foam, gel, film, 
cream , or supposi tory; occl usive cap (di aphragm  or cervi cal/vault caps) wi th a 
spermicidal foam, gel, film, cream, or suppository; or oral hormonal 
contraceptives that do not i nhibit ovul ation. 
Note :  When local gui delines concerning highly  effect ive or effect ive methods 
of birth control  differ fro m the above, the local guidelines must be fo llowed.
c.Females of nonchildbearing potential are not required to use birth control .  
They are defin ed as :  
wom en ≥60 years of age or women who are congenitally  sterile, or
wom en ≥40 and <[ADDRESS_1227504] had a cessat ion of menses for 
≥12months and a fo llicle -stimulat ing horm one (FSH) test confirming 
nonchildbearing potential ( ≥40 m IU/mL or ≥40 IU/L), or women who are 
surgi cally sterile ( ie,have had a hysterectomy  or bilateral  oophorectomy or 
tubal  ligation).
6.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet anyof the fo llowing cri teria:
Medical Conditions Related to AA
[6] Primarily  “diffuse” ty pe of AA (characteri zed by  [CONTACT_878689] r shedding )
[7] Are current ly experi encing other forms of alopecia, including but not limited 
to: androgenetic alopecia (male pattern Grade IV or greater using 
Hamilton -Norwood cl assificat ion,or female pattern), trichotillo mania, telogen 
effluvium, chem otherapy -induced hair loss or any  other concomitant 
condi tions ( eg,tinea capit is, psoriasis, lupus erythematosus, or secondary 
syphilis) that woul d interfere wi th evaluat ions of the effect of s tudy 
medicat ion on AA.
[8] Patients who, in the opi[INVESTIGATOR_3078] n of the invest igator, are currently experiencing or 
have a history  of unstable concomitant disease that requires frequent 
hospi [INVESTIGATOR_878653]/or frequent use of systemic immunosuppressants that may  
interfere wi th parti cipat ion in the study .
[9] Have been treated with the fo llowing therapi [INVESTIGATOR_014]:
a.Corti costeroi ds
i.Topi [INVESTIGATOR_878654] [ADDRESS_1227505] ions for treatm ent of AA wi thin 
8weeks prior to randomizat ion
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227506] ion within 8weeks pri or 
to randomizat ion
Note:  Intranasal , ophthalmic, or inh aled steroi d use i s allo wed during screening and 
throughout the study .
b.JAK inhibitors
i.Topi [INVESTIGATOR_878655] (e g,tofacitinib, 
ruxolitinib) within 4weeks pri or to randomizat ion
.
ii.Oral JAK inhibitor within 8weeks pri or to randomizat ion.
iii.Previously  treated wi th an oral  JAK inhibitor (eg,tofacitinib, 
ruxolitinib) and had an inadequate response (for example, absence of 
significant terminal hair growth after at least 12 weeks of treatment). 
c. Other topi[INVESTIGATOR_12491] (eg, anthralin, d iphenylcyclopropenone or other 
topi[INVESTIGATOR_878656] )for the treatment of AA wi thin 4 weeks pri or to 
rando mizat ion.
d. Monoclonal  antibody (eg, ustekinumab, secukinumab, adalimumab , 
dupi[INVESTIGATOR_12458] ) less than 5 half -lives prior to randomization.
e. Probenecid at the time o f the randomization (Visit 2) that cannot be 
discontinued for the duration of the study (probeneci d may  increase 
baricit inib exposures).
f. Platelet-rich plasma within 8 weeks prior to randomizat ion.
g. Phototherapy  (UV therapy  and laser on scalp lesio ns) within 4 weeks prior 
to randomizat ion.
h. HMG CoA reductase inhibitors or “Stati ns” (eg, simvastatin, simvastatin + 
ezetimibe ) for treatm ent of AA within 4 weeks prior to randomization .
i. Cryotherapy  for treatm ent of AA wi thin 4 weeks pri or to randomizat ion.
j. Finasteri de (or other 5 alpha reductase inhibitors )or mino xidil (topi [INVESTIGATOR_748914]) within 8 weeks pri or to randomizat ion.
k.
Immu nosupp ressants (eg,methotrexate, cy closporine , dimethyl  fumarate
derivat ives, mycophenolate -mofetil,IFNγ, azathio prine )within [ADDRESS_1227507] or hy droxychl oroquine within 4 weeks prior to randomizat ion.
Medical Conditions in General
[10] Are largely or wholly  incapaci tated,permitting litt le or no self - care, such as 
being bedridden
I4V-MC-JAIR( d) Clinical Protocol Page 45
LY3009104[11] Have uncontrolled arterial hypertension characterized by  a repeated systolic 
blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg in a 
seated posit ion.
[12] Have had any  major surgery  within [ADDRESS_1227508] igator (in 
consultation wit h Lilly or its designee ), woul d pose an unacceptable risk to the 
patient if parti cipat ing in the trial.
[13] Are immunocompro mised and in the opi[INVESTIGATOR_3078] n of the invest igator, at an 
unacceptable risk for participatin g in the study .
[14] Have experienced any of the fo llowing wi thin 12 weeks of screening:  
myocardial  infarct ion, unstable ischemic heart disease, stroke, or [LOCATION_001] 
Heart Associ ation Stage III/IV heart failure.
[15] Have a history  of VTE, or are considered at high risk for VTE as deemed by 
[CONTACT_3170], or have 2 or more of the fo llowing ri sk factors for VTE:
a.Aged >65 years
b.BMI >35 kg/m2
c.Oral contraceptive use and current smoker status
[16] Have a history  or presence of cardio vascular, respi[INVESTIGATOR_696], hepat ic, 
gastroint estinal, endocrine, hematological, neurological, or neuropsy chiatri c 
disorders or any  other seri ous and/or unstable illness that, in the opi[INVESTIGATOR_3078] n of the 
investigator, could const itute an unacceptable risk when taking IP or interfere 
with the interpretation of data.
[17] Have a history  of lymphoproliferat ive disease; or have signs or symptoms 
suggest ive of possible lymphoproliferat ive disease, including 
lymphadenopathy  or spl enomegaly; or have act ive primary  or recurrent 
malignant disease; or have been in remissio n from clinically significant 
malignancy for < [ADDRESS_1227509] 3 y ears may  
participate in the study .
[18] Have a current or recent and/or serious viral, bacterial, fungal, or parasit ic 
infection, including but not limited to the following:
a.Symptom atic herpes zoster infect ion within 12 weeks pri or to screening.
b.A history  of disseminated/com plicated herpes zoster (eg ,multidermatom al 
involvement, ophthalmic zoster, central nervous system involvement, or 
post-herpetic neuralgia).
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227510] ion from hepati tis B virus (HBV), hepatit is C 
virus (HCV), or human immunodeficiency virus (HIV).
e.Househo ld contact [CONTACT_4490] a person wi th active tubercul osis (TB) and di d not 
receive appropriate and documented prophylaxis for TB.
f.Evidence of act ive TB or have previously had evidence of active TB and 
did not receive appropriate and documented treatment.
g.Clinically serious infection ,or rec eived intravenous (IV) antibiot ics for an 
infect ion, wi thin [ADDRESS_1227511] igator, would pose an unacceptable risk to the 
patient if par ticipat ing in the study .
Note:  A recent viral upper respi[INVESTIGATOR_878657] d not be considered clinically serious.
[19] A history  of eczema herpeticum wit hin 12 months prior to screening.
[20] A history  of [ADDRESS_1227512].
[21] Have any serious conco mitant illness that is ant icipated to require the use of 
systemic corticosteroids or otherwise interfere with study  parti cipat ion or 
requi re active frequent monitoring (eg ,atopi c dermat itis, unstable chronic 
asthma).
[22] Have been exposed to a live vaccine wit hin 12 weeks prior to planned 
rando mizat ion or are expected to need/receive a live vaccine during the course 
of the study  (with the excepti on of  herpes zoster vaccinat ion).
Note:  Patients eligible for herpes zoster vaccine, who have not received it prior to 
screening will be encouraged (per local guidelines) to do so prior to randomizat ion; 
vaccination wit h the live herpes zoster vaccine can occur during the screening period 
but m ust take place >[ADDRESS_1227513] 4 weeks prior to 
rando mizat ion. For both vaccines, complet ion of the vaccinat ion may require 
rescreen ingthe patients to comply  with the m aximum  allowed durati on of  the 
screening period.  Patients will be ex cluded if they were exposed to herpes zoster 
vaccination wit hin 4 weeks of planned rando mizat ion.
[23] Have a history  of chronic alcoho l abuse, IV drug abuse, or other illicit drug 
abuse within the 2 y ears pri or to screening.
[24] Presence of significant uncontrolle d neuropsy chiatri c disorder, are clinically  
judged by  [CONTACT_47546], or have a “yes”answer to 
any of the fo llowing:
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227514] ion 4 (Active Suicidal Ideat ion with Som e Intent to Act, Without 
Specific Plan) on the “ Suicidal  Ideat ion”porti on of the Co lumbia Suicide 
Severit y Rating Scale (C -SSRS) ;or
b.Quest ion 5 (Active Suicidal Ideat ion with Specific Pl an and Intent) on the 
“Suicidal Ideati on”porti on of  the C -SSRS ;or 
c.Any of the suicide -related behaviors (actual attempt, interrupted attempt, 
aborted attempt, preparatory  act or behavior) on the “Suicidal  Behavi or”
porti on of  the C -SSRS;
andthe ideation or behavior occurred within 2 mo nths of Visit 1.
Note:  A patient do es not necessarily have to be excluded if they have self -injuri ous 
behavior that would be classified as nonsuicidal self- injuri ous behavi or.  If  this 
situation arises, the patient should be referred to a psychiatrist or appropriately  trained 
professio nal,as indicated.
[25] Have donated more than a single unit of blood within 4 weeks prior to 
screening or intend to donate blood during the course of the study .
Diagnostic Assessments
[26] Have screening electrocardiogram (ECG) abnormalit ies that, in the opi[INVESTIGATOR_3078] n of 
the invest igator, are clinically significant and indicate an unacceptable risk for 
the pati ent’s parti cipat ion in the study .
[27] Have evidence of active TB or latent TB
a.Have evidence of active TB, defined in this study  as the fo llowing:
i. Docum ented by  a posi tive PP D test ( ≥5mm of induration between 
approximately  48 and 72 hours after applicat ion, regardless of 
vaccination history ), medical  history , clinical features, and abnormal 
chest x -ray at screening.
ii. The QuantiFERON®-TB Gol d test or T SPOT.®TBtest (as availab le 
and if co mpliant with local TB guidelines) may be used instead of the 
[COMPANY_003] test.  Patients are excluded fro m the study  if the test i s not 
negat ive and there is clinical evidence of act ive TB.
Except ion:  Patients with a history  of active TB who have docu mented evidence of 
appropriate treatment, have no history  of re-exposure since their treatment was 
completed, and have a screening chest x -ray with no evidence of act ive TB may be 
enrolled if other entry criteria are met.  Such patients would not be requir ed to 
undergo the protocol specific TB testing for [COMPANY_003], Quant iFERON -TB Gol d test, or 
TSPOT .TBtest but must have a chest x -ray at screening.
b.Have evidence of untreated/inadequately  or inappropri ately  treated l atent 
TB, defined in this study  as the followi ng:
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227515] ( ≥5 mm of indurat ion 
between approximately  48 and 72 hours after application, regardless of 
vaccination history ), no clinical features consistent with act ive TB, and 
a chest x -ray with no evidence o f active TB at screening; or 
ii. [COMPANY_003] test is posit ive and the patient has no medical history  or chest 
x-ray findings consistent wi th active TB, the patient may have a 
Quant iFERON -TB Gol d test or T SPOT .TBtest (as available and if 
compliant wi th local TB guidelines).  If th e test results are not 
negat ive, the patient will be considered to have latent TB (for purposes 
of this study ); or
iii. Quant iFERON -TB Gol d test or T SPOT .TBtest (as available and if 
compliant wi th local TB guidelines) may  be used instead of the [COMPANY_003] 
test.  If the test results are posit ive, the patient will be considered to 
have latent TB.  If the test is indeterminate , the test may  be repeated 
once wi thin app roximately  [ADDRESS_1227516] latent TB (for purposes of this study ).
Except ion:  Patients who have evidence o f latent TB m ay be enrolled if they com plete
at least 4 weeks of appropriate treatment prior to rando mizat ion and agree to complete 
the rem ainder of treatm ent while in the trial.
Except ion:  Patients with a history  of latent TB who have documented evidence of 
appropriate treatment, have no history  of re-exposure since their treatment was 
completed, and have a screening chest x -ray with no evidence of act ive TB may be 
enrolled if other entry criteria are met.  Such patients would not be required to undergo
the protocol -specific TB testi ng for [COMPANY_003], Qua ntiFERON- TB Gold test, or T SPOT .TB
test but must have a chest x -ray at screening.
[28] Have a posit ive test for HBV infect ion defined as:
a.Positive for hepat itis B surface ant igen (HBsAg), or
b.Positive for hepat itis B core antibody  (HBcAb) and posit ive HBV 
deoxy ribonucleic acid (DNA).
Note:  Patients who are HBcAb -positive and HBV DNA -negat ive may be enro lled in 
the study .  Pati ents who m eet these criteria at screening will be ident ified by [CONTACT_878690] y.
[29] Have HCV infect ion (posit ive for anti -hepat itis C antibody  with confi rmed 
presence of HCV ribonucleic acid (RNA)
Note:  Patients who have documented anti HCV treatment for a past HCV infect ion 
AND are HCV RNA negat ive may be enrolled in the study .
[30] Have evidence of HIV infection and/or posit ive HIV ant ibodies.
I4V-MC-JAIR( d) Clinical Protocol Page 49
LY3009104[31] Have screening laboratory  test val ues, including thyroi d-stimulat ing horm one 
(TSH), outside the reference range for the population or invest igative site that, 
in the opi[INVESTIGATOR_3078] n of the invest igator, pos e an unacceptable risk for the patient’s 
participat ion in the study.
Note:  Patients who are receiving thy roxine as replacement therapy  may parti cipate in 
the study , provi ded stable therapy  has been administered for ≥12weeks and TSH is 
within the laborato ry’s reference range.  Patients who are receiving stable thy roxine 
replacement therapy  who have TSH marginally outside the laboratory’s normal 
reference range may participate if the treating physician has documented that the 
thyroxine repl acement therapy  is adequate for the patient.
[32] Have any of the fo llowing specific abnormalit ies on screening laboratory  
tests:
a.AST or ALT ≥2 ×the upper limit of normal ( ULN )
b.Alkaline phosphatase (ALP) ≥2 ×ULN
c.TBL≥1.5 ×ULN
d.Hem oglobin <10.0 g/dL (100.0 g/L)
e.Total  white blood cell (WBC) count <2500 cells/µL(<2.50 × 103/µL or 
<2.50 GI/L)
f.Neutropenia (abso lute neutrophil count [ANC] <1200 cells/µL) 
(<1.20 ×
103/µL or <1.20 GI/L)
g.Lymphopenia (lymphocy te coun t <750 cells/µL) (<0.75 × 103/µL or 
<0.75 GI/L)
h.Thrombocy topeni a (platel ets <100,000/µL) (<100 × 103/µL or <100 GI/L)
i.eGFR <40 mL/min/1.73 m2(Chroni c Kidney  Disease Epi [INVESTIGATOR_878658] [CKD -EPI] creatinine 2009 equat ion).
Note:  For cases with any  of the aforem entioned laboratory  abnorm alities (Exclusio n 
Criteria [31] and [ 32]), the tests may be repeated during screening, and values 
resul ting fro m repeat testing may  be accepted for enrollment eligibilit y if they meet 
the eligibilit y criterion.
Other Exclusion Criteria
[33] Are unable or unwilling to make themselves av ailable for the duration of the 
study  and/or are unwilling to follow study  restri ctions/procedures. 
[34] A
re current ly enrolled in any other clinical study  involving an IPor any  other 
type of medical research judged not to be scient ifically or medically  
compatible with this study .
[35] Have part icipated within the last 30 day s in a clinical  study  involving an IP.  If 
the previous IP has a long half -life (2 weeks or longer), at least 3 months or 
5half-lives (whichever is lo nger) should have passed.
I4V-MC-JAIR( d) Clinical Protocol Page 50
LY3009104[36] Have previously been rando mized in this study or any other study 
investigat ing baricit inib.
[37] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bi ological or legally adopted.
[38] Are Lilly  or Incy te em ployees or thei r designee.
6.3. Lifestyle Restrictions
Study  parti cipants shoul d be instructed not to donate blood, blood products , or sperm during the 
study .  Itis highly reco mmended that patients remain consistent with hairstyle and hair co loring 
during the study  to facilitate scal p hai r assessments.  Patients who prefer to shave their scalp 
must refrain fro m shaving the scalp wit hin 2weeks prior to a study  visit.  For pati ents who prefer 
to wear a wig, it is recommended that the wig should not be taped at more than 2 places onthe 
periphery  of the scal p to avoi d pulling the hair.
Patients wi th eyebrows and/or ey elashes extensio ns, and/or tattoos, are allowed to be enrolled in 
the trial as l ong as the degree of eyebrows and eyelashes involvement (and regrowth when 
applicable) can be assessed at every  visit. Patients wi th acrylic nails at screening can be enrolled 
and will not be requested to remove them to enter the tri al; nonails assessment will be required 
for these pati ents. Patients who do not wear acrylic nails when they enter the trial should refrain 
fromusing them  before Week 36.
6.4. Screen Failures
Patients who are entered into the study  but do not meet the enrollment criteria for participat ion in 
this study  (screen failure) m ay be rescreened a maximum o f [ADDRESS_1227517] sign a new informed consent form ( ICF) , repeat all necessary  screening 
procedures, and will be assigned a new ident ificat ion number. 
If a patient undergoes rescreening, radiographic images acquired as part of init ial screening and 
within 6 m onths of rando mization may be used.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227518] igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agent(s) to the patient
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion, and
at the end of the study , returning all unused medication to Lilly or its designee, 
unless the Sponsor and sites have agreed all unus ed medicat ion is to be destroyed 
by [CONTACT_779], as allowed by [CONTACT_1769] .
Table JAIR.3. Treatment Regimens
Regimen Investigational Product Supplied Dose
Baricitinib 
4-mg QDaBaricitinib 4-mg tablets 2tablets per 
day Placebo to match 2 -mg tablets
Baricitinib 
2-mg QDBaricitinib 2
-mg tablets 2tablets per 
day Placebo to match 4- mg tablets
Placebo QD Placebo to match 4- mg tablets 2tablets per 
day Placebo to match 2- mg tablets
Abbreviation:  QD = once daily.
aThe baricitinib dose for patients randomized to the [ADDRESS_1227519] renal impairment 
(defined as eGFR <60 mL/min/1.73 m2) will be 2 -mg QD.
7.1.1. Packaging and Labe ling
The Sponsor (or its designee) will provide the fo llowing IPs:
tablets containing 2-mgof baricitinib
tablets containing 4-mgof baricitinib
placebo tabl ets to m atch barici tinib 2-mgtablets, [ADDRESS_1227520] inctive shape and co lor, 2-mgversus 4-mg, and each strength tablet has a 
matching placebo.  
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.
7.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized in a 2:2:3 ratio to receive 
doubl e
-blind treatment with placebo QD, baricit inib2-mgdose QD, or baricit inib 4-mgdose QD 
at Vi sit
2(Week 0).  Randomizat ion will be stratified by  [CONTACT_82724] (North America, 
Asia, and Rest of World) and duration of current epi[INVESTIGATOR_878643] (less than 4 years versus at 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227521] 4 y ears) for the whole study .  Randomizat ion for the randomized -downt itration will not be 
stratified.  Assignment to treatment groups will be determined by a co mputer -generated random 
sequence using an IWRS.  The IWRS will be used to assign bottles, each containing 
doubl e-blind IP tablets, to each pati ent, starting at Visit 2 (Week 0) and at each visit up to and 
including Visit 23(Week 184).  Si te personnel will confirm that they  have l ocated the correct 
bottles by  [CONTACT_45342] a confirmation number found on the bottle into th e IWRS.
7.2.1. Selection and Timing of Doses
The IP shoul d be taken QDwithout regard to food ,and if possible, at approximately the same 
time every  day, usually at the start of the patient’s day , to ai d pati ent com pliance. Patients 
enrolled will take [ADDRESS_1227522] ment for pati ents wi th docum ented renal  impairment (defined as 
screening eGFR ≥40 mL/min/1.73 m2 to <60 mL/min/1.73 m2) is detailed in Section 5.5.[ADDRESS_1227523] ment for renal  impairment will be managed by [CONTACT_832691].  The eGFR value from the screening visit (Visit 1) will be entered into IWRS 
at Vi sit2, and IWRS will assign the treatment doses accordingly.
Patients wi th docum ented renal  impairment (defined as screening eGFR ≥40 mL/min/1.73 m2to 
<60mL/min/1.73 m2) randomized to the [ADDRESS_1227524] ment will be made for patients with screening eGFR ≥60mL/min/1.73 m2.  
These patients who are randomized to active treatment will receive the ir assigned dose, ei ther 
baricit inib 4 -mgor2-mg, respectively.
During the study , for pati ents wi th docum ented renal  impai rment when the subsequent eGFR 
falls <30 mL/min/1.73 m2, 
IP will be wit hheld unt il their eGFR beco mes ≥40mL/min/1.73 m2, 
whereupon ,the IP dosing may resume.  For patients with screening eGFR ≥60mL/min/1.73 m2, 
when the subsequent eGFR falls to <40 mL/min/1.73 m2, IP will be wi thheld until their eGFR 
beco mes ≥50mL/min/1.73 m2, whereupon ,the IP dosing may  resume (see Secti on8.1.2 ).
7.3. Blinding
This is a double -blind study .  To preserve the blinding of the study , a minimum  number of Lilly  
personnel will see the rando mizat ion table and treatm ent assi gnments before the study  is 
complete.  All  study  assessments will be performed by  [CONTACT_878691] ’treatment group s.
Except in clinical circumstances where unblinding is required, the patients, invest igato rs, Lilly 
study  team  managing the study , and any  other personnel interacting direct ly wit h patients or 
investigat ive sites will remain blinded to baricit inib and placebo assignment until after 
completion of the study .  It i s expected that the need for unblinding a patient’s treatment prior to 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227525] igator has the sole responsibilit y 
for determining if unblinding of a patient’s treatment assignment is warranted for medical 
management of the event.  The p atient’ssafet y must always be the first considerat ion in making 
such a determination.  If a patient’s treatment assignment is unblinded, Lilly must be notified 
immediately .  If the invest igator decide s that unblinding is warranted, it is the responsibilit y of 
the invest igator to prompt ly document the decisio n and rationale and notify  Lilly as soon as 
possible.
Emergency  unblinding for AEs m ay be perform ed through the IWRS.  This option may  be used
ONLY if the pat ient’s well -being requires knowledge of the patient’s treatment assignment.  
Allunblinding events are recorded and reported by [CONTACT_8784].  If an investigator, site personnel 
performing assessments, or patient is unblinded, the patient must be discont inued fro m the study .  
In cases where there are ethical reasons to have the patient remain in the study , the investigator 
must obtain specific approval fro m a Lilly clinical research physician (CRP) for the pati ent to 
continue in the study .
7.4. Dosage Modification
As described in Section 5.1.3 , some pat ients may be eligible for rescue to baricit inib at Week 36 
and transit ion to 4-mg or 2 -mg doses of baricitinib at Week 52 .  However, these dose 
modificati ons will occur automat ically through IWRS and
,therefore ,will not requi re dose 
adjustm ent by  [CONTACT_878692].
7.5. Preparation/Handling/Storage/Accountability
All IP (used and partially used) will be returned to the S ponsor or destroyed at site level wit h the 
Sponsor’s written approval.  In some cases, sites may  destroy  the material if, during the 
investigat ive site select ion, the evaluator has verified and documented that the site has 
appropriate facilit ies and written procedures to dispose of clinical trial materials.
Follow storage and handling instructions on the IP packaging.
7.6. Treatment Compliance
Patient com pliance wi th study  medicat ion will be assessed at each visit during the treatment 
period (Vi sit 3 through Visi t 24) by  [CONTACT_878693] .  
A pat ient will be considered significant ly nonco mpliant if he
/she misses more than 20% of the 
prescribed doses of IP during the study unless the patient’s IP is withheld by [CONTACT_878694] y reasons.  Similarly, a patient will be considered significant ly nonco mpliant if he /she is 
judged by  [CONTACT_878695] 20% more than the 
prescribed amount of medication during the study .
Patients will  be counseled by [CONTACT_49124] , as appropri ate,on the importance of taking the IP as 
prescribed.
I4V-MC-JAIR( d) Clinical Protocol Page 54
LY3009104Patients’ com pliance will be further defined in the statist ical analysis plan (SAP).
7.7. Concomitant Therapy
All conco mitant m edicat ion, whether prescription or over -the-coun ter, used at Baseline and/or 
during the course of the study , must be recorded on the Concomitant Medicat ion electro nic case 
report form (eCRF).  Patients will be instructed to consult the invest igator or other appropriate 
study  personnel at the site before taking any  new medicat ions or suppl ements during the study .  
For AA therapi[INVESTIGATOR_878659], see Secti on 7.7.1 .
7.7.1. Permitted Medications and Procedures
The fo llowing m edicat ions are permitted during the study :
Topi [INVESTIGATOR_878660] , eyebrows, and eyelids .
Topi [INVESTIGATOR_878661] , eyebrows, and eyelids.
Intranasal , ophthalmic, or inhaled steroid use .
A maximum of 2 intra-articular or soft tissue (bursa, tendon, and /orligament) 
corticosteroid injections are allowed up unt il the 36-week primary endpoint.  After 
36weeks, such injections are permitted.
Non-live vaccinat ions such as seasonal vaccinat ion, non -live herpes zoster (for subjects 
who beco me eligible during the trial) ,and/or all emergency vaccinat ions such as rabie sor 
tetanus vaccinat ions.
Bimatoprost ophthalmic solut ion (if on stable dose for 8 weeks prior to 
rando mizat ion).
Finasteride (or other 5 alpha reductase inhibitors ) ororal or topi[INVESTIGATOR_878649],if 
on a stabl e dose for 12 months prior to randomizat ion.
HMG CoA reductase inhibitors or “ statins” (eg ,simvastatin, simvastatin + 
ezetimibe) for treatment of hypercho lesterolemia and the prevent ion of 
cardi ovascular di sease .
Treatment with conco mitant therapi [INVESTIGATOR_487043] m edical condi tions,such as diabetes and 
hypertensio n is permitted during the study .
7.7.2. Prohibited Medications and Procedures
Any investigational or commercial topi[INVESTIGATOR_2855], intralesional ,or systemic therapi[INVESTIGATOR_014] (except those listed 
in Section 7.7.1 ), or phototherapy to treat AA are not allowed during the trial.
In addit ion, the fo llowing medicat ions and procedures are prohibited during the study:
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227526]
The fo llowing therapi [INVESTIGATOR_878662] ,and if taken by  [CONTACT_487077], temporary  interrupti on of IP is required :
Live vaccines , including Bacillus Calmette-Guérin [BCG] or herpes zoster, 
(seeExclusio n Cri terion [22]).
oFor BCG vaccinat ion, IP should be temporarily int errupted for 12 weeks .  If BCG 
vaccine is given prior to Week 36, IP should be permanent ly discontinued.
oFor live herpes zoster vaccinat ion, IP should be temporarily interrupted for 
4weeks after the injection .  
Probenecid:  If a patient is inadvertently started on probenecid, IPshould be temporarily 
interrupted ,
and can be resumed after patient has discontinued probenecid.  If a pati ent is 
not able to discont inue probenecid, then IP should be permanent ly discontinued.
Systemic corti costeroi ds may  be used for the treatment of an AE (eg, worsening of an 
exist ing co ndition, such as an asthma flare).  Investigat ional product may  be restarted if 
systemic corticosteroids were used for a short duration (<30 days).If used for ≥30 days, 
Sponsor approval to restart IP is required.  
Phototherapy :  Full body UV therapy .
Prohibited Medications Requiring Permanent Discontinuation of Investigational 
Product
Corticosteroi ds (systemic , intral esionalor topi [INVESTIGATOR_878663] , eyebrows, and ey elids ) for 
the treatment of AA.  
Topi[INVESTIGATOR_878664] p, ey ebrows, a nd eyelids.
Other oral  JAK inhibitors (eg,tofacitinib and ruxo litinib)
.
Any systemic treatment with an immunosuppressive/immuno modulating substance ,
including, but not limited to, cy closporine, mycophenol ate-mofetil, IFNγ, azathioprine, 
methotrexate, dime thyl fumarate derivat ives, hydroxy chloroquine , or bi ologics(eg,
monoclonal antibodies) .
Any other AA treatment that has been inadvertently initiatedand is not discontinued will 
lead to permanent discontinuation.
7.8. Treatment after the End of the Study
7.8.1. Conti nued Access
Period [ADDRESS_1227527] not met criteria for 
perm anent discont inuat ion, the possibilit y to rem ain in the tri al for up to 96 addi tional weeks (up 
to Week 200) and thus provide patients the opport unity to continue study  treatm ent until the 
anticipated approval of baricit inib in this indication.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227528] ion or opi[INVESTIGATOR_3078] n is received in that country  or regi on.
After the conclusio n of the study , continued access to baricit inib will not be provided.  Patients 
will be referred to their local treatment centers for AA therapy ,as clinically  indicated.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227529] should be permanent ly discontinued if the patient or the patient’s 
designee requests to discontinue IP.
Discontinuati on of  the IP for abnormal liver tests should be considered by [CONTACT_82378] 
a pati ent m eets 1 of the fo llowing condit ions after consultation wit h the Lilly -designated m edical 
monitor:
ALT or AST >8 × ULN
ALT or AST >5 × ULN for more than 2 weeks
ALT or AST >3 × ULN and TBL >2 ×ULN or internat ional norm alized rati o (INR) >1.5
ALT or AST >3 × ULN with the appear ance of fatigue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALP >3 ×ULN
ALP >2.5 ×ULN and TBL >2 ×ULN
ALP >2.5 ×ULN with the appearance of fat igue, nausea, vo miting, right quadrant 
pain or tenderne ss, fever, rash, and/or eosinophilia (>5%)
NOTE: Patients who are discontinued from IP due to a hepatic event or liver test 
abnorm ality should have addi tional hepatic safet y data collected via the hepat ic safet y 
eCRF.
Invest igational product should be per manently discontinued if any o f the following laboratory  
abnorm alities are observed:
WBC count <1000 cells/µL (1.00 × 103/µL or 1.00 GI/L)
ANC <500 cells/µL (0.50 × 103/µL or 0.50 GI/L)
lymphocy te count <200 cells/µL (0.20 × 103/µL or 0.20 GI/L)
hemoglo bin<6.5 g/dL (<65.0 g/L)
NOTE:  Tem porary  interrupti on rul es (see Sect ion8.1.2 ) must be fo llowed,where 
applicable.  For laboratory  values that meet permanent discont inuat ion thresho lds, IP 
shoul d be discont inued.  However, if ,in the opi[INVESTIGATOR_3078] n of the invest igator, the laboratory 
abnorm ality is due to intercurrent illness, such as cho lelithiasis or another ident ified 
factor, laboratory  tests m ay be repeated.  Only  when the l aboratory  value meets 
resum ption thresholds ( Table JAIR.4) following the resol ution of the intercurrent 
illness or other identified factor, may the invest igator restart IP, after consultation 
with the Lilly -designated m edical m onitor.
I4V-MC-JAIR( d) Clinical Protocol Page 58
LY3009104In addit ion, pati ents will  be discont inued fro m IP in the fo llowing circumstances:
pregnancy
malignancy (except f or successfully treated basal or squamous cell skin carcinoma)
HBV DNA is detected with a value above limit of quan titation (see Secti on9.4.8 )
certain prohibited medicat ions are taken per Section 7.7.2 (Prohibited 
Medicat ions and Procedures )
develop ment of a VTE 
Note:  Patients who develop a VTE may  have additi onal follow-up and testing recommended 
(see Section 9.4.9 and Appendix 7 ).
If a patient develops mult iple ri sk factors for a VTE dur ing the conduct of the study ,as described 
in Exclusio n Cri terion [15], the invest igator may consider study discont inuat ion if he/she 
believes the risk outweighs the benefits of cont inuing therapy.  I t is recommended that the 
investigator consult with Lill y (or i ts designee) before discont inuing therapy for this reason.  
If a patient discontinues IP for any  reason, the patient is encouraged to remain in the study  
through Week 36 (Visit 8) and fo llow the regul ar visit schedule to provide the primary  efficac y 
and safet y data.  Pati ents di scontinuing fro m the IP prematurely for any reason should co mplete 
AE and other fo llow
-up procedures per Section 2(Schedule of Act ivities), Section 9.2(Adverse 
Events), and Section 9.4(Safet y) of this protocol .
8.1.2. Temporary Interruption of Investigational Product
In some circumstances, it may  be necessary  to temporarily interrupt treatment as a result of AEs 
or abnorm al laboratory  values that m ay have an un clear relati onship to IP.  For example, IP
should be temporarily interrupted if the patien t experiences a cardiovascular AE considered to be 
related tostudy treatm ent,isgraded asmoderate (Grade 2according to Commo nTermino logy
Criteria forAdverse Events [CTCAE] Version 3.0), and that does not resolve promptly with
supportive care.   Except in cases of emergency, it is recommended that the invest igator consult 
with Lilly  (or i ts desi gnee) before tem porarily interrupti ng therapy  for reasons o ther than those 
defined inTable JAIR.4.  
For the abnormal laboratory  findings and clinical events (regardless of relatedness) listed in 
Table JAIR.
4,specific guidance is provided for temporarily interrupting treatment and when 
treatm ent m ay be restarted.  Retest frequency and timing of fo llow-up laboratory  tests to m onitor 
the abnormal finding are at the discret ion of the inve stigator.  Invest igational product that was 
temporarily interrupted because of an AE or abnormal laboratory  value not specifically  covered 
in Table JAIR.4may be restarted at the discretion of the invest igator.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227530] Results or Clinical Events Occur: Investigational Product May Be Resumed When:
WBC count <2000 cells/µL
(<2.00 × 103/µL or <2.00 GI/L)WBC count 2500 cells/µL
(≥2.50 × 103/µL or ≥2.50 GI/L)
ANC <1000 cells/L
(<1.00 × 103/µL or <1.00 GI/L)ANC ≥1200 cells/µL
(≥1.20 × 103/µL or ≥1.20 GI/L)
Lymphocy te count < 500cells/µL
(<0.50 × 103/µL or <0.50 GI/L)Lymphocy te count 750cells/µL
(≥0.75 × 103/µL or ≥0.75 GI/L)
Platelet count <75,000/µL
(<75 × 103/µL or <75 GI/L)Platelet count 100,000/µL
(≥100 × 103/µL or ≥100 GI/L)
eGFR <40mL/min/1.73 m2(from serum creatinine) for 
patients with screening eGFR ≥60mL/min/1.73 m2eGFR 50mL/min/1.73 m2
eGFR <30 mL/min/1.73 m2(from serum creatinine) for 
patients with screening eGFR ≥40 to <60 mL/min/1.73 m2eGFR 40mL/min/1.[ADDRESS_1227531] >5 ×ULN ALT and AST return to <2 ×ULN, and IP is not 
considered to be the cause of enzyme elevation
Hemoglobin <8 g/dL (<80.0 g/L) Hemoglobin 10g/dL ( ≥100.0 g/L)
Symptomatic herpes zoster All skin lesions have crusted and are resolving
Infection that, in the opi[INVESTIGATOR_871], merits the 
IP being interruptedResolution of infection
Clinical features of VTE (such as deep vein thrombosis or 
pulmo nary embolism) are presentaVTE ruled out
Abbreviations:  ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; IP= investigational product; ULN = upper limit 
of normal; VTE = venous thromboembolic event; WBC = white blood cell.
aEvaluate promptly a nd institute appropriate treatment.  If upon evaluation, VTE is ruled out and no other 
temporary or permanent discontinuation criteria are met, then IP may be resumed.
Although temporary  interruption of IP is not a requirement at times of increased potential risk for
VTE (eg ,surgery, significant air travel, or other situations invo lving prol onged immo bilizat ion), 
it is recommended that the invest igator fo llow appropri ate VTE prophylaxis guidelines to help 
manage the VTE ri sk under these circumstances. 
For specific guidance on temporary  interruption of IP after use of a prohibited medicat ion, please 
refer to Section 7.7.2 (Prohibited Medicat ions and Procedures).
Lastly, IPshould be temporarily interrupted for suicidal ideation or any suicide -related behaviors ,
as assessed by [CONTACT_487079] C -SSRS: 
A “yes”answer to Question 4 (Act ive Suicidal Ideation with So me Intent to Act, Without 
Specific Plan) ;or
A “yes” answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and Intent) on 
the “Suicidal  Ideat ion”porti on of  the C -SSRS ;or
I4V-MC-JAIR( d) Clinical Protocol Page 60
LY3009104A “yes”answer to any  of the suici de-related behaviors (actual attempt, interrupted 
attem pt, aborted attempt, preparatory  act or behavior) on the “ Suicidal  Behavi or”porti on 
of the C -SSRS.  
NOTE:  Pri or to resum ption of IP, it is recommended that a patient be assessed by  a psychiatrist 
or appropri ately  trained professio nal to assist in deciding whether the subject should remain on 
IP, and ult imately ,continue participat ion in the study .  A pati ent does not necessarily have to 
have IP interrupted if he/she hasself-injuri ous behavior that would be classified as non -suicidal  
self-injuri ous behavior.  
8.1.3. Discontinuation of Inadvertently Enrolled Patients
If the Sponsor or invest igator ident ify a patient who di d not m eet enrollmen t criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue on 
study  treatm ent.  If the invest igator and the Sponsor CRP agree it is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Sponsor CRP to allow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thout treatm ent wi th IP. Safet y 
follow-up is as outlined in Section 2(Schedule of Act ivities), Section 9.2(Adverse Events), and 
Secti on 9.4(Safet y) of the protocol.
8.2. Discontinuation from the Study
Patients will  be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study involving an invest igational medicinal 
product or enrollment in any other ty pe of m edical  research j udged not to be 
scientifically or medically co mpatible wit h this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , or 
other reasons consistent with appl icable l aws, regulat ions, and good clinical 
practi ce (GCP)
investigator decisio n
othe invest igator decides that the patient should be discontinued from the 
study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic 
agent for AA (not a llowed per protocol  [Secti on7.7.2 ]) that has been 
demonstrated to be effect ive for treatm ent of the study  indicati on, 
discontinuat ion from the stud y occurs pri or to introducti on of  the new 
agent 
oif a pat ient discont inues IP for any  reason, the patient is encouraged to 
remain in the study  through Week 36 (Visit 8) and fo llow the regular visit 
schedule to provide the primary efficacy and safety data  
I4V-MC-JAIR( d) Clinical Protocol Page 61
LY3009104subject decisio n
othe patientor the patient’s designee (eg, parents or legal guardian )requests 
the pati ent to be wi thdrawn from  the study .
Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete AE and other 
safet y follow-up per Secti on2(Schedule of Activit ies), Section 9.2(Adverse Events), and 
Secti on 9.4(Safet y) of this protocol .
8.3. Lost to Follow -Up
A patientwill be considered lost to fo llow-up if he /she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were ,otherwi se,
unable to be fo llowed u p by [CONTACT_4179].
I4V-MC-JAIR( d) Clinical Protocol Page 62
LY30091049.Study  Assessments and Procedures
Secti on 2lists the S OA, with the study  procedures and their t iming (including tolerance limits for
timing).
Appendix [ADDRESS_1227532] results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws , regul ations, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Assessments
[IP_ADDRESS]. Severity of Alopecia Tool (SALT) Score
The SALT uses a visual aid showing the divisio n of the scalp hair into 4 areas with the leftside 
and rightside of scalp 18% each , top constituting 40% of total surface, the posterior/back 24%.  
The percentage of hair loss in each area is determined and is mult iplied by [CONTACT_878696].  The total sum o f the 4 products of each area will give the SALT 
score ,as developed by [CONTACT_878697] W orking Committee 
(Olsenetal.2004).  Only  terminal  hair is included in the SALT; vellus hair or any  fine downy  
hair is not taken into account in the SALT scoring process (Olsen et al. 1999, 2004).
9.1.2. Secondary Efficacy Assessments
[IP_ADDRESS]. Alopecia Areata Patient -Reported Outcomes 
[IP_ADDRESS].1. Scalp Hair Assessment PRO ™
Lilly has developed a novel patient-reported outcome (PRO) assessment of the patient’s current 
extent of scalp invo lvement.  Like the AA-IGA (see Section9.1.4 .),the Scalp Hai r Assessment 
PRO™ is comprised of 5 categor icalresponse options :  0 =No missing hair (0% of my scalp is 
missing hair; I have a full head of hair) ;1 = A limited area (1% -20% of my scalp i s missing 
hair) ;2 = A m oderate area (21% -49% of my scalp is missing hair) ;3 = A large area (50% -94% 
of my scalp is missing hair) ;and 4 = Nearly all or all (95% -100% of my  scalp is missing hair). 
[IP_ADDRESS].2. Other Patient Reported Outcomes for Appeara nce of Eyebrows, 
Appearance of Eyelashes, Eye Irritation, and Nail Appearance
Lilly has developed 4 other novel PRO assessments measuring 3 important AA signs and 
1important AA symptom: PRO Measure for Ey ebrows™, PRO Measure for Ey elashes™, PRO 
Measure for Eye Irri tation™, and PRO Measure for Nail Appearance™ .  Each of these other 
PRO assessments uses a 4- point response scale , ranging fro m 0 = norm al appearance /no probl em 
to 3 = severe appearance /severe problem.
I4V-MC-JAIR( d) Clinical Protocol Page 63
LY30091049.1.2.2. Other Clinician -Reported Outcomes for Eyeb row Hair Loss ,Eyelash Hair 
Loss , and Nail Appearance
Lilly has developed 3 other novel ClinRO assessments measuring 3important AA signs: 
ClinRO Measure for Ey ebrow Hai r Loss ™, ClinRO Measure for Ey elash Hair Loss ™, and 
ClinRO Measure for Nail Appearance ™.  Each of these other ClinRO assessments uses a 4- point 
response scale, ranging fro m 0 = norm al appearance/no hair loss to 3 = severe appearance/severe 
hair l oss.
9.1.3. Health Outcomes and Quality -of-Life Measures
The fo llowing pati ent self -reported questi onna ires will be administered via an electronic tablet . 
In other coun triesoutsi de of  the US, where necessary , 
the questionnaires have been translated 
into the nat ive language of the region and linguistically validated.
[IP_ADDRESS]. Skindex -16 Adapted for Alopecia Areata
Skindex -16 has been used to assess the healt h-related quali ty of life in pat ients with skin diseases.  
The Skindex -16 items’ wordings were adapted for use among adultswith AA (Skindex -16 AA) .  
It is composed of 16 items grouped under 3 domains :  Symptom s (4 items), Em otions (7 i tems), 
and Functioning (5 items).
[IP_ADDRESS]. Medical Outcomes Study 36 -Item Short -Form Health Survey Version 2 
Acute
The Short Form -36Health Survey  (SF-36), Versi on [ADDRESS_1227533] ive, generic, 
healt h-related qualit y-of-life instrum ent that i s pat ient-reported and consists of 36 questions 
covering 8 healt h domains :  physical funct ioning;bodily  pain ;role limi tations due to physical 
probl ems;role limi tations due to em otional problems ;general  heal th percept ions;mental  heal th;
social function;and vitalit y.  Each dom ain is scored by  [CONTACT_154200] a norm -based T -score, wit
h higher scores indicating better health 
status or funct ioning.  In addition, 2 summary scores, the physical c omponent score (PCS ) and 
the mental  com ponent score (MCS ) will be evaluated based on the 8 SF-36 a cute domains 
(Marui sh 2011).
[IP_ADDRESS]. EQ-5D-5L
The European Qualit y of Life –5 Dimensio ns –5 Level (EQ-5D-5L) is a standardized measure 
of heal th status that provi des a simple, generic measure of healt h for clinical and econo mic 
apprai sal.  The EQ -5D- 5L consists of 2 components:  a descript ive system o f the respondent’s 
healt h;and a rati ng of  his/her current health state using a 0 to 100 mm  visual  a nalog scale (VAS).   
The descriptive system comprises the fo llowing 5 dimensio ns:  m obilit y, self -care, usual 
activit ies, pain/disco mfort, and anxiet y/depressi on.  Each dimensio n has 5 levels:  no problems, 
slight problems, moderate problems, severe problems, and extreme pro blems.  The respondent is 
asked to indicate his /her healt h state by  [CONTACT_13158] (or pl acing a cross) in the box associated with the 
most appropri ate statement in each of the [ADDRESS_1227534] no arithmet ic properti es and shoul d not be used as an ordinal score.  The VAS 
records the respondent’s self -rated heal th on a vertical VAS where the endpoints are labeled 
“best imaginable healt h state” and “worst imaginable health state.”  This informat ion can be used 
as a quan titative m easure of healt h outcome.  The EQ-5D- 5L states of healt h, as defined by [CONTACT_941] 
I4V-MC-JAIR( d) Clinical Protocol Page 64
LY3009104EQ-5D- 5L descript ive system, may be converted into a single summary index by [CONTACT_2931] a 
formula that essent ially attaches values (also called weights) to each of the leve ls in each 
dimensio n (Herdm an et al . 2011; EuroQo L2015).
[IP_ADDRESS]. Hospi[INVESTIGATOR_878665] y and Depressio n Scale ( HADS )is a 14 -item self-assessment scale that 
determines the levels of anxiet y (7 items) and depressio n (7 i tems) that a patient is experiencing 
over the past week.  The HADS ut ilizes a 4 -point Likert response scale (eg ,0 to 3) for each item ,
and is intended for ages 12 y ears to 65 year (Zigmond and Snait h 1983; White et al. 1999).  
Scores for each domain (anxiet y and depressio n) can range from 0 to 21, with higher scores 
indicat ing greater anxiet y or depression (Zigmo nd and Snaith 1983; Snait h 2003).
9.1.4. Alopecia Areata Investigator Global Assessment 
The AA -IGA is a categori zation of overall scalp hair loss based on the patient’s SALT score, 
which is assigned by [CONTACT_878698]’s scalp at each visit 
(seeSecti on9.1.1.1 ).  The AA-IGA contains 5 categories:  0 = None (SALT score of 0%); 
1 =Limit ed(SALT score of 1% -20%) ;2 = Moderate (SALT score of 21% -49%) ;3 = Severe 
(SALT score of 50% -94%) ;and 4 = Very  Severe (SALT score of 95% -100%).  The AA -IGA 
will be automat ically derive d from the SALT score entered into the electroni c clinical  outcom e 
assessment (eCOA) by [CONTACT_878699] .
9.1.5. Appropriateness of Assessments
All o f the clinical and safet y assessments in this study  are standard, widely used, and generally 
recogni zed as reliable, accurate, and relevant.  Measurement properties (including reliabilit y and 
validit y) of the newly  devel oped single -item assessments (AA -IGA, ClinROs ,and PROs
[seeSecti ons9.1.1 and 9.1.2 ]) and the healt h outcomes and qualit y of life m easures will be 
evaluated using the Phase [ADDRESS_1227535] all relevant AE/SAE informat ion in the CRF. The Invest igator 
remains responsible for fo llowing, through an appropri ate heal thcare opti on, AEs that are : 
serious or ,otherwise ,medically important ;considered related to the IP or the study ;or that 
caused the patient to discontinue the IP before complet ing the study.  The patient should be 
followed unt il the event resolves, stabilizes with appropriate diagnostic evaluat ion, or is 
reasonably  explained.  The frequency  of follow-up evaluat ions of the AE is l eft to the discret ion 
of the invest igator.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227536] ,via eCRF , the occurrence and nature of 
each patient’ s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addi tion, si te personnel  will record any  change in the 
condi tion(s) and any  new condi tions as AEs. Investi gators shoul d record thei r assessment of the 
potenti al relatedness of each AE to IP, via eCRF.
The invest igator will interpret and document whether an AE has a reasonable possibilit y of being 
related to study  treatm ent, to a study devic e, or to a study  procedure, taking into account the 
disease, concomit ant treatm ent, or pathol ogies.  A “reasonable possibilit y” means that there is a 
cause- and-effect relationship between the IP, study device ,and/or study  procedure and the AE.   
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient’s IP is discont inued as a res ult of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via eCRF, clarifying, if possible, the circumstances leading to any dosage 
modificati ons or di scont inuat ions of treatment.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience ( ie, immediate ri sk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_3094],but may  jeopardi ze the pati ent or may  requi re 
intervent ion to prevent one of the other outcomes listed in the definit ion above.  
Examples of such medical eve nts include : allergic bronchospasm requiring 
intensive treatm ent in an emergency  room  or at home ;blood dy scrasias or 
convulsio ns that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of 
drug dependency  or drug abuse.
All AEs occurring aft ersigning the ICF are recorded in the eCRF and assessed for seri ousness 
criteria.  The SAE reporting to the Sponsor begins after the pati ent has signed the ICF and has 
received IP.  However, if an SAE occurs after signing the ICF, but pri or to receiving IP, the SAE 
shoul d be reported to the Sponsor ,as per SAE -reporting requi rements and timelines (see Secti on9.2)
if it is considered reasonably  possibl y related to study  procedure.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227537] addit ional data collected using the 
eCRF.
Pregnancy (during maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements, any pregnancy  should be reported following the 
SAE process to collect data on the outcome for both the mother and the fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the pati ent disposi tion eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reac tions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IP or procedure.  [LOCATION_002] 21 CFR 
312.32 and European Unio n Clinical Trial Directive 2001 /20/EC and the associated detailed 
guidances or nati onal regulatory  requi rements in parti cipat ing countries require the reporting of 
S[LOCATION_003]Rs.  Lilly has procedures that will be fo llowed for the i dentificat ion,recording, and 
expedited reporting of S[LOCATION_003]Rs th at are consistent with global regulat ions and the associated 
detailed guidances.
9.2.2. Adverse Events of Special Interest
Adverse events of special interest will include the fo llowing:
infect ions (including TB, herpes zoster, or opportunist ic infections)
maligna ncies
hepat ic events (see Section [IP_ADDRESS] )
major adverse cardiovascular events (MACE) (see Section 9.4.10 )
thrombotic events (such as deep vein thro mbosis [ DVT ]and pulmo nary embo lism [ PE])
and arterial thrombotic event (see Section 9.4.9 ).
Sites will provide details on these AEs, as instructed on the eCRF ,and may  be asked for 
additional descripti on by [CONTACT_11007] .
9.2.3. Complaint Handling
Lilly co llects product complaints on IPs and drug delivery  systems used in clinical studies in 
order to ensure the safet y of study  partici pants, to monitor qualit y, and to facilitate process and 
product improvements.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227538] ECG will be obtained locally at Visit 1 and read by a qualified 
physician (the invest igator or qualified designee) at the site to determine whether the patient 
meets entry  criteria.
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary .
9.4.2. Vital Signs
For each patient, vital signs shoul d be m easured according to the SOA (Section 2).
9.4.3. Physical Exam ination
For each patient, a complete physical examinat ion (excluding pelvi c and rectal  examinat ions) 
will be performed at Visit 1 (Screening).  A symptom -directed physical  examinat ion will be 
perform ed at other visits ,as specified in the SOA (Section 2).  A com plete physical  examinat ion 
may be repeated ,at the invest igator’s discretion ,any time a patient presents with physical 
complaints.
9.4.4. Laboratory Tests
For each patient, laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
SOA (Section 2).  Home vis its to collect blood and urine samples may be allo wed upon written 
approval  from the sponsor and if consistent with local regulations. With the except ion of 
laboratory  test resul ts
that may unblind the study , Lilly or i ts desi gnee will  provide the 
investigator with the results of laboratory  tests analyzed by  a central  vendor, if a central vendor 
is used for the clinical trial.  
9.4.5. Columbia Suicide Severity Rating Scale
The C -SSRS capt ures the occurrence, severit y, and f requency of suicidal ideat ion and/or 
behavior during the assessment period.  The scale includes suggested questions to solicit the ty pe 
of inform ation needed to determine if suicidal ideation and/or behavior occurred.  T he C-SSRS i s 
administered by  [CONTACT_878700] 1 year of pat ient 
care/clinical experience.  The tool was developed by [CONTACT_389788] h trial 
I4V-MC-JAIR( d) Clinical Protocol Page 68
LY3009104group for the purpose of being a counterpart to the Col umbia Classificat ion Algori thm of Suicide 
Assessment categorizat ion of suicidal events.  For this study, the scale has been adapted (with 
permission fro m the scale authors) to include only  the porti on of  the scale that captures the 
occurrence of th e [ADDRESS_1227539] ion, sites should not change the AE form.  If an event is serious or leads to 
discontinuat ion, thi s is an except ion where the SAE and/or AE leading to discont inuat ion should 
be included on the AE form and the process for reporting SAEs should be fo llowed.
9.4.6. Self-Harm an d Follow -Up Supplement Forms
Suicide-related events (behavior and/or ideat ions) will be assessed and evaluated at every visit 
with the administrati on of  the C -SSRS and the Self -Harm Supplement Form.  The Self -Harm  
Suppl ement Form  is a single quest ion to en ter the number of suicidal behavior events, possible 
suicide behavi ors, or nonsui cidal self -injuri ous behavi ors.  If  the number of behavioral events is 
greater than zero, it will lead to the complet ion of the self -harm fo llow-up form.  The self -harm 
follow-up form  is a seri es of  quest ions that provides a more detailed descript ion of the behavior 
cases.
9.4.7. Chest X -Ray and Tuberculosis Testing
A posteri or–anterior view chest x -ray will be obtained l ocally  at Screening (Vi sit 1), unl ess one 
has been performed in the past 6 m onths and the x -ray and/or the report is available.   
The chest 
x-ray will be reviewed by  [CONTACT_878701] /her desi gnee to excl ude pat ients with active TB 
infect ion.  In addit ion, pati ents will  be tested at screening (Visit 1) for evidenc e of active or 
latent TB ,as described in the Exclusio n Criteria, Section 6.2.
Invest igators should fo llow local guidelines for m onitoring pat ientsfor TB if a pat ient is at hi gh 
risk for acqui ring TB or reactivat ion of latent TB.
9.4.8. Hepatitis B Virus DNA Monitoring
Hepati tis B vi rus DNA testi ng will be performed in enrolled pat ients who tested posit ive for 
HBcAb at screening.  
Patients who are HBcAb p ositive and HBV DNA negat ive (undetectable) at screening (Visit 1) 
will require measurement of HBV DNA approximately every  3 months during treatment (as 
detailed in the SOA [Secti on 2]) and at the follow -up visit (V801), regardless of their hepat itis B 
surface ant ibody  (HBsAb) status.
The fo llowing acti ons shoul d be taken in response to HBV DNA test results:
If a single result is obtained with a value “below limit of quant itation,” the test should 
be repeated within approximately 2 weeks.  
If the repeat test result is “target not detected,” monitoring will resume according to 
the study  schedule.  
I4V-MC-JAIR( d) Clinical Protocol Page 69
LY3009104If the pati ent has [ADDRESS_1227540] results with a value “below limit of quantitation,” 
HBV DNA testing should be performed approximately once per month for the 
remainder of the study ,and referral to a hepatologist is reco mmended.
Note: Unscheduled visits may be used to monitor HBV DNA m onthly.
If a result is obtained with a value above the limit of quant itation at any  time during 
the study , the pati ent will be permanent ly discont inued fro m IP (see Section 8.1.1 ),
and should be referred to a hepatology  specialist.  
oIn selected cases, investigators may temporarily cont inue IP in accordance 
with current immuno modulator m anagement in the setting of HBV DNA 
positivity.  This opti on m ay be considered in consultat ion with Lilly  (or i ts 
designee) and evaluat ion of individual pat ient risks and benefits.
9.4.9.
Venous Thromboembolism Assessment
If a patient develops the signs and symptoms of a DVT or PE, appropriate local labor atory  tests 
and imaging should be performed, as necessary , for diagnosis of the event.  For confirmed cases, 
additional laboratory  testing m ay be performed, as outlined in Appendix 7 . The cho ice and 
optimal t iming of these tests will be directed by [CONTACT_102]’s management and may require 
ongoing fo llow-up after study  discont inuat ion.  All suspected VTE events will be in dependently 
adjudicated by  a blinded Clinical Event Committee (see Section [IP_ADDRESS] ).
9.4.10. Safety Monitoring
Lilly will periodically  review evolving agg regate safet y data wi thin the study  by [CONTACT_82393].
In the event that safet y monitoring uncovers an issue that needs to be addressed by [CONTACT_92357] l evel, only  members of the data monitoring co mmit tee (DMC ),an advisory  group for 
this study formed to protect the integrit y of data ,can conduct additional analyses of the safet y 
data (refer to Interim Analyses sect ion [Section 10.3.6 ]).
The Lilly CRP will mo nitor safet y data throughout the course of the study .  Lilly  will review 
SAEs within time frames mandated by  [CONTACT_221056].  The Lilly  CRP will, as is 
appropriate, consult with the funct ionally independent Global Pat ient Safet y (GPS) therapeuti c 
area physician or clinical scient ist and periodically review trends in safety data and laboratory 
analytes.  Any concerning trends in frequency or severit y noted by  [CONTACT_629292]/or Lilly  
(or designee) may require further evaluat ion.
All deaths and SAE reports will be reviewed in a blinded manner by [CONTACT_878702].  These reports will be reviewed to ensure completeness and accuracy ,but will not be 
unblinded to Lilly during the clinical trial.  If a death or a clin ical AE i s deemed serious, 
unexpected, and possibly related to IP, only  Lilly GPS will  be unblinded for regul atory  reporting 
and safet y monitoring purposes.  These measures will preserve the integrit y of the data collected 
during thi s trial and minimize an y potenti al for bias while providing for appropri ate safet y 
monitoring.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227541] igators will mo nitor vital signs and carefully  review findings that may be associated with 
cardi ovascular events and VTE.  Adverse event reports and vital signs will be co llected at each 
study  visit.  The cardi ovascular monitoring plan includes the fo llowing:
regul ar monitoring of lipid l evels
potenti al MA CE (cardi ovascular death, my ocardial infarct ion, stroke), other 
cardi ovascular events, such as hospi[INVESTIGATOR_878666], hospi[INVESTIGATOR_832666], serious arrhy thmia, resuscitated sudden death, cardiogenic shock, coronary  
revascularization (eg, coronary  artery  by[CONTACT_226411]), venous and arterial thrombotic events, and noncar diovascular deaths will
be ident ified by [CONTACT_878703] a 
blinded Clinical Event Committee for adjudicat ion at regul ar intervals.
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3×ULN, ALP ≥2 ×ULN, or elevated TBL 
≥2×ULN, liver testing ( Appendix 4 ) shoul d be repeated wi thin [ADDRESS_1227542] ion8.1.
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the hepat ic eCRF if 1 or more of the fo llowing 
condi tions occur: 
elevation of serum  ALT to ≥5 × ULN on 2 or more consecutive blood tests
elevated serum  TBL to ≥2 ×ULN (except for cases of known Gilbert’s 
syndrom e)
elevation of serum  ALP to ≥2 ×ULN on 2 or more consecutive blood tests
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
hepat ic event considered to be a SAE .
See Appendix 4 and Appendix 5 for a descri ption of  hepati c laboratory  values that warra nt 
patient exclusio n from the study , tem porary  or permanent di scont inuat ion of IP, or addit ional 
safet y collection via the hepat ic eCRF.
9.5. Pharmacokinetics
Not applicable.
I4V-MC-JAIR( d) Clinical Protocol Page 71
LY30091049.6. Pharmacodynamics
Not applicable.
9.7. Pharmacogenomics
9.7.1. Whole Blood Samples for Pharmacogene tic Research
A who le blood sample will be co llected for pharmacogenet ic analysis ,as specified in the SOA 
(Secti on2),where local regulat ions allow.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research ,either 
now or in the future.  Samples will be used to investigate va riable response tobaricit inib and to 
investigate genet ic variants though t to pl ay a rol e in AA.  Assessment of variable response may  
include evaluat ion of AEs or differences in efficacy. 
All samples will be coded with the patient number.  These samples a nd any data generated can 
be linked back to the patient only by [CONTACT_82394].  
Samples will  be retained at a facilit y selected by  [CONTACT_242936] a m aximum  of 15years after the last 
patient visi t for the study , or f or a shorter peri od if loc al regulati ons and/or ethical review boards 
(ERBs)/invest igational review boards (IRBs) impose shorter time limit s.  Thi s retenti on peri od 
enables use of new techno logies, response to regulatory  quest ions, and invest igation of variable 
response that may no t be observed unt il later in the development of baricit inib or after baricit inib 
beco mes commercially available.
Molecular techno logies are expected to improve during the [ADDRESS_1227543] ion. 
9.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, pharmacodynamics ( PD), mechanism of act ion, variabilit y of pat ient response 
(including safet y), and clinical outcome.  Sample collect ionis incorporated into clinical studies 
to enable examinat ion of these quest ions through measurement of bio molecules including DNA, 
RNA, proteins, lipi[INVESTIGATOR_805], and other cellular elements.
Blood sam ples f or biomarker research will be co llected at the times speci fied in the SOA 
(Secti on2),where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable response to 
baricit inib, pathways associated with AA, mechanism of act ion of baricit inib, and/or research 
method or i n validat ing diagnost ic tools or assay(s) related to AA.  
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_82394].  
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227544] igation of variable response that may not be observed unt il later in the 
development of baricit inib or after baricit inib beco mes commercially  available.
9.9. Medical Resource Utilization and Health Economics
Health econo mics will be evaluated in this study utilizing the EQ-5D- 5L (see Section 9.1.3 ). 
Medical resource utilizat ion parameters will not be evaluated in this study .
I4V-MC-JAIR( d) Clinical Protocol Page 73
LY300910410.Statistical Considerations
10.1. Sample Size Determination
Approximately 678patients will be screened in order to en roll approximately  476 patients in 
Study  JAIR.  The enrolled pat ients will be randomized in a 2:2:3 ratio for placebo QD 
(approximately 136subjects) , bari citinib2-mgdose QD ( approximately 136 subjects) , or
baricit inib 4-mgdose QD ( approximately 204subjects) .  This sample size will provide 
approximately 90% power to test the superiorit y of baricit inib4-mgdose toplacebo or the 
superi ority of baricit inib2-mgdose toplacebo in the primary endpoint (the proportion of pat ients 
achieving SALT ≤20at Week 36) based on a 2-sided Fisher exact testwithin the graphical 
testing scheme , 
at an initialsignificance l evel of 0.0 4 for the 4-mgdose and 0.01 for the 2-mg
dose. The assumpt ions used for the power calculatio n are as fo llows: 30% response rate for 
baricit inib 4-mgdose, 20% response rate for baricitinib 2-mgdose, and 5% response rate for 
placebo (Kennedy Crispin et al. 2016; Mackay -Wiggan et al. 2016). The init ial alpha allocat ion 
may be adjusted in the SAP when newer informat ion is obtained on the endpo ints that are being 
tested and will be finalized prior to the primary database lock.   
Patients who achieve a SALT ≤20at Week 52 (responders) AND who have remained on the 
4-
mgdose of baricit inib fro m rando mizat ion (Visit 2) to Week 52, will e nter the rando mized 
downti tration,which is meant to evaluate the change in clinical response after treatment 
downti tration,and does not account for whether the sample size is sufficient to detect statistical
difference between baricit inib4-mg dose and 2-mg dose. Itis expected that there would be 
approximately  60patients eligible for the randomized downti tration. 
I4V-MC-JAIR( d) Clinical Protocol Page 74
LY300910410.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Full Analy sis Set (FAS) All patients randomized in Study JAIR will be included in the FAS.  Patients 
will be analyzed according to the IPto which they were randomized at Baseline 
(Visit 2). Of note, FAS is essentially the ITT population.
Modified Full Analy sis Set
(mFAS ) Population All patients randomized in Study JAIR and received at least 1 dose of IP, will be 
included in the mFAS.  It exclude spatients with female pattern baldness and 
male patients with diffuse AGAa(Grade IV and above ) (Norwood 1975)
identified at W eek 36 .  Patients will be analyzed according to the IPto which 
they were randomized at Baseline (Visit 2) .
Per-Protocol Set (PPS) The PPS will include all m FAS patients who are not deemed noncompliant with 
treatment, who do not have any of the important protocol deviations that 
exclude patients from the PPS, and w hose investigator site does not have 
significant GCP deviations that require a report to regulatory agencies .  The 
important protocol deviations, including the subset that result in exclusion fro m 
the PPS, will be determined while the study team remains blinded, prior to the 
primary  outcome database lock .
Safety Population The Safety Population is defined as all patients who were randomized in 
Study JAIR, who receive dat least 1 dose of IP,and who did not discontinue 
from the study for the reason “Lost to F ollow -up” at the first post -Baseline visit .  
Patients will be analyzed according to the treatment group towhich they were 
assigned. 
Abbreviations: AGA = androgenetic alopecia ;GCP = good clinical practice; IP= Investigational product, 
ITT=intent -to-treat .
aSome male patients with Grade IV AGA and female patients with patterned baldness may only be identified after 
hair regrowth.
Any addit ional analysis populati ons will be defined in the SAP.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly. 
The efficacy analysis o f the primary and key  secondary  endpoints will be conducted in the full 
analysis set (FAS) popul ation.  All other e fficacy or heal th outcom eanalyses will be conducted 
inthe FAS popul ation or other populat ions described in the SAP .  Safet y analyses will be 
conduc ted using the safet y popul ation.Addit ional efficacy  or saf ety interim analy ses may be 
perform ed prior to final database lock (F -DBL) to support regulatory submissi onsand will be 
described in detail  in the SAP .
All tests of treatment effects will be conducted at a 2 -sided al pha level of 0.05 unless otherwise 
stated.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
I4V-MC-JAIR( d) Clinical Protocol Page 75
LY3009104methods described in the protocol (and the just ification for making the change )will be described 
in the clinical study  report ( CSR ).  Additional exploratory analyses of the data will be conducted ,
as deemed appropriate.   Com plete details o f the planned analyses will be documented in the 
SAP.
[IP_ADDRESS]. Analysis Methods
The primary  analysis of discrete efficacy  and heal th outcom es vari ables will use a logist ic 
regression analysis with geographic region, durati on of  current epi [INVESTIGATOR_878643] (<4 years vs 
≥4 years) ,baseline value, and treatment group in the model unless otherwise stated .  The p -value 
and 95% confidence interval (CI) for the odds ratio fro m the logistic regressio n model are used 
for primary stati stical inference.  Inthe case when logistic regressio n model does not produce 
statist ical results due to sparse data, Fisher exact test will be used .  The difference in percentages 
and 95% CI of the difference in percentages using the Newcombe -Wilson method without 
continuit y correcti on are used for descript ive purposes unless otherwise specified.  Missing data 
will generally be imputed using nonresponder imputation (NRI), as described in Secti on10.3.1.2 .
The primary  analyses for the continuous efficacy and healt h outcome variables will use analysis 
of covari ance (A NCOVA) wi th geographi c regi on, durati on of  current epi [INVESTIGATOR_878643] (<4 
years vs ≥4 years), treatm ent group, and baseline value in the model unless otherwise stated. 
Type III tests for the least-squares (LS)means will be used for statist ical comparison between 
treatm ent groups. The LS m ean difference, standard error, p -value, and 95% CI willalso be 
reported. The method used to handle missing data will be modified last observat ion carri ed 
forward (mLOCF) and is reasonable for this indicati onas very  few pati ents experi enced waxing 
and waning in scalp hair during the course of treatment from the Phase 2 porti on of  study  JAHO
andseveral  external  studies on al opecia areata . Addit ional details o f the mLO CFmethod are 
described in Section [IP_ADDRESS] .
Analysis of cont inuous eff icacy and healt h outcome variables over time may be made using a 
restri cted maximum likelihood -based mixed model for repeated measures (MMRM) analysis.  
The m odel will include geographic region ,durati on of current epi[INVESTIGATOR_878643] (<4 years vs 
≥4 years), treatm ent group, vi sit, treatm ent-by-visit interaction as fixed categorical effects, and 
baseline value/baseline value -by-visit interacti on as fixed continuous effects unless otherwise 
stated.  An unstructured covariance structure will be used to model the between -and within -
patient errors.  If this analysis fails to converge, the heterogeneous autoregressive [ARH(1)], 
followed by [CONTACT_878704]  (CSH), followed by  [CONTACT_878705] 
(TOEPH) will be used.  The variance -covariance structure that results in the smallest Akaike 
inform ation criterion will be used.  The Kenward- Roger m ethod will be used to estimate the 
deno minator degrees of freedo m.  Type III tests for the LS means will be used for the statist ical 
comparisons.  The LS mean difference, standard error, p -value, and CIs will also be reported.  
Contrasts will be set up within the model to test treatment groups at specific time po ints of 
interest . Additional details o f the MMRM method are described in Sect ion [IP_ADDRESS] .
Time -to-event analysis willbe performedand analyzed using log-rank test. ACox proportional 
hazards model may be used with treatm ent an d other stratificat ion vari ables in the m odel.  
Hazard rati o with CIs maybe reported .  Kaplan -Meier curves willalso be produced .  Diagnostic 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227545] ical comparison between treatm ent groups.  Shift tables for categorical safet y analyses (eg ,
“high”or “low”laboratory  resul ts) will also be produced.
[IP_ADDRESS]. Missing Data Imputation
As wi th any clinical study , pati ent dropouts and consequent ly missing data is an expected issue 
for this study .  Pati ents who di scont inue treatment, unless they withdraw consent, will be 
encouraged to remain in the study  and f ollow the scheduled visit s unt il the primary analysis t ime 
point at Week [ADDRESS_1227546] missing 
data.  
The fo llowing imputati on rul es will  be used for the double -blind treatment period (Period 2).  
Details for handling missing data in later periods will be provided in the SAP.
Non-responder imputati on:  Analysis o f categori cal efficacy and heal th outcom es variables 
will be assessed using NRI unless otherwise stated.  Patients will be considered 
nonresponders for the NRI- based analysis if they do not meet clinical response criteria or if 
they perm anently discont inued study  treatm ent or di scontinued fro m the study  at any  time 
prior to the time po int of interest for any  reason.  An addit ional analysis may  be perform ed 
on all available data up to permanent tre atment discontinuat ion.
Modified l ast observat ion carried forward :  For cont inuous variables, the primary analysis 
will be A NCOVA wi th missing data imputed by [CONTACT_878706], which us es the most 
recent non -missing postbaseline assessment. The specific modificat ion to the LOCF is data 
afterpermanent study  treatm ent discont inuat ion will not be carried forward.
Mixed -effects m odel for repeated m easures :  For continuous variables, an MMRM analysis 
with a missing- at-random assumpt ion for handling missing da tamay also be conducted .  Thi s 
analysis takes into accoun t both the missingness of data and the correlat ion of the repeated 
measurements.  No addit ional imputati on methods will be applied to the MMRM analysis.  
For pati ents who perm anently discont inue the study  or the study  treatm ent, data after 
discontinuat ion will  be excluded.
Addit ionalanalyses, including addit ional methods forhandling missing data ,such as placebo 
multiple imputati on (pMI) and tippi[INVESTIGATOR_11300] a nalys is, are specified in Appendix 6 and finalized 
details (if necessary) will be included in the SAP. 
I4V-MC-JAIR( d) Clinical Protocol Page 77
LY300910410.3.1.3. Multiple Comparisons/Multiplicity
Multiplicity adjusted analyses will be performed on the primary  and key secondary  objectives in 
order to con trol the overall family -wise Ty pe I error rate at a 2 -sided alpha l evel of 0.05. The 
graphical mult iple testing procedure described in Bretz et al. (2011) will be used.  The graphical 
approach i s a cl osed testing procedure; hence, it strongly  control s the familywise error rate 
across all endpo ints (Alosh et al. 2014).  Figure JAIR. 2illustrates the graphical testing 
procedures that will be used; a summary o f the procedures is provided in Appendix 6 .  Details of 
the specific graphical testing scheme (including testing order, interrelat ionships, Ty pe I error 
allocat ionfor the primary  and key secondary  endpoints , and the associated propagation) will be 
pre-specified i n Appendix 6 and the SAP.   These details may be revised in the SAP when newer 
inform ation is obtained on the endpo ints that are being tested.  However, the graphical testing 
scheme will be finalized prior to primary database lock.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227547] of primary  and key secondary  hypothe ses to be tested.  The subscript for 
H denotes the selected 2doses, the numerical identifier of the endpo int within the dose, and the 
type of hypothesis (0 for null, 1 for alternat ive), respect ively.

I4V-MC-JAIR( d) Clinical Protocol Page 79
LY3009104Primary Null Hypothesis:
H1,1,0:  Proporti on of  patients in the baricit inib 4-mgdose group achieving SALT ≤20at 
Week 36 is less than or equal to placebo.
H2,1,0:  Proportion of patients in the baricit inib 2-mgdose group achievin g SALT ≤20 at 
Week 36 is less than or equal to placebo.
Key Secondar yNull Hypotheses:
H1,2,0:  Proporti on of  patients in the baricit inib 4-mgdose group with a PRO for Scalp 
Hair Assessment score of 0 or 1 with a ≥2-point improvement at Week [ADDRESS_1227548] acebo (
among patients with a score of ≥3 at baseline ).
H2,2,0:  Proporti on of  patients in the baricit inib 2-mgdose group with a PRO for Scalp 
Hair Assessment score of 0 or 1 with a ≥2-point improvement at Week [ADDRESS_1227549] acebo (among patients with a score of ≥3 at baseline) .
H1,3,0:  Proporti on of pati
ents in the baricit inib 4-mgdose group achieving SALT ≤20 at 
Week 24 is less than or equal to placebo.
H2,3,0:  Proporti on of  patients in the baricit inib 2-mgdose group achieving SALT ≤20 at 
Week 24 is less than or equal to placebo.
H1,4,0:  Proporti on of  patients in the baricit inib 4-mgdose group achieving SALT ≤20 at 
Week 16 is less than or equal to placebo.
H2,4,0:  Proportion of patients in the baricit inib 2-mgdose group achieving SALT ≤20 at 
Week 16 is less than or equal to placebo.
H1
,5,0:  Proporti on of  patients in the baricit inib 4-mgdose group achieving an abso lute 
SALT score ≤10at Week 36is less than or equal to placebo.
H2,5,0:  Proporti on of  patients in the baricit inib 2-mgdose group achieving an abso lute 
SALT scor e ≤10at Week 36is less than or equal to placebo.   
H1
,6,0:  Proporti on of  patients in the baricit inib 4-mgdose group achieving an abso lute 
SALT score ≤10at Week 24is less than or equal to placebo.
H2,6,0:  Proporti on of  patients in the baricit inib 2-mgdose group achieving an abso lute 
SALT score ≤10at Week 24is less than or equal to placebo.
H1,7,0:  Proportion of patients in the baricit inib 4-mgdose group with SALT 90at Week 36 
is less than or equal to placebo.
H2,7,0:  Proportion of patients in t he baricit inib 2-mg dose group with SALT 90at Week 36 
is less than or equal to placebo.
H1,8,0:  Proportion of patients in the baricit inib 4-mgdose group with SALT 5 0at Week 12 
is less than or equal to placebo.
H2,8,0:  Proporti on of  patients in the baricit inib2-mgdose group with SALT 5 0at Week 12 
is less than or equal to placebo.
H1,9,0:  Proporti on of  patients in the baricit inib 4-mgdose group achieving ClinRO 
Measure for EB Hair Loss 0 or 1 with ≥2-point improvem ent from baseline at Week 36 is 
less than or equal to placebo (among patients with ClinRO Measure for EB Hair Loss
≥2at Baseline) .
I4V-MC-JAIR( d) Clinical Protocol Page 80
LY3009104H2,9,0:  Proporti on of  patients in the baricit inib 2-mgdose group achieving ClinRO 
Measure for EB Hair Loss 0 or 1 with ≥2-point improvem ent from baseline at Week 36 is 
less than or equal to placebo (among patients with ClinRO Measure for EB Hair Loss
≥2at Baseline) .
H1,10,0:  Proportion of pat ients in the baricit inib 4-mgdose group achieving ClinRO 
Measure for E LHair Loss 0 or 1 with ≥2-point improvem entfrom baseline at Week 36 is 
less than or equal to placebo (among patients with ClinRO Measure for EL Hair Loss
≥2at Baseline) .
H2,10,0:  Proportion of pat ients in the baricit inib 2-mgdose group achieving ClinRO 
Measure for E LHair Loss 0 or 1 with ≥2-point improvem ent from baseline at Week 36 is
less than or equal to placebo (among patients with ClinRO Measure for EL Hair Loss
≥2at Baseline) .
H1,11,0: Percent change from Baseline in SALT score of patients in the baricit inib 4 -mg 
dose group at Week
36 is greater than or equal to placebo.
H2,11,0: Percent change from Baseline in SALT score of patients in the baricit inib 2 -mg 
dose group at Week 36 is greater than or equal to placebo.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposit ion
A detailed description o f patient di sposi tion by  [CONTACT_878707].  Frequency  counts and percentages will be presented for each treatment group.  
All patients who discont inue from the study  or the study  treatment will be i dentified, along with 
their reason for di scont inuat ion. 
[IP_ADDRESS]. Patient Characteristics
Dem ographic and Baseline characterist ics will be summarized descript ively by [CONTACT_1570].  
Descript ive statistics including number of patients, mean, standa rd deviat ion, median, minimum, 
and maximum will be provided for continuous measures, and frequency counts and percentages 
will be tabulated for categorical measures.  No formal statist ical co mpar isons will be made 
among treatm ent groups unl ess otherwi se stated.   A co mplete list of patient characterist ics and 
Baseline clinical measures will be provided in the SAP.
[IP_ADDRESS]. Concomitant Therapy
Concomitant medicat ions will be descript ively summarized by [CONTACT_878708].  The medicat ions will be coded 
accordingly.  
[IP_ADDRESS]. Treatment Compliance
Treatment compliance wit h the randomly assigned study  medicati on will  be evaluated at every  
clinic visit through the counts of returned IP tabletsper bottle .  A pati ent wil l be considered 
significant ly noncom pliant if he /she misses more than 20% of the prescribed doses during the 
study , unless the patient ’s IP is wit hheld by [CONTACT_405748] y reasons ( ie, com pliance 
<80%).  Similarly, a patient will be considered s ignificant ly nonco mpliant if he /she is j udged by 
[CONTACT_878709] m ore than the prescribed amount of 
I4V-MC-JAIR( d) Clinical Protocol Page 81
LY3009104medicat ion (ie, com pliance ≥120%).  Patients who are significantly nonco mpliant will be 
excluded fro m the per-protocol set (PPS ) (see Sectio n10.2).
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  efficacy  measure is the binary  outcome of response defined as SALT score ≤20 (see 
Secti on9.1.1 ) at Week 36.  The primary analysis testing the treatment difference between each 
of the baricitinib dose sincluded in Study JAIR and placebo will be conducted using a logist ic 
regression model, as described in Section [IP_ADDRESS] .Inthe case when logistic regressio n model 
does not produce statist ical results due to sparse data, Fisher exact test will be used .  As
ment ionedin Sect ion10.3.1.[ADDRESS_1227550] ion10.3.1.2 ,as it is a conservat ive imputation 
approach for handling missing data for patients who permanently discont inued study  treatment or 
discontinued fro m the study  before primary  endpoint due to reasons other than lack of efficacy 
(eg, lost to follow -up). Additional analysis o f the primary  efficacy  outcom e may  be conducted 
and will include all available data up to permanent treatment discont inuat ion.
[IP_ADDRESS]. Secondary Analyses
Treatment comparisons in th e proporti on of  patients achieving a binary response will be 
analyzed using the logist ic regressio n model defined in Section [IP_ADDRESS] .  Inthe case when 
logistic regressio n model does not produce stati stical resul tsdue to sparse data, Fisher exact test 
will be used.  For binary responses, missing data will be imputed using the NRI method 
described in Section [IP_ADDRESS] unless otherwise stated .  Treatm ent com parisons in the cont inuous 
measures will be analyzed using the ANCOVA method defined in Sect ion10.3.1.1unless 
otherwi se specified.  Time -to-event data will be analyzed using log -rank test al ong wi th 
Kaplan -Meier curves.  Additional analysis of the secondary efficacy  outcom e may  be conducted 
and will include all available data up to permanent treatment discont inuat ion.
[IP_ADDRESS]. Exploratory Analyses 
Analyses will be conducted for the other exploratory  objectives defined in Sect ion 4.  Specific 
details o f analyses will be specified in the SAP.
10.3.4. Safety Analyses
All safet y data will be descript ively summarized by [CONTACT_878710] y popul ation unless otherwise stated.
Treatment -emergent adverse events are defined as AEs that first occurred or worsened in 
severit y after the first dose of study  treatm ent.  The number of TEAEs ,as well as the number and 
percentage of patients who experienced at lea st 1 TEAE ,will be summarized using the Medical 
Dictionary for Regulatory  Activities(MedDRA ) for each system  organ cl ass (or body  system ) 
and each preferred term by [CONTACT_1570].  Serious adverse events and AEs that lead to 
discontinuat ion of IP will a lso be summarized by  [CONTACT_3227].  The Fisher exact test will be 
used to perform comparisons between each baricit inib dose and the placebo group.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227551] will be 
docum ented in the program safet y analysis plan and study  SAP.
10.3.5. Other Analyses
[IP_ADDRESS]. Subgroup Analyses 
To assess whether the treatment effect is similar across subgroups f or the primary  efficacy 
outcom e, a l ogistic model will be used and will include treatment, baseline value, stratificat ion 
variables, the subgroup variable (eg ,sex), and the subgroup -by-treatm ent interacti on.  If the 
interact ion is statist ically significan t at al pha=0.10, the nature of the interaction will be explored, 
that is, wi thin each subgroup, the treatment effect will be estimated.
Subgroups to be evaluated will include : demographic characteri stics (such as regio n or country , 
gender, age, race), ren al function, and Baseline disease characterist ics.  Addit ional subgroups, as 
well as detailed descript ions of the subgroup variables, will be defined in the SAP.
Further definit ions for the levels of the subgroup variables, the analysis methodology , and an y 
additional subgroup analyses will be defined in the SAP .  Because this study is not adequately 
powered for subgroup analyses, subgroup analyses will generally be treated as exploratory . 
10.3.6. Interim Analyses
[IP_ADDRESS]. Data Monitoring Committee
A DMC will oversee the c onduct of thi s trial.  The DMC will consist of members external to 
Lilly.  This DMC will fo llow the rul es defined in the DMC charter, focusing on potential and 
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227552] udy discont inuat ion data, AEs /SAEs, clinical laboratory  data, 
vital sign data, etc.  The DMC may reco mmend : continuat ion of the study , as designed; 
temporary  suspensi on of enro llment; or the discontinuat ion of a particular dose regimen or the 
entire study .  The DMC m ay request to revi ew efficacy  data to invest igate the benefit/risk 
relationship in the context of safet y observations for ongoing patients in the study .  However, the 
study  will not be stopped for posit ive efficacy results.  Details of the DMC will be docum ented 
in a DMC charter and DMC analysis plan.
The DMC is authorized to evaluate unblinded interim efficacy and safet y analyses during the 
study .  Study  sites will receive information about interim result s if they need to know for the 
dose chan ge or safet y of their patients.
Unblinding details will be specified in a separate unblinding plan document.
[IP_ADDRESS]. Adjudication Committee
A blinded Clinical Event Committee will adjudicate potential MACE (cardiovascular death, 
myocardial  infarct ion, stroke), other cardiovascular events (such as hospi[INVESTIGATOR_878667], hospi[INVESTIGATOR_266438], serious arrhyt hmia, resuscitated sudden death, 
cardi ogenic shock, coronary  revascularizat ion [eg,coronary  artery  by[CONTACT_878711]]), venous and arterial thromboti c events, and noncardio vascular deaths.  
Details o f membership, operations, recommendat ions from the Committee, and the 
communicat ion plan will be documented in the Charter.
[IP_ADDRESS]. Week 36 Primary Outcomes Analyses and Other Interim Analyses
After all rando mized pat ients com plete the primary  efficacy assessment at Week 36 (Visit 8) or 
discontinue early , the database will be l ocked ,and data will be unblinded to a limited number of 
pre-identified individuals to init iate work for submissio n. Although it i s called an interim 
analysis, the primary outcome database lock (PO -DBL) interim analysis is the only and final 
analysis for the primary endpo int.Therefore, no alpha adjust ment for thisinterim analysis 
isplanned. 
Addit ional efficacy or safet y interim analyses may  occur after the PO -DBL and prior to the 
Final-DBL to support regulatory  submissi ons and scientific disclo sures and will be described in 
detail in the SAP .
Inform ation that may unblind the study  during the analyses will not be reported to study  sites or 
blinded study  team  until  the study  has been unblinded.
Unblinding details will be specified in a separate unblinding plan document .
I4V-MC-JAIR( d) Clinical Protocol Page 84
LY300910411. References
Alosh M, Bretz F, Huque M. Adva nced m ultiplicity adjustm ent m ethods in clinical tri als. 
StatMed. 2014;33(4):693 -713.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multip le comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J.
2011;53(6):894 -913.
Clark JD, Flanagan ME, Telliez JB. Discovery  and devel opment of Janus kinase (JAK) inhibitors 
for inflammatory  diseases. J Med Chem . 2014;57(12):5023-5038.
Colón EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky  MK . Lifet ime prevalence of 
psychiatric disorders in pat ients with alopecia areata. Compr Psychiatry. 1991;32(3):245 -251.
Craiglow BG, Li u LY, King BA. Tofacit inib for the treatment of alopecia areata a nd variants in 
adolescents. J Am Acad Dermatol. 2017;76(1):29 -32.
EuroQol  Group. EQ -5D- 5L User Guide. Version 2.1. Available at:  
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/EQ -5D-
5L_UserGuide_2015.pdf. April 2015. Accessed March 2017.
Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li  J, Covington MB, Thomas B, Collier P, 
Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G , 
Newton RC, Metcalf B, Friedman SM, Vaddi K. Select ive inhibit ion of  JAK1 and JAK2 is 
efficacious in rodent models of arthritis: preclinical characterizat ion of INCB028050. 
JImmunol . 2010;184(9):5298-5307.
Herdm an M, Gudex C, Llo yd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development 
and preliminary  testing of the new five -level version of EQ- 5D (EQ -5D- 5L). Qual Life Res . 
2011;20(10):1727 -1736.
Hordinsky M, Donati A. Alopecia areata: an evidence -based treatment update. Am J Clin 
Dermatol. 2014;15(3):231 -246.
Hordinsky M, Junqueira AL. Alopecia areata update. Semin Cutan Med Surg . 2015;34(2):[ADDRESS_1227553] of alopeci a. BMJ. 2005;331(7522):951 -953.
Islam N, Leung PS, Huntley  AC, Gershwin ME. The autoimmune basis of alopecia areata: a 
comprehensive review. Autoimmun Rev . 2015;1 4(2):81 -89.
Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach -Mansky  R, 
Christiano AM, Clynes R, Zlotogorski A. Reversal of alopecia areata fo llowing treatm ent wi th 
the JAK1/2 inhibitor baricit inib. EBioMedicine. 2015;2(4):[ADDRESS_1227554] 
Dermatol . 2018 :138(7):1539 -1545.
Janković S, Perić J, Maksimo vić N, Ćirković A, Marinković J, Janković J, Reljić V, Medenica L. 
Qualit y of life in pat ients with alopecia areata: a hospi[INVESTIGATOR_307] -based cross -sectional study . J Eur 
Acad Dermatol Ve nereol. 2016;30(5):840 -846.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227555], Naghavi M, Coffeng LE, Lott JP, Wulf S, Hay  R, Williams HC, 
Weinstock MA, Norton SA, Armstrong AW, Dunnick CA, Norris DA, Dellavalle RP. The 
global burden of disease associated with alopecia areata. Br J Dermatol. 2015;172(5):[ADDRESS_1227556] iano AM, Oro AE, King BA. Safet y and 
efficacy  of the JAK inhibitor tofacit inib citrate in patients with alopecia areata. JCI In sight.
2016;1(15):e89776.
Korta DZ, Christ iano AM, Bergfeld W, Duvic M, Ellison A, Fu J, Harris JE, Hordinsky MK, 
King B, Kranz D, Mackay -Wiggan J, McMichael A, Norris DA, Price V, Shapi[INVESTIGATOR_2152] J, 
Atanaskova Mesinkovska N. Alopecia areata is a medical disease. J Am Acad Dermatol. 
2018;78(4):832 -834.
Krakowski AC, Eichenfield LF, Dohil MA. Managem ent of  atopi c derm atitis in the pediatric 
popul ation. Pediatrics . 2008;122(4):812
-824.
Liu LY, Crai glow BG, Dai  F, King BA. Tofacit inib for the treatment of severe alopecia areata 
and variants: a study  of 90 patients. J Am Acad Dermatol. 2017;76(1):22 -28.
Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and 
adolescents. J Investig Dermatol Symp Proc . 2018;19(1):S18 -S20.
Liu LY, King BA, Craiglow BG. Health -related quali ty of life (HRQoL) am ong pati ents wi th 
alopecia areata (AA): a sy stem atic review. J Am Acad Dermatol . 2016;75(4):806 -812.
Mackay -Wiggan J, Jabbari  A, Nguy en N, Ceri se JE, Cl ark C, Uleri o G, Furniss M, Vaughan R, 
Christiano AM, Clynes R. Oral ruxo litinib induces hair regrowth in patients with moderate -to-
severe alopecia areata. JCI Insight. 2016;1(15):e89790.
Maruish ME .User’s manual for the SF -36v2 Healt h Survey (3rd ed.). Linco ln, RI: Qualit yMetri c 
Incorporated. 2011 .
Norwood OT. Male pattern baldness: classificat ion and incidence. South Med J.
1975;68(11):1359 –1365.
Olsen EA. Invest igative guidelines for alopecia areata. Dermatol Ther . 2011;24
(3):[ADDRESS_1227557] MS, Coté NL. The presence of loose anagen hairs obtained by [CONTACT_878712]. J Investig Dermatol Symp Proc . 1999;4(3):258 -260.
Olsen EA, Hordi nsky MK , Price VH, Roberts JL, Shapi[INVESTIGATOR_2152] J, Canfield D, Duvic M, King LE Jr, 
McMichael AJ, Randall VA, Turner ML, Sperling L, Whit ing DA, Norris D; Nat ional 
Alopecia Areata Foundation. Alopecia areata investigat ional assessment guidelines –Part II. 
National Al opecia Areata Foundati on. J Am Acad Dermatol. 2004;51(3):440 -447.
Paus R, Nicko loff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol . 2005;26(1):32 -40.
Rencz F, Gulácsi L, Péntek M, Wikonkál N, Baji P, Brodszky  V. Al opecia areata and healt h-
related quali ty of life: a systemat ic review and meta -analysis . Br J Dermatol. 
2016;175(3):561 -571.
Snait h RP. The Hospi[INVESTIGATOR_469487] y and Depressio n Scale. Health Qual Life Outcomes . 2003;1:29.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227558] iano AM, Shapi[INVESTIGATOR_2152] J. Alopecia 
areata: di sease characteri stics, c linical evaluat ion, and new perspect ives on pathogenesis. J Am 
Acad Dermatol. 2018;78(1):[ADDRESS_1227559] ivation without parallel  
TH17/TH22 skewing. J Allergy Clin Immunol . 2015;136(5):1277
-1287.
Tan E, Tay  YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singap ore –
a study  of 219 Asians. Int J Dermatol. 2002;41(11):748 -753.
Villasante Fricke AC, Miteva M. Epi[INVESTIGATOR_878668]: a sy stem atic 
review. Clin Cosmet Investig Dermatol. 2015;8:397 -403.
Wasserman D, Guzman -Sanchez DA, Scott K, McMic hael A. Alopecia areata. Int J Dermatol.
2007;46(2):121 -131.
White D, Leach C, Sims R, Atkinson M, Cottrell D. Validat ion of the Hospi[INVESTIGATOR_469487] y and 
Depressio n Scale for use with ado lescents. Br J Psychiatry . 1999;175:[ADDRESS_1227560] iano AM, Clynes R. Alopecia 
areata i s driven by  [CONTACT_878713] c T lymphocy tes and is reversed by  [CONTACT_878714]. Nat Med.
2014;20(9):1043 -1049.
Zigmond AS, Snai th RP. The Hospi [INVESTIGATOR_469487] y and Depressi on Scale. Acta Psychiatr Scand . 
1983;67(6):361 -370.
I4V-MC-JAIR( d) Clinical Protocol Page 87
LY300910412. Appendices
I4V-MC-JAIR( d) Clinical Protocol Page 88
LY3009104Appendix 1. Abbreviations and Definitions
Term Definition
AA alopecia areata
AA-IGA Alopecia Areata Investigator Global Assessment
AD atopic dermatitis
AE adverse event:  any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can ,therefore ,be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
ANCOVA analy sis of covariance
AST aspartate aminotransferase
AT alopecia areata totalis
AU alopecia areata universalis
BCG Bacillus Calmette -Guérin vaccine
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the Sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
Sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
BMI body mass index
CI confidence interval
CKD- EPI [INVESTIGATOR_878669]- reported outcome
CPK creatinine phosphokinase
CRF case report form
I4V-MC-JAIR( d) Clinical Protocol Page 89
LY3009104CRP clinical research physician
CSR clinical study report
C-SSRS Columbia Suicide Severity Rating Scale
CTCAE Common Terminology Criteria forAdverse Events
DMC data monitoring committee
DNA deoxyribonucleic acid
DVT deep vein thrombosis
ECG electrocardiogram
eCOA electronic clinical outcome assessment
eCRF electronic case report form
eGFR estimated glomerular filtration rate
ePRO/PRO electronic patient -reported outcome/patient -reported outcome
EQ-5D-5L European Quality of Life – 5Dimensions – 5Level
ERB ethical review board
ET early  termination 
FAS full analy sis set
FDA Food and Drug Administration
F-DBL final database lock
FSH follicle -stimulating hormone
GBD Global Burden of Disease 
GCP good clinical practice
GGT gamma -glutamyltransferase
GPS Global Patient Safety
HADS Hospi[INVESTIGATOR_878670] B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
I4V-MC-JAIR( d) Clinical Protocol Page 90
LY3009104HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IFNγ interferon gamma
Ig immunoglobulin
IL interleukin
INR internatio nal no rmalized ratio
IP investigatio nal product:  apharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the 
autho rized form, or market ed products used for an unauthorized indication, or marketed 
products used to gain further information about the authorized form.
IRB institutional review board
IV intravenous
IWRS interactive web -response sy stem
JAK Janus kinase
LS least squares 
LTE Long -term Extension
MACE major adverse cardiovascular events
MCMC Markov chain Monte Carlo method
MCS mental component score
MedDRA Medical Dictionary for Regulatory Activities
MHC major histocompatibility complex
mFAS modified full analysis set
MI multiple imputation
mLOCF modified last observation carried forward
I4V-MC-JAIR( d) Clinical Protocol Page 91
LY3009104MMRM mixed-effects model of repeated measures
mRNA messenger RNA
NRI nonresponder imputation
PCS physical component score
PD pharmacodynamics(s)
PE pulmo nary embolism
PK pharmacokinetic
pMI placebo multiple imputation
PO-DBL primary  outcome database lock
[COMPANY_003] purified protein derivative
PPS per-protocol set
PRO/ePRO patient -reported outcome/electronic patient -reported outcome
QD once daily administration
RA rheumatoid arthritis
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SALT Severity  of Alopecia Tool
SALT [ADDRESS_1227561] 50% improvement from Baseline in SALT score
SALT [ADDRESS_1227562] 75% improvement from Baseline in SALT score
SALT [ADDRESS_1227563] 90% improvement from Baseline in SALT score
SAP statistical analysis plan
SF-36 Short Form -36Health Survey
SOA Schedule of Activities
STAT signal transducer and activator of transcription
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB tuberculosis
I4V-MC-JAIR( d) Clinical Protocol Page 92
LY3009104TBL total bilirubin level
TEAE treatment -emergent adverse event:  an untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, which does not n ecessarily have to have a causal relationship 
with this treatment.
TSH thyroid-stimulating hormone
TYK2 tyrosine kinase [ADDRESS_1227564] upper limit of normal 
VAS visual analog scale
VTE venous thromboembolic event
WBC white blood cell
I4V-MC-JAIR( d) Clinical Protocol Page 93
LY3009104Appendix 2. Clinical Laboratory  Tests
Hematology a,b Clinical Chemistry a,b
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Absolute Reticulocyte Count Total bilirubin
Mean cell volume Direct bilirubin
Mean cell hemoglobin Alkaline phosphatase
Mean cell hemoglobin concentration Alanine aminotransferase (ALT)
Leukocytes (WBC) Aspartate aminotransferase (AST)
Platelets Blood urea nitrogen (BUN)
Absolute counts of: Creatinine
Neutrophils, segmented Cystatin C
Neutrophils, juvenile (bands) Uric acid
Lymphocy tes Calcium
Monocytes Glucose
Eosinophils Albumin
Basophils Total protein
Estimated glomerular filtration rate (eGFR)e
Creatine phospho kinase (C PK)
Urinalysis a,b,d
Color Other Testsa
Specific gravity Hepatitis B surface antigen ( HBsAg)f
pH Anti-Hepatitis B core antibody ( HBcAb)f
Protein Hepatitis B virus ( HBV )DNA l
Glucose Anti-Hepatitis B surface antibody ( HBsAb)f
Ketones Human immunodeficiency virus (HIV)f
Bilirubin Hepatitis C antibodyf,g
Urobilinogen Thyroid-stimulating hormone (TSH)f
Blood Explo ratory  storage samples (serum, plasma ,and mRNA)
Leukocyte esterase Pregnancy Testh
Nitrite Follicle -stimulating hormonef,i
QuantiFERON -TB Goldj(central testing preferred) or T-SPOT. TBk 
(local testing)
Lipi[INVESTIGATOR_878671],c[COMPANY_003] (local testing /reading )
Total cholesterol Serum immunoglobulin (IgE)
Low-density  lipoprotein
High -density lipoprotein
Triglycerides
Abbreviations:  DNA = deoxyribonucleic acid; mRNA = messenger ribonucleic acid; FSH = follicle -stimulating 
hormone; HBV = hepatitis B virus; IgE=immunoglobulin E; [COMPANY_003] = purified protein derivative; RBC = red 
blood cell; TB= tuberculosis; WBC = white blood cell.
aAssay ed by [CONTACT_2728] -designated laboratory.
bUnscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227565] will be performed at Visit 2 and at all subsequent study visits .  If required per local regulations 
and/o r institutional guidelines, pregnancy testing can occur at other times during the study treatment period.
iTo confirm postmenopausal status for women ≥40 and <[ADDRESS_1227566] will be performed.  Nonchildbearing potential is defined as an FSH ≥40mIU/mL and a cessation of 
menses for at least [ADDRESS_1227567] (central testing) is the preferred alternative to the [COMPANY_003] test for the evaluation of 
TB infection, and it may be used instead of the [COMPANY_003] test or T -SPOT.TB test.  If the QuantiFERON -TB Gold test 
is indeterminate, [ADDRESS_1227568] is allowed.
kT-SPOT. TBmustbe read locally.
lHBV DNA testing will be done in those patients who are HBcAb+ at screening, regardless of HBsAb status.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227569] igator is responsible for:
ensuring that the patient understands the nature of the study , the potential risks 
and benefits of participat ing in the study , and that their participat ion is vo luntary.
ensuring that informed consent is given by [CONTACT_57996].  
This includes obtaining the appropriate signatures and dates on the informed 
consent form (ICF) pri or to the performance of any  protocol  procedures and pri or 
to the administration of invest igational product.
answering any quest ions the pati ent m ay have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be relevant to the pati ent’s 
willingness to continue his/her participation in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the participant’s 
legal representative and is kept on file.
ensuring that the medical record includes a statem ent that wri tten inform ed 
consent was obtained before the participant was enrolled in the study  and the date 
the wri tten consent was obtained.  The authorized person obtaining the informed 
consent must also sign the ICF.
Appendix 3.1.[ADDRESS_1227570] (ERB) w as properly 
constituted and convened ,as requi red by [CONTACT_178363] (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investigative site(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the protocol and related amendments and addenda, current Invest igator’s 
Brochure (IB) and updates during the course of the study
I4V-MC-JAIR( d) Clinical Protocol Page 96
LY3009104inform ed consent form  
other rel evant docum ents ( eg, curri cula vi tae, adverti sements)
Appendix 3.1.4. Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with the:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences Internat ional Ethi cal Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the Sponsor will be assigned to a third party .
Appendix 3.1.5. Investigator Information
Physicians with expert ise in the diagnosis and treatment of alopecia areata will participate as 
investigators in this clinical trial.
Appendix 3.1.6. Protocol Signatures
The Sponsor’s responsible medical officer will approve the pr otocol , confirming that, to the best 
of his/her knowl edge, the protocol accurately describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the s igned page to a Lilly representative.
Appendix 3.1.7. Final Report Signature
[CONTACT_487101] a qualified investigator(s) fro m among invest igators participat ing in the design, 
conduct, and/or analysis o f the study  to serve as the clinical study  report (CS R) coordinat ing 
investigator.  If this investigator is unable to fulfill this function, another invest igator will be 
chosen by [CONTACT_248192].
The CSR coordinat ing invest igator will sign the final CSR for this study, in dicating agreement 
that, to the best of his /her knowl edge, the report accurately  describes the conduct and results of 
the study .
The Sponsor’s responsible medical officer and statist ician will approve the final CSR for this 
study , confirming that, to the b est of  his/her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal material to the study  sites, as appropriate .
I4V-MC-JAIR( d) Clinical Protocol Page 97
LY3009104sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the case report 
forms (CRFs ), and study  procedures.
make pe riodic visi ts to the study  site.
be available for consultation and stay  in contact [CONTACT_129237], tel ephone, and/or fax .
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion.
conduct a qua lity review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the Sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate sourc e 
for the data entered by  [CONTACT_338286] -provided electronic data capture sy stem .
Electronic pat ient-reported outcome (ePRO) measures (eg ,a rating scale) and electronic clinical 
outcom e assessments (eCOAs) are entered into an ePRO/eCOA instrume nt at the time that the 
inform ation is obtained.  In those instances where there is no prior written or electronic source 
data at the site, the ePRO/eCOA instrument record will serve as the source.
If ePRO/eCOA records are stored at a third -party  site, inv estigator sites will have cont inuous 
access to the source documents during the study  and will receive an archival copy  at the end of 
the study  for retenti on.
Any data for which the ePRO/eCOA instrument record will serve to collect source data will be 
ident ified and documented by [CONTACT_140842]’s study file .
Case report form data will be encoded and stored in InForm.  
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system .  Data will subsequent ly be transferred fro m the central  
vendor to the Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227571] igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP. Study terminat ion may occur in a specific country  or 
region when baricit inib is approved for the treatment of A Aand beco mes reimbursed or 
commercially  available in that country  or regi on, or a negative regulatory  action or opi[INVESTIGATOR_3078] n is 
received in that country  or regi on.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3 .4. Publication Policy
The publicat ion policy for Study  I4V-MC-JAIRis described in the Clinical Tri al Agreement.
I4V-MC-JAIR( d) Clinical Protocol Page 99
LY3009104Appendix 4. Hepatic Monitoring Tests for
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnorm ality and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , its designee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
Erythrocy te count ( RBC ) Prothrom bin Time
Leukocytes (WBC) Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig= immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I4V-MC-JAIR( d) Clinical Protocol Page 100
LY3009104Appendix 5. Liver Function Testing and Hepatic Safety  
Monitoring
Liver Function Testing and Hepatic Safety Monitoring
AnalyteExclusion
CriteriaAdditional 
Hepatic 
TestingHepatic eCRF 
ReportingTemporary 
Interruption 
ofIPPermanent Discontinuation 
of IPafter Consultation with 
the Lilly -Designated Medical 
Monitor
Protocol 
SectionSection 6.2 Section [IP_ADDRESS] Section [IP_ADDRESS] Section 8.1.2 Section 8.1.1
ALT /AST ≥2×ULN As per protocol ,
only ALT 
≥3×ULNAs per protocol ,
only ALT 
≥5 × ULN on 
≥2consecutive 
tests≥5×ULN >8×ULN
>5×ULN for >2 weeks
>3×ULN AND TBL 
>2×ULN or INR >1.5
>3×ULN with 
symptoms a
ALP ≥2 ×ULN ≥2×ULN ≥2×ULN on 
≥2consecutive 
testsNo applicable 
criteria>3×ULN
>2.5 ×ULN AND TBL 
>2×ULN 
>2.5 ×ULN with 
symptoms a
TBL ≥1.5 ×ULN ≥2×ULN ≥2×ULN
(excluding 
Gilbert’s 
syndrome)No applicable 
criteriaALT or AST (as per 
protocol) >3×ULN 
AND TBL >2 ×ULN
ALP >2.5 ×ULN AND
TBL >2 ×ULN
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
eCRF = electronic case report form; INR = international normalized ratio; IP= investigational product; 
TBL =total bilirubin level; ULN = upper level of normal .
aFatigue, nausea, vomiting, right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) .
I4V-MC-JAIR( d) Clinical Protocol Page 101
LY3009104Appendix 6. Additional Information on Statistical 
Methods
Appendix 6.1.Statistical Methods for Additional Analyses
Appendix 6.1.1. Placebo Multiple Imputation
The placebo multiple imputati on (pMI) m ethod may be used as a n addit ionalanalysis for the 
analysis of the primary  efficacy  endpoint , as well as key secondary endpo ints.  Mult iple 
imputati ons are used to replace missing outcomes ( defined in SAP) (Severit y of Alopecia Tool  
[SALT] score , patient -reported outcome [ PRO] for Scal p Hair Assessment score , etc. ) for drug -
and placebo -treated patients using mult iple draws from the posterior predictive distribut ion 
estimated from the placebo arm.  The binary outcomes ( SALT ≤20, PRO for Scalp Hair 
Assessment score of 0 or 1 with a ≥2-point improvement , etc.) will be derived fro m the 
imputed data.
Data are processed sequent ially by [CONTACT_487098]® PROC MI to impute missing 
outcom es at vi sits t=1,.., T :
1.Initialization :  Set t=0 (Baseline visit)
2.Iteration:  Set t=t+1.Create a data set combining records from drug -and 
placebo -treated pati ents wi th columns for covari ates Xand outcomes at visit s 
1,..,twith outcom es for all drug -treated pati ents set to missing at visit tand set 
to observed or imputed values at visits 1,.., t-
1.
3.Imputa tion:  Run Bayesian regressio n in SAS® PROC MI on this data to 
impute missing values for visit tusing previous outcomes for visits [ADDRESS_1227572] imputed data for all drug -treated pati ents at visit twith their observed 
values, whenever available up to permanent study  drug di scontinuati on or 
study  discont inuat ion.If t< T,then go to S tep 2, otherwi se proceed to Step 5.
5.Repeat steps [ADDRESS_1227573] in the presence of intermit tent missing data.
Analysis :  For the primary  and keysecondary  efficacy  endpoints, the missing outcomes will be 
derived fro m the imputed data for each patient before fitt ing into the analysis model.  A logistic 
regression or analysis of covariance ( ANCOVA )will be applied, as appropri ate.  
I4V-MC-JAIR( d) Clinical Protocol Page 102
LY3009104The number of imputed data sets will be m=100 and a 6 -digit seed value will be pre -specified for 
each analysis.  Wit hin the program, the seed will be used to generate the mseeds needed for 
imputati on.  The init ial seed values are given belo w:  
Analysis Seed V alue
Proportio n of patients achieving SALT score ≤20atWeek s 16, 24, and 36 123450
Proportio n of patients achieving a PRO for Scalp Hair Assessment 0 or 1 with a ≥2-point 
improvement from Baseline at Week 36among patients with a score of ≥3 at Baseline123451
Proportio n of patients achieving an absolute SALT score ≤10 at Week s 24 and 36 123450
Proportio n of patients achieving SALT 90at Week 36 123450
Proportio n of patients achieving SALT 50 at Week 12 123450
Percent change from Baseline in SALT score at Week 36 123450
Proportio n of patients achieving ClinRO Measure for E BHair Loss 0 or 1 with a ≥2-point 
improvement from Baseline at Week 36 (among patients with ClinRO Measure for EB Hair 
Loss ≥2 at Baseline)123452
Proportio n of patients achieving ClinRO Measure for EL Hair Loss 0 or 1 with a ≥2-point 
improvement from Baseline at Week 36 (among patients with ClinRO Measure for EL Hair 
Loss ≥2 at Baseline)123453
Abbreviations:  ClinRO = clinician -reported outcome; EB = eyebrow; EL = eyelash ;PRO = patient -reported 
outcome; SALT = Severity of Alopecia Tool; SALT 50= at least 50% improvement from Baseline in SALT 
score ;SALT 90= at least 90% improvement from Baseline in SALT score .
The final inference on treatment difference is conducted from the mult iple data sets using 
Rubin’s co mbining rules, as implemented in SAS® PROC MIANALYZE. 
Thus, in the effect iveness context, pMI assumes no pharmacological benefit of the drug after 
dropout .  It limits bias by [CONTACT_878715]/placebo effects. In the efficacy context, 
pMI is a specific form of a missing not at random analysis expected to yield a conservat ive 
estimate of efficacy. 
Appendix 6.1.2. Tippi[INVESTIGATOR_878672], an addit ionalanalysis using mult iple imputation 
(MI) under the missing not at rando m assumpt ion may be provided for the primary object ive, 
which co mpares the SALT ≤[ADDRESS_1227574] ives.
All patients in the full analysis set (FAS) popul ation are included .Within each analysis, the 
most extrem e case will be considered, in which all missing data (defined in SAP) for pati ents 
rando mized to thebaricit inib doses will be imputed using the worst possible result ,and all 
missing data (defined in SAP) for pati ents randomized to placebo will be imputed with the best 
possible result.  Treatment differences will be analyzed using logist ic regressio n or analysis o f 
covari ance ( ANCOVA ),as appropri ate.  
I4V-MC-JAIR( d) Clinical Protocol Page 103
LY3009104For continuous variables, the fo llowing process will be used to determine the tippi[INVESTIGATOR_11300]:
1.To handle intermittent missing visit data, a Markov chain Monte Carlo method 
(SAS® Proc MI with MCMC option) will be used to create a monotone missing 
pattern. 
2.A set of Bay esian regressio ns (using SAS® Proc MI with MONOTONE opti on) will 
be used for the imputation of monotone dropouts.  Starting fro m the first vi sit with at 
least 1missing value, the regression models will be fit sequent ially wi th treatm ent as 
a fixed effect and values from the previous visit s as cova riates.  
3.A delta score is added to all imputed scores at the time point where the analysis is 
conducted for pati ents in the baricit inib treatment groups, thus ,worsening the 
imputed value.  The delta score is capped for patients, based on the range of the
outcom e measure being analyzed.
4.Treatment differences between baricit inib and placebo are analyzed for each imputed 
data set using ANCOVA.  Results across the imputed data sets are aggregated using 
SAS® Proc MIANALYZE in order to compute a p -value for the treatm ent 
comparisons for the given delta value.
5.Steps 3 and 4 are repeated, and the delta value added to the imputed baricit inib scores 
is gradually  increased.  The tippi[INVESTIGATOR_878673] a l oss of stati stical signi ficance (aggregated p -value >0.05) when evaluating 
baricit inib relat ive to the placebo group.
As a reference, for each delta value used in Steps [ADDRESS_1227575] ion of delta values (ranging 
from slight ly negative to slightly posit ive) will be added to i mputed values in the placebo group, 
and Step [ADDRESS_1227576], with the columns representing the delta values added to the imputed placebo 
responses, and the rows repr esenting the delta values added to the imputed baricit inib responses.  
Separate 2 -d tables will co mpare each baricit inib dose group to placebo.
A similar process will be used for the categorical variables:
1.Missing responses in the baricit inib groups will b e imputed wi th a range of l ow response 
probabilit ies, including probabilit ies of 0, 0.1, and 0.2.
2.For missing responses in the placebo group, a range of response probabilit ies 
(eg,probabilit y = 0, 0.2 ,… 1) will be used to impute the missing values.  Mult iple 
imputed data sets will be generated for each response probabilit y.
3.Treatment differences between baricit inib and placebo are analyzed for each imputed 
data set using logist ic regressio n.  Results across the imputed data sets are aggregated 
using SAS® Proc MIANALYZE in order to compute a p -value for the treatment 
comparisons for the given response probabilit y.  If the probabilit y values do not allow for 
any variation between the mult iple imputed data sets ( eg, all missing responses in the 
I4V-MC-JAIR( d) Clinical Protocol Page 104
LY3009104placebo and ba ricitinib groups are imputed as responders and nonresponders, 
respectively ), then the p -value fro m the single imputed data set will be used.
The ti ppi[INVESTIGATOR_11300] i s identified as the response probabilit y value wit hin the placebo group that 
leads to a loss of statistical significance when evaluating baricit inib relat ive to placebo. 
For ti ppi[INVESTIGATOR_878674] m=100 and the seed value to
start the pseudorandom number generator of SAS Proc MI (same values for MCMC option an d
for MONOTONE option) will be:
Analysis Seed value
Proportio n of patients achieving SALT ≤20at Week 36 123461
Abbreviation:  SALT = Severity of Alopecia Tool .
Appendix 6.2. Graphical Testing Procedures
The primary  hypothes es H1,1,0and H 2,1,[ADDRESS_1227577] tested at a two -sided α=0.[ADDRESS_1227578] is considered “spent” and cannot be passed to other endpoints. If at least 1 of the 
null hypothes es is rejected ,thetesting process continues, with the rem aining αpropagated 
according to the weights on the corresponding edges displayed in ( Figure JAIR. 2).The testing 
process con tinues as long as there is at least 1hypothesis in the scheme that can be rejected at its 
allocated α level at that point.  Each time a hypothesis is rejected, the graph is updated to reflect 
the reallo cation of α, which is considered “recycled” by [CONTACT_487100] . (2014).  Thi s iterative 
proces s of updat ing the graph and reallo cating α is repeated until all hypotheses have been tested 
or when no remaining hypotheses can be rejected at their corresponding α levels.
There will be no adjust ment for multiple com parisons for any  other analyses. 
I4V-MC-JAIR( d) Clinical Protocol Page 105
LY3009104Appendix 7. Moni toring Tests for Confirmed VTE
Selected tests m ay be obtained in the event of a confirmed venous thromboembo lic event (VTE) 
and may  be requi red in fo llow-up wi th patients in consultation wit h Eli Lilly and Co mpany, its 
designee, or the clinical research ph ysician.  
Protein C Functional
Protein S Clottable
Antithrombin III
APC Resistance
PT
APTT
Fibrinogen
Cardiolipin Antibodies
PT Gene
Factor VIII C Assay
Hexagonal Phase Phospholipid Neutralization
C-Reactive Protein
PTT Incubated Mixing 
Dilute Russell Viper Venom 
Platelet Neutralization 
Factor V Leiden 
MTHFR 
Thrombin Time 
Reptilase 
Fibrinogen Antigen 
Protein C Immunologic 
Protein S Immunologic 
Heparin fXa Inhibition 
Abbreviations:  APC = activated protein C; APTT = activated partial thromboplastin time; fXa = clotting factor Xa; 
MTHFR = methylene tetrahydrofolate reductase; PT= prothrombin time; PTT = partial thromboplastin time.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227579] planned study  procedures.
Implementing changes under exceptional circumstances
In an except ional circumstance, after receiving the sponsor’s written approval, sites may  
implement changes if permitted by [CONTACT_24550]. 
After approval by [CONTACT_878716] (ERBs) , regul atory  bodies,and any other relevant 
local authori ties, im plementati on of  these except ional circumstances changes will not ty pi[INVESTIGATOR_878675], unless they  have specific condit ions in which 
notification is required. To protect the safet y of study  parti cipants, urgent changes may be 
implemented before approval but need to be reported as soon as possible. All approvals must be 
retained in the study  records.
In the event written approval is granted by [CONTACT_878717], a dditional 
written guidance ,if needed, will be provi ded by [CONTACT_456] .
Considerations for making a change
The prevailing considerat ionfor making a change is e nsuring the safet y of study  participants.
Addit ional important considerat ions for making a change are compliance with Good Clinical 
Practi ce, enabling participants to continue safely  in the study and maintaining the integrit y of 
thestudy . 
Informed consent
The site should document the parti cipant’s verbal consent for having remote visits and remote 
dispensing of invest igational product ( IP), ancillaries, prior to implementation o f theseactivit ies.
Addit ional consent fro m the parti cipant will  be obtained , if required, for
participat ion in remote visits, as defined in Section “Remote Visits”
a change in the method , locati on, or both, of study  intervent ion administration
dispensat ion of addit ional study  interventi onduring an extended treatment period
I4V-MC-JAIR( d) Clinical Protocol Page 107
LY3009104alternate delivery  of study  interventi on and ancillary  supplies, and
provi sion of their personal  or medical  information requi red pri or to implementation 
ofthese act ivities. 
Changes in study conduct during exceptional circumstances
Changes in study  conduct not described in this appendix, or not consistent with applicable local 
regul ations, are not allowed .
The fo llowing changes in study  conduct will not be considered protocol deviat ions.
1.Remote visits
Visit 8 (Week 36) require slive clinical assessment because it is the primary outcome visit. 
To facilitate an onsite visit , the visi t window m ay be extended (see below in Adjust ment to 
Visit Windows of this Appendix).
All other visits (including assessment of loss of benefit during rando mized 
downti trationpost Week 52) may be conducted remotely if the visit could not otherwise be 
conducted due to local or national restrict ions.
In source document sand the CRF , the study site should capture the visit location and method ,
with a specific explana tion for any  data missing because of missed in -person site visit s.
Telemedicine: Live, onsite clinical efficacy assessments are preferred for ALL visits ;
however, if a remote visit is the only option , telephone or techno logy-assisted virtual visits , 
or both, are acceptable to complete appropriate assessments (with the except ion of V isit 8).
Assessments to be completed in this manner include :
Patient-reported outcome ( PRO) Scalp, Severit y of Alopecia Tool  (SALT ) score, and 
clinician -reported outcom es (ClinROs )for Eyebrows/Ey elashes if visual assessment 
by [CONTACT_878718]. If NO visual assessment AND ONLY verbal assessment 
by [CONTACT_878719] , 
SALT score , ClinROs  for Ey ebrows /Eyelash esandNails, 
and PROs for Ey eIrritationshoul d not be assessed.
AEs and product complaints .
Concomitant m edicat ions.
Columbia Suici de Severi ty Rating Scale (C-SSRS )(Since Last Visit Version), 
Self-Harm Suppl ement Form , and Self -Harm Form .
Regardless of the ty pe of  remote visi ts implemented, the protocol r equirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged . Furtherm ore, every 
effort should be made to enable participant sto return to on -site visits as soon as reasonably  
possible, while ensuring the safet y of both the participant sand the sitestaff.
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227580] be qualified in accordance with applicable local regulat ions.
Obtain local labsfor safet y (hematol ogy, chemistry) and urine pregnancy test when 
applicable, as per the study  protocol  schedule of activit ies.
A urine pregnancy test should be sent to female patient sof childbearing potential.  
The patient should conduct the test and pro vide verificat ion of results to the site per a 
method agreed to between the patient and the site.   Invest igational product must be 
temporarily held unt il site can review a photo of pregnancy  test resul ts.
All labs will be reviewed by [CONTACT_473]. Lilly Medical should be informed of 
any labs that meet criteria for temporary  or perm anent study  drug discont inuat ion.
Sign and date review of local labs per normal process and fo llowup wi th the pati ent 
as needed.  Results will not be recorded in the eC RF.
Safety labs shoul d be obtained at a minimum of every  [ADDRESS_1227581] ions 
may includ e
asking the participant to go to the site and receive study supplies from site staff 
without com pletion of a full study  visit 
asking theparticipant ’s designee to go to the site and receive study supplies on a 
participant’s behalf, and
arranging delivery  of study  supplies .
These requi rements m ust be m etbefore action is taken :
Sponsor approves the alternat ive method of del ivery , taking l ocal regulatory  
requi rements into considerat ion.
Participant consents verbally  to al ternate m ethod of delivery .
Site confirms the participant’s receipt of the trial supplies .
Site/sponsor confirms appropriate ERB notificat ion.
Alternate delivery  of IPshoul d be performed in a manner that does not compromise 
treatm ent blinding and ensures product integrit y. The exist ing protocol requirements 
for product accoun tabilit y remain unchanged , including verificat ion of participant’s 
receipt of study  supplies.
When delivering supplies to a locat ion other than the study  site (for exam ple, 
participant’s ho me), the invest igator , sponsor , or both shoul d ensure oversight of the 
shippi[INVESTIGATOR_226369] y and product qualit y (thatis, storage 
condi tions maintained and intact packaging upon receipt) .
Instructi ons may be provided to the participant or designee on the final disposit ion of 
any unused or com pleted study  supplies .
I4V-MC-JAIR( d) Clinical Protocol Page [ADDRESS_1227582] ments to visit windows .
Visit Number Tolerance
Visits 8 Visits8 (Week 36) may  be conducted wi thin [ADDRESS_1227583] will be documented:
Sites will ident ify and document the details o f how participants, visits t ypes, 
andconducted activit ies were affected by [CONTACT_52022] . 
Dispensing/shipment records of study  intervent ionand relevant communicat ions, 
includ ing delegat ion, should be filed with site study records.
Source documents generated at a location other than the study site should be part of 
the invest igator’s source documentation and should be transferred to the site in a 
secure and t imely manner. 
I4V-MC-JAIR( d) Clinical Protocol Page 110
LY3009104Appendix 9. Protocol A mendment I4V-MC-JAIR(d) 
Summary A Multicenter, Randomized, Double -Blind, 
Placebo- Controlled, Phase 3 Study  to Evaluate the 
Efficacy  and Safety  of Baricitinib in A dult Patients with 
Severe or Very  Severe A lopecia A reata (BRA VE-AA2)
Overview
Protocol I4V-MC-JAIR (A Mult icenter, Rando mized, Double -Blind, Pl acebo -Controlled, 
Phase 3 Study  to Eval uate the Efficacy and Safet y of Bari citinib in Adult Pati ents wi th Severe or 
Very  Severe Alopecia Areata [ BRAVE -AA2 ])has been amended.  The new protocol is indicated 
by [CONTACT_61504] ( d) and will be used to conduct the study in place of any preceding versio n of 
theprotocol.
This protocol has been amended to
finalize key  secondary  endpoints pri or to primary  outcome database l ock
update and clarify  stati stical analysis
modify graphical test ing to align with the updates to key secondary endpoints
add Appendix [ADDRESS_1227584] ty pographical errors , and
clarify study  procedures.
The overall changes and ration ale for the changes made to this protocol are described in the 
following tab le.
I4V-MC-JAIR( d) Clinical Protocol Page 111
LY3009104Amendment Summary for Protocol I4V-MC-JAIRAmendment ( d)
Section # and Name [CONTACT_19523] 1 :  Synopsis Added proportio n of patients achieving SALT 50at Week 12 to Key Secondary  Objectives
Moved week 24 timepoint for Proportion of patient achieving a SALT 90to Other Secondary 
Endpoints
Changed time point for percent change from baseline in SALT score to Week 36 and moved 
Week 12 to Other Secondary Endpoints
Moved proportion of patients achieving SALT 50at Week 12 to Other Secondary Endpoints 
to key  Secondary  Endpoints
Moved ClinROs for EB and EL to Key Secondary Endpoints at Week 36 from Other 
Secondary ” 
Moved P roportion of patients achieving ClinRO Measure for EB Hair Loss 0 or 1 with ≥2-
point improvement from baseline at Week 36(among patients with ClinRO Measure for EB 
Hair Loss ≥2 at Baseline) to other Secondary Endpoints to Key Secondary Endpoints
Moved Wee ks 16 and 24 for Proportion of patients with PRO for Scalp Hair Assessment 
score of 0 or 1 to Other Secondary Endpoints
Clarified ClinRO and PRO endpoints
Change f rom Baseline in SALT score at Weeks 12, 16, 24, and 36 added to other secondary
Clarified Mean change from Baseline in HADS total score at Weeks 24 and 36 to specify 
HADS -A and HADS -D
Added clarifying statement in regard to the potential for additional database locks and 
Interim AnalysisUpdated key 
secondary 
endpoints to reflect 
the analy sisthat
will be conducted
Rem oved SALT score percentages for sever e or very severe AA 
Updated language regarding interim analysis in Statistical Analysis Clarification per 
regulato ry feedback
For flexibility
Rem oved baseline testing for Fisher exact test Error correction
Section 2 :  Schedule of Activities Added leading statement regarding addition of Appendix [ADDRESS_1227585] under exceptional circumstancesClarification
Corrected error introduced inlast amendment.   Hamilton -Norwood Scale – changed Week 
56 collection to Week 52Error correction
Corrected error introduced inlast amendment –hematology to be collected at Week 8 Error correction
I4V-MC-JAIR( d) Clinical Protocol Page 112
LY3009104Section # and Name [CONTACT_19523] 3.3 :  Benefit/Risk Assessment Corrected i ncomplete sentence at the end of the first paragraph Errorcorrection
Section 4 :  Objectives and Endpoints Added proportion of patients achieving SALT 50at Week 12 to Key Secondary  Objectives
Moved week 24 timepoint for Proportion of patient achieving a SALT 90to Other Secondary 
Endpoints
Changed time point for percent change from baseline in SALT score to Week 36 and moved 
Week 12 to Other Secondary Endpoints
Moved proportion of patients achieving SALT 50at Week 12 to Other Secondary Endpoints 
to key  Secondary Endpoints
Moved ClinROs for EB and EL to Key Secondary Endpoints at Week 36 from Other 
Secondary ”
Moved P roportion of patients achieving ClinRO Measure for EB Hair Loss 0 or 1 with ≥2-
point improvement from baseline at Week 36 (amo ng patients with ClinR O Measure for EB 
Hair Loss ≥2 at Baseline) to other Secondary Endpoints to Key Secondary Endpoints
Moved Weeks 16 and 24 for Proportion of patients with PRO for Scalp Hair Assessment 
score of 0 or 1 to Other Secondary Endpoints
Clarified ClinRO and PRO endpoints
Change f rom Baseline in SALT score at Weeks 12, 16, 24, and 36 added to other secondary
Clarified Mean change from Baseline in HADS total score at Weeks 24 and 36 to specify 
HADS -A and HAD S-D
Added clarifying statement in regard to the potential for additional database locks and 
Interim AnalysisClarification
Section 5.1 :  Overall Design Rem oved wording referring to AA severity to improve clarity of stratification Clarification per 
regulato ry feedback
Section 6.1:  Inclusion Criteria Update dpregnancy language for Inclusio n Criterion [5a] Clarification
Section 7.2 :  Method of Treatment
  AssignmentRem oved SALT score percentages for severe or very severe AA to improve clarity of 
stratification
Corrected information on visit and week for IP assignment by [CONTACT_10966]Clarification per 
regulato ry feedback
Error correction
Section [IP_ADDRESS]:  Severity of
  Alopecia ToolAdded “(SALT) Score” tosection head ing Errorcorrection
Section 9.4.4 :  Laboratory Tests Clarified that home visits to collect blood and urine samples may bepermitted under normal 
protocol operationsFor flexibility of
study conduct
Section 10.3.1 :  General Statistical Updated language regard ing interim analyses being conducted For flexibility 
I4V-MC-JAIR( d) Clinical Protocol Page 113
LY3009104Section # and Name [CONTACT_878720] [IP_ADDRESS]. Analysis Methods 95% CI will also be reported change d to may be reported Error
Section [IP_ADDRESS] .  Missing Data
ImputationStatements removed to clarify  sensitivity  analy sismay be conducted
The specification for additional analysis was updated
pMI analy sis was changed from will be included to may be includedFor flexibility
Section [IP_ADDRESS] :  Multiple
Comparisons/MultiplicityUpdate graphical testing procedures to reflect planned analysis (Figure JAIR .2)
Updated Key Secondary  Null Hypotheses to reflect updates to Key Secondary  ObjectivesUpdated based on 
revision sto key 
secondary  
endpoints
Section [IP_ADDRESS] :  Primary  Analy ses Added language to clarify missing data imputation for data collected during remote visits
Added language t o clarify what data may be included in additional analy sisClarification of 
analy ses 
description per
regulatory feedback
Section [IP_ADDRESS] :  Secondary Analyses Added statement that additional analysis of the secondary efficacy outcome may be 
performedClarification of 
analysis description 
per r egulatory 
feedback
Section 10.3.4 :  Safety Analyses Updated wording to clarify data included in the safety analysis Clarification
Section [IP_ADDRESS]. Subgroup Analyses Added baseline value wording to logistic model For Clarity 
Section [IP_ADDRESS]:  Week 36 Primary
  Outcomes Analyses and Other Interim
  AnalysesAdded wording to state that interim analysis will be described in the SAP Clari fication
Appendix 6.1.1:  Placebo Multiple
  ImputationSentence added stating that a Markov chain Monte Carlo method will be used
Adjusted analysis table to reflect planned analysis
   Removed statement about mLOCFClarification
Appendix 8 :  Provisions for Changes in
Study Conduct During Exceptional
CircumstancesAdded Appendix 8, Provisions for Changes in Study Conduct During Exceptional 
CircumstancesTo enable 
continued conduct 
of the study using 
remote visits
Abbreviations: AA=alopecia areata; ClinRO =clinician -reported outcome ; EB = eyebrow ; EL =eyelash ; IP=investigational product; IWRS =interactive web -
response system; mLOCF =modified last observation carried forward ;PRO =patient -reported outcome ;SALT 50=at least 50% improvement from Baseline 
in Severity of Alopecia Tool score ; SAP = statistical a nalysis plan .
Leo Document ID = a20c70c5-7cc5-4fc3-b70d-468f9514e75b
Approver: 
Approval Date & Time: 02-Nov-2020 19:28:21 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 02-Nov-2020 21:01:24 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]